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Abstract 
Cisplatin is one of the most widely used anticancer drugs, however, its clinical effi-
cacy is hampered by severe side effects and acquired or intrinsic resistance. These 
limitations have prompted a search for metal-based antitumor drugs with improved 
effectiveness. Consequently, a large number of metal complexes were synthesized 
and biologically tested. Switching from platinum to other metal ions may result in 
altered cytotoxicity profiles due to different targets, or chemical and biological 
properties in general. Complexes of gallium (KP46) and ruthenium (KP1019 and 
NAMI-A) have already entered clinical trials. Very recently, half-sandwich ruthe-
nium(II)- and osmium(II)-arene complexes have shown great potential for the de-
velopment of anticancer drugs.  Different approaches have been explored in this 
regard which resulted in compounds with cytotoxicity comparable or even superior 
to cisplatin. 
In this thesis, different strategies were employed, including coordination of bio-
molecules to the metal-arene scaffold, with the aim to improve pharmacological 
properties such as bioavailability, lipophilicity and solubility as well as anticancer 
activity. The first part of this thesis comprises the synthesis and biological evalua-
tion of ruthenium(II)- and osmium(II)-arene compounds bearing sugar-derived bicy-
clophosphite ligands. The complexes were characterized with regard to their stabil-
ity in aqueous solution, and reaction with proteins and the DNA models 5’-GMP and 
9-ethylguanine. In order to establish structure-activity relationships, structural modi-
fications such as change of arene, metal center and leaving group were made.  
The second part of this thesis deals with the synthesis as well as chemical and bio-
logical characterization of ruthenium(II)- and osmium(II)-arenes complexes of 3-
hydroxy-2-pyridones. Hydrolysis, reactivity to biomolecules and CDK2/Cyclin A 
protein kinase inhibition were investigated, which is discussed with regard to anti-
cancer activity and reactivity to biomolecules. 
The chemical and biological data presented in this thesis provide the basis and ra-
tionale to follow in future drug design strategies with carbohydrate- and pyridone-
derived metal complexes.  
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Zusammenfassung 
Cisplatin ist eines der meistverwendeten Chemotherapeutika in der Krebstherapie, 
jedoch wird die klinische Anwendung und Wirksamkeit von Cisplatin durch starke 
Nebenwirkungen und erworbene oder intrinsische Resistenz eingeschränkt. Diese 
Einschränkungen waren der Anlass metallbasierte Antitumormedikamente mit ande-
ren Zentralatomen als Platin zu untersuchen. Die Metallionen wurden mit dem Ziel 
ausgewählt geänderte Zytotoxizitätsprofile und Aktivität an einem weiteren Tumor-
spektrum zu erhalten. Der Galliumkomplex KP46 und die beiden Ru(III) Verbin-
dungen KP1019 und NAMI A werden zurzeit in klinischen Studien untersucht. Ru-
thenium(II)- und Osmium(II)-Aren Komplexe zeigen großes Potential zur Entwick-
lung tumorhemmender Medikamente und verschiedene Ansätze wurden in dieser 
Hinsicht erforscht. Einige dieser Verbindungen besitzen vergleichbare oder sogar 
bessere Zytotoxizität in Zellkulturen als Cisplatin.  
Im Rahmen dieser Dissertation wurden unterschiedliche Strategien angewandt, in-
klusive Koordination von Biomolekülen an das Metall-Aren Gerüst, um pharmako-
logische Eigenschaften, wie Bioverfügbarkeit, Lipophilie, Löslichkeit und tumor-
hemmende Aktivität zu verbessern. Im ersten Teil der Doktorarbeit werden die Syn-
these und biologische Evaluierung von Ruthenium(II)- und Osmium(II)-
Arenverbindungen mit von Zuckern abgeleiteten Bicyclophosphit-Liganden be-
schrieben. Die Komplexe wurden in Bezug auf ihre chemische Stabilität in wässri-
ger Lösung und die Reaktivität mit Proteinen und den DNA-Modellverbindungen 
5’-GMP und 9-Ethylguanin charakterisiert. Verschiedene strukturelle Modifikatio-
nen wie zum Beispiel Austausch der Arengruppe, des Metallzentrums oder der Ab-
gangsgruppe wurden durchgeführt, um Struktur-Aktivitätsbeziehungen abzuleiten.  
Der zweite Teil dieser Doktorarbeit behandelt die Synthese und Charakterisierung 
von Ruthenium(II)- und Osmium(II)-Arenkomplexen mit 3-Hydroxy-2-pyridonen 
als Liganden. Das Verhalten in wässrigen Systemen, die Reaktion mit diversen 
Aminosäuren und die CDK2/Cyclin A Proteinkinase-Inhibition werden in Bezug auf 
ihre Zytotoxizität diskutiert.  
5
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 1. Introduction 
1.1 Platinum-based anticancer drugs  
The serendipitious discovery of the anticancer activity of cisplatin in the 1960ies has 
opened new horizons for the development of metal-based drugs and the last four 
decades have seen immense interest in metallopharmaceuticals. The increasing 
knowledge of molecular structural biology, in particular information of genomic, 
proteomic and other cellular functions has not only helped in understanding mecha-
nism of action of existing metal-based drugs but also set the basis for the rational 
design of new metal-therapeutics.  
Cisplatin [cis-diamminedichloridoplatinum(II)] (Fig. 1) was first synthesized by 
Michele Peyrone in 18441 and about hundred years later, its tumor-inhibiting proper-
ties were discovered accidentally2 by Barnett Rosenberg who was investigating the 
influence of an electric field on the growth of Escherichia coli bacteria. 
 
Figure 1. Cisplatin, the first metal-based anticancer drug approved by the FDA  
 
Today cisplatin is one of the most widely used anticancer drugs with a very impres-
sive cure-rate, particularly in testicular and ovarian cancer, and is also used in com-
bination therapy of many other solid tumors, such as bladder, head and neck and 
                                                 
1
 Peyrone M. Ann Chemie Pharm. (1844) 51 (1): 1–29 
2
 Rosenberg, Barnett; Van Camp, Loretta; Krigas, Thomas, Nature (1965), 205,  698-699.  
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small cell lung cancers.3 The success of cisplatin in cancer therapy stimulated scien-
tists to search for novel metal-based antitumor drugs, with improved effectiveness, 
broader spectrum of activity and fewer side effects. Thus thousands of other plati-
num complexes have been synthesized and biologically evaluated for their antitumor 
properties, from which about fourty entered clinical phase I trials but only two car-
boplatin4 and oxaliplatin5 (Fig. 2) have received worldwide approval so far. Car-
boplatin exhibits a tumor inhibiting profile identical to that of cisplatin, however 
with fewer side effects, whereas oxaliplatin is used in a combination therapy against 
metastatic colorectal cancer.6 In addition three platinum-based drugs have gained 
regional approval. These include nedaplatin (Japan), lobaplatin (China) and hepta-
platin (South Korea).  
 
 
 
 
 
Figure 2. Structures of carboplatin (left) and oxaliplatin (right) 
 
 
1.2 Mode of action of cisplatin and analogous drugs 
In the last 30 years, much research has been focused on the understanding of the 
mechanism by which cisplatin and its analogues induce apoptosis; however, the ex-
act mode of action is still elusive. Cisplatin is administered by intravenous injection 
or infusion into the bloodstream,7,8,9 where it remains intact due to the presence of 
                                                 
3
 Galanski, Markus; Jakupec, Michael A.; Keppler, Bernhard K. Current Medicinal Chemistry 
(2005), 12(18), 2075-2094. 
4
 O'Dwyer, Peter J.; Stevenson, James P.; Johnson, Steven W., Drugs (2000), 59(Suppl. 4), 19-27. 
5
 Cvitkovic, Esteban; Bekradda, Mohamed,   Seminars in Oncology (1999), 26(6), 647-662. 
6
 Graham, Joanne; Muhsin, Mohamed; Kirkpatrick, Peter., Nature Reviews Drug Discovery (2004), 
3(1), 11-12. 
7
 Kelland, Lloyd. Nature Reviews Cancer (2007), 7(8), 573-584.  
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relatively high chloride concentration (100 mM), resulting in the suppression of hy-
drolysis of the drug. It enters the cell by passive diffusion or by active transport 
mechanisms10 such as the copper transporter Ctr1.11,12 Inside the cell, the hydrolysis 
is promoted due to low chloride concentration (4 mM). Cisplatin undergoes aquation 
to form mainly monoaqa species cis-[Pt(NH3)2Cl(OH2)]+ by exchange of one chlo-
rido ligand with a water molecule.13 This reactive species then binds preferably to 
nitrogen atoms of the DNA bases, particularly to the N7 of guanine, forming ini-
tially monofunctional DNA adducts and later on bifunctional intrastrand cross-links 
of the type 1,2-d(GpG) and 1,2-d(ApG).14 These adducts induce a kink (conforma-
tional changes) in the DNA, resulting in the inhibition of DNA replication and tran-
scription which leads towards the programmed cell death in cancerous tissue.  
 
 
Figure 3. DNA adduct formation with cisplatin.8 
                                                                                                                                         
8
 Wang, Dong; Lippard, Stephen J. Nature Reviews Drug Discovery (2005), 4(4), 307-320. 
9
 Jakupec, M. A.; Galanski, M.; Keppler, B. K., Reviews of Physiology, Biochemistry and Pharma-
cology (2003), 146 1-53.  
10
 Gately, D. P.; Howell, S. B., British Journal of Cancer (1993), 67(6), 1171-6. 
11
 shida, Seiko; Lee, Jaekwon; Thiele, Dennis J.; Herskowitz, Ira, Proceedings of the National Acad-
emy of Sciences of the United States of America  (2002),  99(22),  14298-14302.  
12
 Lin, Xinjian; Okuda, Tsuyoshi; Holzer, Alison; Howell, Stephen B.,     Molecular Pharmacology 
(2002), 62(5), 1154-1159.  
13
 Appleton, Trevor G.; Hall, John R.; Ralph, Stephen F.; Thompson, Craig S. M., Inorganic Chemis-
try (1989), 28(10), 1989-93. 
14
 Fichtinger-Schepman, Anne Marie J.; Van der Veer, Johannis L.; Den Hartog, Jeroen H. J.; Loh-
man, Paul H. M.; Reedijk, Jan., Biochemistry (1985), 24(3), 707-13.  
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1.3 Non-platinum metal complexes as anticancer agents  
Platinum compounds are widely used in cancer therapy but they are not devoid of 
problems like toxic side effects, limited spectrum of activity and intrinsic or ac-
quired resistance. There is an increasing demand for novel anti-cancer drugs which 
show reduced side effects, higher selectivity towards tumor cells, and a broader 
spectrum of activity. This stimulated investigations in the design of drugs based on 
metals other than platinum, such as gold, galliun, titanium, rhodium, iron, ruthenium 
and osmium. Non-platinum metals may have different chemical behavior (oxidation 
state, redox potential, coordination geometry, additional coordination sites, binding 
preferences to biomolecules according to the HSAB principle etc.), rate of hydroly-
sis or kinetics of ligand exchange reactions and the ability to replace essential met-
als.15 Therefore, it is likely that non-platinum metal-based compounds may have 
different mechanisms of action, biodistribution and biological activity. The antitu-
mor properties of a number of different metal ions and their complexes have been 
evaluated, but only a few non-platinum metal-based drugs are currently in clinical 
studies, the most promising ones contain ruthenium and gallium ions.16  
 
 
Figure 4. The chemical structures of titanocene dichloride, gold tetraphenylporphyrin and 
gallium maltolate. 
 
 
                                                 
15
 Clarke, Michael J.; Zhu, Fuchun; Frasca, Dominic R., Chemical Reviews, (1999), 99, 2511-2533. 
16
 Jakupec, Michael A.; Galanski, Markus; Arion, Vladimir B.; Hartinger, Christian G.; Keppler, 
Bernhard K., Dalton Transactions (2008),   (2), 183-194.  
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1.4. Ruthenium and Osmium Anticancer Complexes 
1.4.1 General features 
Both ruthenium and osmium, along with iron, are members of group 8 and are 
placed in the second and third row of the periodic table, respectively. They are clas-
sified as the ‘Platinum group’ along with rhodium, palladium, iridium and platinum. 
All these metals often occur together in the same mineral deposits and have closely 
related physical and chemical properties. Although osmium was discovered before 
ruthenium, however its chemistry and also its anticancer activity are much less ex-
plored than that of its homologue in the second row, most likely due to the higher 
cost of the metal and the greater difficulty with compound synthesis.17   
The application of group 8 metal complexes in anticancer drug design has long tra-
dition with iron in the ferrocenyl derivative of tamoxifen (ferrocifen) as the leading 
example18, and ruthenium in two drug candidates NAMI-A and KP1019 in clinical 
trials.  
1.4.2 Ruthenium(III) and Osmium(III)  complexes  
Among the non-platinum complexes tested so far, ruthenium-based compounds have 
shown great promise for the development of anticancer agents. The ruthenium(III) 
drug candidates NAMI-A and KP1019 are already in clinical trials.19,20,21,22 In addi-
                                                 
17
 Lay, Peter A.; Harman, W. Dean, Advances in Inorganic Chemistry (1991), 37 219-379. 
18
 Jaouen, Gerard; Top, Siden; Vessieres, Anne, Bioorganometallics (2006),     65-95. 
19
 Rademaker-Lakhai, Jeany M.; Van Den Bongard, Desiree; Pluim, Dick; Beijnen, Jos H.; Schellens, 
Jan H. M, Clinical Cancer Research  (2004),  10(11),  3717-3727. 
20
 Hartinger, Christian G.; Zorbas-Seifried, Stefanie; Jakupec, Michael A.; Kynast, Bernd; Zorbas, 
Haralabos; Keppler, Bernhard K., Journal of Inorganic Biochemistry (2006), 100(5-6), 891-904. 
21
 Hartinger, Christian G.; Dyson, Paul J., Chemical Society Reviews (2009), 38(2), 391-401.  
22
 Lentz, Frederike; Drescher, Anne; Lindauer, Andreas; Henke, Magdalena; Hilger, Ralf A.; Hart-
inger, Christian G.; Scheulen, Max E.; Dittrich, Christian; Keppler, Bernhard K.; Jaehde, Ulrich, 
Anti-Cancer Drugs  (2009),  20(2),  97-103. 
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tion to the well developed synthetic coordination chemistry and predictable geome-
tries, ruthenium compounds have a number of unique properties which make them 
ideal candidates for the design of therapeutics. The drugable features associated with 
ruthenium are low ligand exchange rates (similar to platinum complexes), low sys-
temic toxicity, a range of oxidation states accessible under physiological conditions, 
some physicochemical properties similar to iron and  more importantly its affinity to 
serum transport proteins such as albumin and transferrin.15,16,23 For example, trans-
ferrin receptors are overexpressed in tumor cells due to their high demand for iron, 
therefore ruthenium species can be better delivered owing to their high affinity to 
bind with serum transferin and transferin-bound metal ions can be easily released in 
the relatively low pH of tumor cells. Moreover, ruthenium(III) complexes are usu-
ally considered as prodrugs that can be activated by reduction to ruthenium(II) spe-
cies in vivo. The reduced form of ruthenium can bind more rapidly to bio-
molecules.15,24 As the tumor cells have relatively low electrochemical potential due 
to the low oxygen content and low pH, the reduction of Ru(III) to Ru(II) is favored 
in tumor tissue relative to healthy ones. Biomolecules such as glutathione, ascorbate 
and redox proteins in the cell also play a part in reduction of Ru(III). 
In recent years, the anticancer activity of Ru drug candidates has often been com-
pared to that of their Os analogues; however, no clear-cut structure-activity relation-
ship could be derived. The growing family of ruthenium compounds with antitumor 
activity has sparked interest in the investigation of the heavier homologue osmium. 
Sadler et al. have shown that the design of osmium compounds with tumor inhibit-
ing properties can be realized by effectively tuning the reactivity, particularly the 
hydrolysis and nucleobase binding, by systematic variation of ancillary ligands. 
Nevertheless, there are only few studies on the antitumor activity of osmium com-
plexes.25,26,27,28 Osmium offers several features distinct from ruthenium including 
                                                 
23
 Allardyce, Claire S.; Dyson, Paul J., Platinum Metals Review (2001), 45(2), 62-69. 
24
 Clarke, Michael J., Coordination Chemistry Reviews (2003), 236(1-2), 209-233. 
25
 Peacock, Anna F. A.; Habtemariam, Abraha; Fernandez, Rafael; Walland, Victoria; Fabbiani, 
Francesca P. A.; Parsons, Simon; Aird, Rhona E.; Jodrell, Duncan I.; Sadler, Peter J., Journal of the 
American Chemical Society  (2006),  128(5),  1739-1748.  
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synthetic approaches to coordination and organometallic compounds, the preference 
for higher oxidation states, slow ligand exchange kinetics,  the stronger pi back-
donation from lower oxidation states and the much stronger spin-orbit coupling.  
These properties can be exploited to design osmium compounds with sufficient sta-
bility and inertness under physiological conditions.29,30  
1.4.2.1 NAMI-A 
The first ruthenium complex entered clinical trials in 1999 is NAMI-A, HIm[trans-
RuCl4(DMSO)(Im)] (Im = imidazole). This complex has demonstrated potent activ-
ity against tumor metastasizing processes, but its activity against the primary tumor 
is low. Reduction of NAMI-A to the corresponding dianionic ruthenium(II) species 
can be rapidly accomplished by biological reductants such as ascorbic acid, glu-
tathione or cysteine. Reduction is then followed by stepwise hydrolysis of chlorido 
ligands without dissociation of the dimethylsulfoxide and imidazole ligands. Chlo-
ride hydrolysis under physiological conditions is tremendously accelerated upon 
prior reduction but since NAMI-A is unstable under physiological conditions and 
hydrolysis products have higher redox potentials than the parent compound, hy-
drolysis prior to reduction is also possible.  Anyhow, reduction seems to be slightly 
advantageous for inhibition of metastasis growth in vivo. Eventually, hydrolysis 
                                                                                                                                         
26
 Peacock, Anna F. A.; Parsons, Simon; Sadler, Peter J., Journal of the American Chemical Society 
(2007), 129(11), 3348-3357.  
27
 Dorcier, Antoine; Ang, Wee Han; Bolano, Sandra; Gonsalvi, Luca; Juillerat-Jeannerat, Lucienne; 
Laurenczy, Gabor; Peruzzini, Maurizio; Phillips, Andrew D.; Zanobini, Fabrizio; Dyson, Paul J.,   
Organometallics  (2006),  25(17),  4090-4096. 
28
 Dorcier, Antoine; Dyson, Paul J.; Gossens, Christian; Rothlisberger, Ursula; Scopelliti, Rosario; 
Tavernelli, Ivano, Organometallics  (2005),  24(9),  2114-2123. 
29
 Stepanenko, Iryna N.; Cebrian-Losantos, Berta; Arion, Vladimir B.; Krokhin, Artem A.; Nazarov, 
Alexey A.; Keppler, Bernhard K.,    European Journal of Inorganic Chemistry  (2007),   (3),  400-
411.  
30
 Peacock, Anna F. A.; Parsons, Simon; Sadler, Peter J.,    Journal of the American Chemical Society 
(2007), 129(11), 3348-3357.  
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results in formation of uncharacterized oxo-bridged polymeric species.31 The finding 
that partially hydrolyzed species and in particular poly-oxo products are taken up to 
a higher extent than freshly dissolved NAMI-A by metastatic tumor cells in vitro 
with maintained effects on the cell cycle have prompted investigators to attribute the 
activity of NAMI-A to hydrolysis products. 
In serum, NAMI-A binds to proteins such as albumin and transferrin to a high ex-
tent. Reactivity with albumin is increased upon reduction of the complex. However, 
in vitro and in vivo experiments employing both albumin- and transferrin-bound 
NAMI-A in comparison for pure NAMI-A argue against a tumor-targeting effect of 
binding to these proteins rather than for deactivation.32,33 
  
N
NH
Ru
Cl
Cl Cl
Cl
N
NH
H
N
HNS
Ru
Cl
Cl Cl
Cl
N
NH
HN
H
N
O
 
Figure 5. Ruthenium antitumor complexes: NAMI-A (left), KP1019 (right). 
 
1.4.2.2 KP1019 
Another ruthenium(III) drug candidate currently in clinical trials is KP1019, 
HInd[trans-RuCl4(Ind)2] (Ind = indazole). In order to increase the solubility of 
KP1019, its corresponding sodium salt Na [trans-[RuCl4(Ind)2] has also been pre-
pared and biologically evaluated for its anticancer activity. Both in vitro and in vivo 
                                                 
31
 Alessio, Enzo; Mestroni, Giovanni; Bergamo, Alberta; Sava, Gianni, Current Topics in Medicinal 
Chemistry, 2004, 4, 1525-1535. 
32
 Bergamo, A.; Sava, G., Dalton Transactions  (2007),   (13),  1267-1272. 
33
 Dyson, Paul J.; Sava, Gianni, Dalton Transactions  (2006),   (16),  1929-1933. 
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experiments with KP1019 have shown high anti-proliferative activity in human co-
lon carcinoma cell lines and tumor models. Protein-binding studies have been per-
formed and it was shown that KP1019 interacts with serum proteins especially with 
albumin and transferrin. For the latter binding preference toward the histidine resi-
dues in the iron-binding site was determined with lactoferrin as model protein.34 A 
comparison of DNA binding studies of KP1019 and cisplatin showed that KP1019 is 
capable of binding to DNA irreversibly by affecting its conformation in a different 
mode than that of cisplatin.35  
1.4.3 Metal-Arene Compounds as Anticancer Agents  
In recent years, Ru(arene) compounds have become a focus of interest due to their 
applications in medicine. Different approaches have been explored in this regard 
including Ru(arene) complexes with P- or N- donor ligands or N,N-, N,O- or O,O-
chelating ligands, dinuclear complexes, oxo caped trinuclear clusters, photoactive 
tetranuclear porphyrin derivatives, hexanuclear cages or attaching bioactive  mole-
cules such as paullone derivatives to the arene ruthenium unit.36,37 The first or-
ganometallic ruthenium compound tested for anticancer activity was [Ru(η6-
C6H6)Cl2(metronidazole)] (metronidazole = 1-β-hydroxyethyl-2-methyl-5-
nitroimidazole). The metronidazole ligand itself is used for the treatment of infec-
tions and marketed under the tradename Flagyl®. When bound to ruthenium, it ex-
hibited more selective cytotoxicity than metronidazole itself under hypoxic reducing 
conditions.38 The two best investigated examples of this class are RAPTA 
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[RuII(arene)(pta)Cl2] (pta = 1,3,5-triaza-7-phoshatricyclo-[3.3.1.1]decane) and 
[RuII(arene)(en)Cl]+ (en=1,2-diaminoethane) compounds. 
1.4.3.1 Monofunctional M(II)-arene complexes 
Sadler and coworkers found that Ru(II)-arene complexes of general formula [(η6- 
arene)Ru(X)(Y)(Z)]  where X is a leaving group such as Cl-, and YZ is a chelating 
diamine such as ethylenediamine (en), are cytotoxic to cancer cells, including cis-
platin-resistant cell lines.39,40,41 It has been shown that cytotoxicity increases with the 
size of the arene ligand. The complexes with more hydrophobic arenes like tetrahy-
droanthracene are much more cytotoxic than those having the less hydrophobic ben-
zene ligand. The cytotoxicity increases in the following order benzene < cymene < 
biphenyl < dihydroanthracene < tetrahydroanthracene. It has been found that the 
presence of a hydrophobic arene, a single ligand exchange site and the other two 
coordination sites being occupied by a stable bidentate chelating ligand are associ-
ated with high cytotoxicity for Ru(arene) compounds.42 These complexes are acti-
vated by the formation of reactive aqua complexes [(η6-arene)Ru(en)(H2O)]2+ by 
exchange of the chlorido ligand with water. This active species has shown reactivity 
with DNA models.  Under physiologically-relevant conditions in the bloodstream 
([Cl−] ca. 100 mM), Ru(arene) complexes should remain largely in the form of the 
less-reactive chlorido complexes, whereas in the cell nucleus at chloride concentra-
tions of ca. 4 mM significant amounts of the more reactive aqua species are formed. 
Deprotonation of the coordinated aqua ligand of [(η6-arene)Ru(en)(H2O)]2+ gives 
hydroxido complexes [(η6-arene)Ru(en)(OH)]+.43 A number of neutral Ru(arene) 
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complexes bearing N,O- or O,O-chelating ligands has also been investigated. These 
compounds show low activity as compared to complexes with N,N-chelating ligands 
and were also less stable and form hydroxido-bridged dimers in aqueous solu-
tion.44,45,46  
Recently, Os(arene) complexes have demonstrated potential for the design of anti-
cancer drugs. Influence on the ligand systems such N,N-,  N,O- and O,O-chelating 
moieties have been investigated  for their tumor inhibiting properties. Interestingly, 
[(η6-biphenyl)Os(en)Cl]+ exhibits promising anticancer activity against the human 
ovarian cancer A2780 cell line (IC50 9 µM),47 although it hydrolyzes about 40 times 
slower than the RuII analogue. A switch from a neutral N,N-chelating (ethylenedia-
mine, en) to an anionic O,O-chelating ligand (acetylacetonate, acac) has a remark-
able effect on both the extent and rate of hydrolysis. The hydrolysis rate of [(η6-
arene)Os(acac)Cl] is too fast to be monitored by NMR spectroscopy at 298 K and 
aqua species are immediately converted into the hydroxido-bridged dimer, [(η6-
arene)Os(µ2-OH)3Os(η6-arene)]+, with the release of the acac ligand. This hy-
droxido-bridged dimeric species is present predominantly at micromolar concentra-
tions in solutions used in biological cell culture tests.48     
Os(arene) complexes with anionic O,O-chelating ligands such as maltolato also hy-
drolyze and bind to purine nucleobases rapidly. The hydrolytic stability of these 
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Os(arene) complexes is increased by the presence of a five-membered maltolato 
chelate ring, compared to the acac analogues. 
 
Figure 6. General structures of half-sandwich, piano-stool configurated Ru(arene) com-
plexes.41  
 
However, they are still deactivated to a significant extent due to the formation of 
hydroxido-bridged dimers at biologically relevant (micromolar) concentrations. Ow-
ing to the unstability of the aqua complex which leads to the formation of hy-
droxido-bridged adducts, compounds containing O,O-chelators such as maltolato or 
acetylacetonato are biologically inactive toward human ovarian (A2780) and human 
lung (A549) cancer cell lines.49 
However, Os(arene) complexes containing anionic N,O-chelators such as picolinate 
(pico) exhibit rates of hydrolysis intermediate between those of the neutral N,N- and 
anionic O,O-chelated compounds. These are stable in aqueous solution at micromo-
lar concentrations and some of them display promising activity toward a human 
ovarian cancer cell line with IC50 values (4.5 µM) similar to that of carboplatin.50,51 It 
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is obvious from these studies that both the kinetics and thermodynamics have sig-
nificant impact on the biological activity of these complexes. These factors can be 
controlled by choice and design of ligands for the optimization of anticancer activity 
of Os(arene) compounds.52,  
Ru
H2N
NH2
Cl
Arene
benzene biphenyl p-cymene
dihydroanthracene tetrahydroanthracene
Arene
 
Figure 7. Ru(II) arene complexes with various arene ligands 
 
1.4.3.2 Bifunctional M(II)-arene complexes 
RAPTA is a class of anticancer active organometallic M(arene) complexes with one 
(or two) monodentate 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (pta) ligand, 
chlorido ligand(s) and a η6-arene moiety (Fig. 8).53,54,55,56 RAPTA complexes un-
dergo hydrolysis of the chloride ligands in aqueous solution. The extent of the hy-
drolysis depends on the concentration of the complex in solution, the amount of 
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chloride present and the pH. Hydrolysis was found to be suppressed in the blood 
plasma with its high chloride concentration (ca. 100 mM), but occurs once the com-
pound penetrates into the cell cytoplasm. This represents a possible activation path-
way for the compound.57  
The reaction with DNA under in vitro conditions is pH dependent: at pH < 7, which 
is characteristic of poorly oxygen-supplied cancer cells, DNA is damaged, whereas 
normal cells with pH > 7 are not affected. Such behavior was attributed to the ba-
sicity of the pta ligand and the protonation of pta-N.58 The reaction of RAPTA-C 
with model oligonucleotides and proteins results in adducts under loss of chlorides 
and in some cases of the arene ring.58 The arene ligand appears to be more labile 
than the pta ligand, an observation supported by calculations. However, in vitro 
studies have shown that proteins and RNAs are more probable targets than DNA.57 
Similar to NAMI-A,  RAPTA-C exhibited very low in vitro activity on primary tu-
mors, however, excellent inhibition of lung metastases in CBA mice bearing MCa 
mammary carcinoma. RAPTA-C was shown to reduce the weight and number of the 
metastases,58 at low general toxicity combined with excellent clearance rates. In fact, 
RAPTA-C resulted in 40% of the animals being completely free of metastasis after 
treatment and in general only drug combination therapies showed better cure rates.59  
 
Figure 8. RAPTA complexes with various arene ligands 
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 In order to improve their efficacy, a number of structural modifications have been 
made to the basic RAPTA framework such as introduction of H-bonding functiona-
lities,60 change of the arene ligand61 or the leaving group62 and tethering to bioactive 
segments such as ethacrynic acid63 or human serum albumin,64 the latter resulted in a 
twenty-fold increase in cytotoxicity with respect to prototype RAPTA-C.  
 
1.5 Linking biological molecules to an organometallic motif 
To achieve tumor specificity is an important goal in drug design. Specificity means 
that drugs should ideally target the tissue or organ for which it is designed. One very 
promising approach is to conjugate drugs with biomolecules or antibodies. These 
biomolecules, often called vectors can be essential nutrients for cells (sugars and 
amino acid) or cofactors (e.g., vitamin B12).65 This strategy has already been suc-
cessfully used to incorporate an organometallic motif into biologically active mole-
cules such as tamoxifen,66,67,68 or staurosporine.69,70,71 The resulting conjugates have 
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enhanced activity than parent compounds. The metal ion in these bioorganometallic 
compounds has either a structural or a functional role, important for biological activ-
ity (Fig. 9).  
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Figure 9.  Biocojugates of staurosporine (DW1/2) and tamoxifen (ferrocifen) with or-
ganometallic moiety. 
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2. Results 
2.1. Designing carbohydrate-based anticancer drugs  
Carbohydrates are fundamental biomolecules and are the constitutional parts of 
many lipids (glycolipids), proteins (glycoprotein), nucleic acids and ADP/ATP (en-
ergy storage system). Sugars perform a range of (bio)chemical and cellular functions 
in living organisms such as modification of many proteins and fats on cell surfaces, 
participation in immunity and cell to cell communication, etc.72 Moreover, carbohy-
drates play critical roles in diseases from viral infections to cancer and, therefore, 
they have been increasingly targeted for design and development of new medicines. 
In recent years, modified carbohydrates and their specific glycoconjugates have not 
only been targeted for effective vaccines for viral, bacterial and parasitic infections 
as well as cancer but have also been developed as adjuvants and drug delivery sys-
tems. Furthermore, modified carbohydrate structures can interfere with carbohy-
drate-protein interactions, and subsequently inhibit cell-cell recognition and adhe-
sion processes, both of which play a critical role in tumor growth and progression.73  
 
2.1.1 Tumor-induced alterations in carbohydrate metabolism 
Tumor cells exhibit a number of distinct biophysical properties which distinguish 
them from normal cells. Alterations of carbohydrate metabolism, structures and their 
organization are a hallmark of the tumor cells. These features can be potentially ex-
ploited to design drugs which can selectively target the tumor cell.   
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2.1.2. Switch in energy supply and increased glucose uptake 
Healthy cells generate their energy in the form of ATP by glycolysis in the cyto-
plasm and oxidative phosphorylation in mitochondria. In glycolysis, one molecule 
of glucose is converted into two molecules of pyruvate with the production of two 
ATP in a sequence of reactions. Pyruvate then is converted into acetyl co-enzyme A 
that enters into citric acid cycle to produce NADH and FADH2 which upon oxida-
tion in the respiratory chain results in 36 ATP per 1 molecule glucose (oxidative 
phosphorylation, Fig. 10).  Therefore a single glucose molecule is converted into a 
total of about 38 mol of ATP (2 during glycolysis and 36 from oxidative phosphory-
lation). As tumor tissues are often under hypoxia due to rapid tumor growth and 
insufficient vascularization, oxidative phosphorylation does not remain functional to 
the same extent and cancer cells have to rely on glycolysis for their energy. Conse-
quently, in order to meet the increasing energy demand, cancer cells must upregulate 
glycolytic activity.74  This results in upregulation of certain metabolic enzymes and 
glucose transporters and eventually, to increased glucose uptake.75  This physiologi-
cal difference has been exploited in the development of an oncological imaging tool, 
namely 18fluorodeoxyglucose positron emission tomography (FdG PET). FdG is 
injected intravenously and is ingested by the cells but cannot be metabolized (Fig. 
11). This leads to an increased intracellular accumulation of the radio labeled glu-
cose analogue in cancer cells and hence, a higher local radioactivity.76,77  
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Figure . 10 Glucose metabolism in healthy cell and generation of ATP.75 
 
2.1.3 Manipulation of tumor cell metabolism for therapeutic pur-
poses 
Alterations in tumor micro-environments, offers many possibilities to design drugs 
that can selectively target tumor tissue. Many approaches such as designing glycoly-
sis inhibitors, linking drugs to carbohyderates and glycosylation have been investi-
gated to exploit these alterations in tumor micro-environments. The following two 
strategies are described briefly.  
2.1.3.1 Designing glycolysis inhibitors 
Due to increased energy demand, cancer cells are much more sensitive to lack of 
glucose than normal cells. Therefore, the absence of glucose in cancer cells results 
in cellular stress subsequently followed by cell death.78 The tumor growth can be 
suppressed by modified glucose derivatives that can inhibit glycolysis by interfering 
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with involved enzymes, depriving the cancer cells from its energy supply.79 One 
example of a glycolysis inhibitor is 2-deoxyglucose, being in phase I clinical trials 
(Fig. 12). 80,81 Preliminary in vivo and in vitro studies showed that 2-deoxyglucose 
can induce apoptosis in cancer cells.82  
 
 
 
Figure 11. Comparison of metabolism of 18FdG and glucose, 18FdG is ingested by the cell 
but cannot be metabolized because 18FdG-6-P (= 18fluorodeoxyglucose-6-phosphate) is not a 
substrate for glycolysis. 
 
2.1.3.2 Linking carbohydrates to drugs  
Another approach is to link carbohydrates with drugs in order to enhance the cellular 
uptake. Since a tumor cell has high desire for glucose, the drug may be preferentially 
transported into cancer cells as compared to normal cells.  Inside cells, the active 
drug component is released by cleavage of the linker between glucose and the drug. 
This strategy had already been used for ifosfamide-mustard, a known cytotoxic alky-
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lating compound. The glucose conjugate of ifosfamide is called glufosfamide (Fig. 
12)  that entered clinical trials phase III as drug candidate for second line treatment 
of pancreatic cancer but failed in February 2007 due to insignificant increase of the 
overall survival time.  The same drug is currently undergoing phase I and II clinical 
trials as a first-line treatment of pancreatic cancer.80,81  
 
 
Figure 12. Structures of 2-deoxyglucose and glufosfamide. 
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The synthesis and in vitro anticancer activity of OsII–arene complexes with carbohydrate-derived
phosphite co-ligands are reported. The compounds were characterized by standard methods and the
molecular structure of dichlorido(h6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-
glucofuranoside)osmium(II) was determined by X-ray diffraction analysis. Complexes with chlorido
leaving groups undergo hydrolysis by consecutive formation of aqua compounds, followed by cleavage
of a P–O bond of sugar phosphite ligands, as demonstrated by NMR studies. These observations are
similar to those of analogous RuII–arene complexes; however the rate of hydrolysis is very slow for
osmium compounds. The complexes with oxalato leaving groups resist hydrolysis; no hydrolytic species
were detected by 31P{1H} NMR spectroscopy over several days. Within this series of Os compounds, in
vitro anticancer activity is highest for the most lipophilic chlorido complex dichlorido(h6-p-
cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-a-D-glucofuranoside)osmium(II).
Introduction
The limitations of current metal-based chemotherapeutics have
prompted a search for novel antitumor drugs with improved
effectiveness and fewer side effects.1–3 Thousands of novel platinum
and non-platinum compounds have been synthesized and evalu-
ated for their antitumor properties.4 Among the tested transition
metal compounds, ruthenium compounds have shown consider-
able potential as anticancer drugs.5-7 Ruthenium compounds are
usually less toxic than cisplatin and are therefore better tolerated in
vivo. In animal models, ruthenium compounds are effective in the
treatment of cancer types which cannot be treated by platinum-
based compounds, most probably due to a different mode of
action. Two ruthenium(III)-based drugs, KP1019 and NAMI-
A (Fig. 1), have successfully completed phase I clinical trials.6,8
Both ruthenium(III) compounds differ considerably from cisplatin
in their in vivo behaviour; NAMI-A strongly inhibits metastasis
without effects on the primary tumour,whereasKP1019 effectively
reduces colorectal tumours in which cisplatin is inactive.
Recently, half-sandwich organometallic Ru(II)–arene complexes
of the general formula [(h6-arene)Ru(X)(Y)(Z)] have attracted
great attention as putative anticancer drugs, where X is a
monodentately boundmoiety, often a leaving group (e.g. chloride),
and Y and Z are bidentate chelating or two monodentate ligands,
resulting in neutral or positively charged complexes (the latter of-
aUniversity of Vienna, Institute of Inorganic Chemistry, Waehringer Str.
42, A-1090, Vienna, Austria. E-mail: christian.hartinger@univie.ac.at,
alex.nazarov@univie.ac.at; Fax:+43-1-4277-52680;Tel:+43-1-4277-52609
bInstitut des Sciences et Inge´nierie Chimiques, Ecole Polytechnique Fe´de´rale
de Lausanne (EPFL), CH-1015, Lausanne, Switzerland
cUniversity of Vienna, Research Platform “Translational Cancer Therapy
Research”, Waehringer Str. 42, A-1090, Vienna, Austria
† CCDC reference number 766305. For crystallographic data in CIF or
other electronic format see DOI: 10.1039/c003085f
‡Dedicated to Prof. Tama´s Kiss on the occasion of his 60th birthday.
Fig. 1 Ruthenium compounds evaluated in clinical trials (KP1019,
NAMI-A), and Ru–arene complexes and their Os analogues with bio-
logical activity (M = Ru, Os).
ten with Cl-, BF4-, PF6-, etc. as counter ions). Various approaches
have been investigated in this regard including coordination
of ethylenediamine (en),9,10 paullone derivatives,11 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane (pta),12 pyr(id)ones13–15 or per se
bioactive groups, such as staurosporine derivatives,16 to the metal
centre. These water-soluble ruthenium–arene complexes offer a
This journal is © The Royal Society of Chemistry 2010 Dalton Trans., 2010, 39, 7345–7352 | 7345
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
t W
ie
n 
on
 1
9 
O
ct
ob
er
 2
01
0
Pu
bl
ish
ed
 o
n 
02
 Ju
ly
 2
01
0 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C0
030
85F
View Online
30
potential to ﬁne-tune the lipophilicity of the molecule, which is an
important parameter for drug development. For example, Ru(II)
complexes of the type [(h6-arene)Ru(en)X]+ (X = halide) exhibit
high cytotoxicity in vitro comparable or, in some cases, superior
to that of cisplatin.17,18 On the other hand, RAPTA complexes
of the type [(h6-arene)Ru(pta)Cl] exhibit selective cytotoxicity
towards the TS/A tumourigenic cell line as opposed to the HBL-
100 non-tumourigenic cell line, and notably in vivo some of the
compounds reduce signiﬁcantly the growth of lung metastases
in CBA mice bearing MCa mammary carcinoma.12 Other Ru–
arene complexes target kinases or other proteins, some of them
being very inert.11,16,19 Osmium analogues of many of these half-
sandwich organometallic complexes have been synthesized and
shown to inhibit cancer cell growth in vitro, in some cases
with potencies comparable to the clinical drugs carboplatin and
cisplatin.11,13,16,20–23 There are no clear-cut structure–activity rela-
tionships allowing to predict the effect of exchanging ruthenium
for osmium in anticancer compounds: as observed by Sadler et al.
the Os compounds can be more active than their Ru analogues,21
whereas in other cases no difference was observed,11,16 probably
due to an exclusively structural function of the metal centre.16
In this paper we describe the inﬂuence of the metal cen-
tre (Ru vs. Os) on hydrolysis and cytotoxicity of a series of
carbohydrate–metal complexes. With the intention to target Ru–
arene compounds selectively to the tumour micro-environment,24
we have linked such metal moieties to glucose-derived ligands
via a phosphorus atom, resulting in RAPTA-C analogues with
increased in vitro activity.25 Glucose uptake is increased in cancer
cells due to upregulation of glycolysis and glucose transporters.26
This property is being exploited for the visualization of tumours by
using the glucose analogue tracer 18ﬂuorodeoxyglucose in positron
emission tomography (FdG-PET).26 As far as we are aware, these
are the ﬁrst examples of osmium compounds with carbohydrate-
based ligands, and in addition to their synthesis, their solid state
structures, behaviour in aqueous solution and cytotoxicity in
cancer cells are discussed.
Experimental
Materials
All reactions were carried out in dry solvents under an inert
atmosphere. All chemicals were obtained from commercial
suppliers and used as received and were of analytical grade.
OsO4 (99.8%) and N2H4·2HCl were purchased from Johnson
Matthey and Fluka, respectively. Methanol and CH2Cl2 were
dried using standard procedures. The dimer bis[dichlorido(h6-
p-cymene)osmium(II)] [(h6-p-cymene)OsCl(m-Cl)]2 a,27 3,5,6-
bicyclophosphite-1,2-O-isopropylidene-a-D-glucofuranoside 1
and 3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-a-D-gluco-
furanoside 228 and disilver oxalate29 were synthesized using
literature procedures. 1H, 13C{1H} and 31P{1H} NMR spectra
were recorded at 25 ◦C on a Bruker FT NMR spectrometer
Avance III 500 MHz at 500.10 (1H), 125.75 (13C{1H}) and
202.44 MHz (31P{1H}). 2D NMR spectra were collected in
a gradient-enhanced mode. Speciﬁc optical rotations were
determined on a Perkin-Elmer 341 polarimeter in a 10 cm cell at
20 ◦C. Melting points were measured on a Bu¨chi B-540 apparatus
and are uncorrected. Elemental analysis was determined by
Table 1 Crystal data and details of data collection for 3†
Compound 3
Chemical formula C19H23.70Cl2O6.35Os P
M/g mol-1 645.75
T/K 100(2)
Crystal size/mm 0.30 ¥ 0.30 ¥ 0.20
Crystal colour, habit Orange, block
Crystal system Orthorhombic
Space group P212121
a/A˚ 8.7180(4)
b/A˚ 14.8768(7)
c/A˚ 17.0012(8)
V/A˚3 2204.99(18)
Z 4
Dc/g cm-3 1.945
m/cm-1 6.133
F(000) 1254
H range for data collection/◦ 2.71 to 30.09
h range -12/12
k range -20/20
l range -23/23
No. reﬂs. used in reﬁnement 6470
No. parameters 269
Rint 0.075
R1 (obs.) 0.0240
wR2 (all data) 0.0505
Flack parameter -0.010(4)
S 1.011
Reﬁnement was by full-matrix least-squares (F o2) for all reﬂections,
R1 =
∑‖F o| - |F c‖/
∑
w|F o|, wR2 = [
∑
(F o2 - F c2)2/
∑
wF o4]1/2, w =
1/[(s 2(F o2) + (0.0173P)2 + 5.64P, with P = {[F o2 + 2F c2)/3}. Goodness
of ﬁt, S =∑[(Fo2 - F c2)2]/(n - p)1/2.
the Laboratory for Elemental Analysis, Faculty of Chemistry,
University of Vienna, on a Perkin-Elmer 2400 CHN Elemental
Analyzer. Electrospray ionization mass spectra were recorded on
a Bruker esquire3000.
X-Ray diffraction measurements of 3 were performed on a
Bruker X8APEXII CCDdiffractometer at 100K. The crystal was
positioned at 35 mm from the detector and 1522 frames for 5 s
over 1◦ were measured. The data were processed using the SAINT
software package.30 Crystal data, data collection parameters, and
structure reﬁnement details are given in Table 1.
The structure was solved by direct methods and reﬁned by
full-matrix least-squares techniques. Non-hydrogen atoms were
reﬁned with anisotropic displacement parameters. H atoms were
inserted at calculated positions and reﬁned with a riding model.
The following computer programs were used: structure solution,
SHELXS-97;31 reﬁnement, SHELXL-97;32 molecular diagrams,
ORTEP-3;33 computer, Pentium IV; scattering factors.34
Dichlorido(g6 -p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopro-
pylidene-a-D-glucofuranoside)osmium(II) (3). A solution of
bis[dichlorido(h6-p-cymene)osmium(II)] a (79 mg, 0.1 mmol)
in dry CH2Cl2 (5 mL) was added to a solution of 3,
5,6-bicyclophosphite-1,2-O-isopropylidene-a-D-glucofuranoside
(50 mg, 0.2 mmol) in dry CH2Cl2 (15 mL). The reaction mixture
was stirred at 40 ◦C for 2 h. The solvent was reduced to ca. 5 mL
and the product was precipitated by the addition of pentane (ca.
20 mL). The solid was ﬁltered, washed with pentane (3 ¥ 2 mL)
and dried under vacuum. Crystals suitable for X-ray diffraction
studies were grown from D2O in the NMR tube.
7346 | Dalton Trans., 2010, 39, 7345–7352 This journal is © The Royal Society of Chemistry 2010
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Yield: 126 mg (98%), m.p. 186–187 ◦C (decomp.), Elemental
analysis, found% C, 35.02; H, 4.14; calcd. for C19H27Cl2O6POs·
0.15CH2Cl2, C, 35.05; H, 4.19. MS (ESI+): m/z: 667.0 [M + Na]+,
1309.7 [2M + Na]+; [a]20D = 6 (c 0.25, CH2Cl2).
1HNMR (500.10MHz, CDCl3, 25 ◦C): d = 6.13 (d, J = 3.5 Hz,
1 H, H-1), 5.75 (d, J = 6.0 Hz, 1 H, H-Ar), 5.60 (d, J = 8.2 Hz,
2 H, H-Ar), 5.59 (d, J = 8.2 Hz, 2 H, H-Ar), 5.04 (m, 1 H, H-5),
4.78 (d, J = 2.0 Hz, 1 H, H-3), 4.67 (d, J = 3.5 Hz, 1 H, H-2), 4.45
(dd, J = 9.4, 11.8 Hz, 1 H, H-6), 4.32 (m, 2 H, H-6¢, H-4), 2.86 (m,
1 H, CH(CH3)2), 2.33 (s, 3 H, CH3), 1.51 (s, 3 H, C(CH3)2), 1.36
(s, 3 H, C(CH3)2), 1.28 (d, J = 6.9 Hz, 6H, CH(CH3)2). 13C{1H}
NMR (125.75 MHz, CDCl3, 25 ◦C): d = 112.6 (C(CH3)2), 105.7
(C-1), 102.5 (C-Ar), 100.6 (C-Ar), 83.6 (J = 7.3 Hz, C-2), 82.0
(C-Ar), 81.8 (C-Ar), 81.4 (C-Ar), 78.6 (J = 8.2 Hz, C-3), 76.7 (J =
5.5 Hz, C-4), 74.5 (J = 4.5 Hz, C-5), 69.6 (J = 8.2 Hz, C-6), 30.8
(CH(CH3)2), 26.9 (C(CH3)2), 26.2 (C(CH3)2), 22.4 (CH(CH3)2),
22.4 (CH(CH3)2), 18.4 (CH3) ppm. 31P{1H} NMR (202.44 MHz,
CDCl3, 25 ◦C): d = 87.3 ppm.
Dichlorido(g6 -p-cymene)(3,5,6-bicyclophosphite-1,2-O -cyclo-
hexylidene-a-D-glucofuranoside)osmium(II) (4). A solution of
bis[dichlorido(h6-p-cymene)osmium(II)] a (79 mg, 0.1 mmol) in
dry CH2Cl2 (5 mL) was added to a solution of 3,5,6-bicyclo-
phosphite-1,2-O-cyclohexylidene-a-D-glucofuranoside (58 mg,
0.2 mmol) in dry CH2Cl2 (15 mL). The mixture was stirred at
40 ◦C for 2 h. The solvent was then reduced to ca. 5 mL and the
compound was precipitated as yellow powder by the addition of
pentane (ca. 20 mL). The solid was ﬁltered, washed with pentane
(3 ¥ 2 mL) and dried under vacuum.
Yield: 135 mg (98%), m.p. 159–161 ◦C (decomp.), Elemental
analysis, found% C, 37.48; H, 4.42; calcd. for C22H31Cl2O6POs·
0.15CH2Cl2, C, 37.22; H, 4.44. MS (ESI+): m/z: 649.0 [M - 2
H2O + H]+, 705.0 [M + Na]+; [a]20D = 12 (c 0.25, CH2Cl2).
1HNMR (500.10MHz, CDCl3, 25 ◦C): d = 6.13 (d, J = 3.8 Hz,
1 H, H-1), 5.75 (d, J = 6.0 Hz, 1 H, H-Ar), 5.60 (d, J = 8.2 Hz,
1 H, H-Ar), 5.58 (d, J = 8.2 Hz, 2 H, H-Ar), 5.03 (m, 1 H, H-5),
4.79 (d, J = 2.5 Hz, 1 H, H-3), 4.67 (d, J = 3.5 Hz, 1 H, H-2), 4.45
(dd, J = 7.0, 11.8 Hz, 1 H, H-6), 4.32 (m, 2 H, H-6¢, H-4), 2.86
(m, 1 H, CH(CH3)2), 2.33 (s, 3 H,CH3), 1.68 (m, 4 H, C6H10), 1.56
(m, 6 H, C6H10), 1.28 (d, J = 6.9 Hz, 6H, CH(CH3)2). 13C{1H}
NMR (125.75 MHz, CDCl3, 25 ◦C): d = 113.3 (C(CH3)2), 105.3
(C-1), 102.5 (C-Ar), 100.7 (C-Ar), 83.2 (J = 6.4 Hz, C-2), 82.0
(C-Ar), 81.6 (C-Ar), 81.4 (C-Ar), 78.8 (J = 8.2 Hz, C-3), 76.6
(J = 5.5 Hz, C-4), 74.5 (J = 4.5 Hz, C-5), 69.4 (J = 9.1 Hz, C-6),
36.5 (C6H10), 35.7 (C6H10), 30.8 (CH(CH3)2), 24.8 (C6H10), 23.8
(C6H10), 23.5 (C6H10), 22.4 (CH(CH3)2), 22.4 (CH(CH3)2), 18.4
(CH3) ppm. 31P{1H} NMR (202.44 MHz, CDCl3, 25 ◦C): d =
87.3 ppm.
Oxalato(g6 -p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropy-
lidene-a-D-glucofuranoside)osmium(II) (5). [(h6-Cymene)OsCl(m-
Cl)]2 (158 mg, 0.2 mmol) and silver oxalate (133 mg, 0.44 mmol)
were stirred in distilled water (25 mL) for 12 h. The mixture was
ﬁltered through a bed of Celite to remove the AgCl precipitate.
The solvent was removed under vacuum, and the residue was
redissolved in methanol (25 mL) and 3,5,6-bicyclophosphite-
1,2-O-isopropylidene-a-D-glucofuranose (100 mg, 0.4 mmol) was
added. The reaction mixture was stirred for 2 h, the volume of the
solvent was reduced to ca. 5 mL and diethyl ether (25 mL) was
added. The slurry was cooled to 4 ◦C for 12 h to complete the
precipitation. The yellow crystalline product was ﬁltered, washed
with diethyl ether (2 ¥ 5 mL) and dried under vacuum.
Yield: 195 mg (74%), m.p. 190–192 ◦C (decomp.), Elemental
analysis, found% C, 37.14; H, 3.98; calcd. for C21H27O10POs·
0.75H2O, C, 37.41; H, 4.26., MS (ESI+): m/z: 683 [M + Na]+;
[a]20D = -2 (c 0.25, CH2Cl2).
1HNMR (500.10MHz, CDCl3, 25 ◦C): d = 6.06 (d, J = 3.5 Hz,
1H; H-1), 5.97 (d, J = 4.7 Hz, 1H; H-Ar), 5.94 (d, J = 5.0 Hz, 1H;
H-Ar), 5.80 (d, J = 4.7 Hz, 2H; H-Ar), 5.10 (m, 1H; H-5), 4.71
(brs, 1H; H-3), 4.63 (d, J = 3.2 Hz, 1H; H-2), 4.52 (m, 1H; H-6),
4.40 (s, 1H;H-4), 4.35 (m, 1H;H-6¢), 2.76 (m, 1H;CH(CH3)2), 2.29
(s, 3H; CH3), 1.48 (s, 3H; C(CH3)2), 1.31 (s, 3H; C(CH3)2), 1.29 (d,
J = 6.6 Hz, 3H; CH(CH3)2), 1.28 (d, J = 6.7 Hz, 3H; CH(CH3)2)
ppm; 13C{1H} NMR (125.75 MHz, CDCl3, 25 ◦C): d = 165.1
(J = 6.0 Hz; C=O), 112.7 (C(CH3)2), 105.7 (C-1), 102.7 (C-Ar),
99.1 (C-Ar), 83.6 (J = 6.1 Hz; C-2), 81.5 (C-Ar), 80.9 (C-Ar),
80.1 (C-Ar), 78.5 (J = 7.8 Hz; C-3), 76.7 (J = 10.1 Hz; C-4), 74.6
(J = 3.8 Hz; C-5), 69.5 (J = 7.1 Hz; C-6), 31.2 (CH(CH3)2), 26.9
(C(CH3)2), 26.2 (C(CH3)2), 22.7 (CH(CH3)2), 22.6 (CH(CH3)2),
18.2 (CH3) ppm; 31P{1H} NMR (202.44 MHz, CDCl3, 25 ◦C):
d = 94.7 ppm.
Oxalato(g6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexy-
lidene-a-D-glucofuranoside)osmium(II) (6). [(h6-Cymene)OsCl(m-
Cl)]2 (158 mg, 0.2 mmol) and silver oxalate (133 mg, 0.44 mmol)
were stirred in distilled water (25 mL) for 12 h. The mixture
was ﬁltered through a bed of Celite to remove the AgCl pre-
cipitate. The solvent was removed under vacuum, the residue was
redissolved in methanol (25 mL) and 3,5,6-bicyclophosphite-1,2-
O-cyclohexylidene-a-D-glucofuranose (115 mg, 0.4 mmol) was
added. The reaction mixture was stirred for 2 h, the volume of
the solvent was reduced to ca. 5 mL and diethyl ether (25 mL)
was added. The slurry was cooled to 4 ◦C for 12 h to complete
the precipitation. The yellow crystalline product was ﬁltered off,
washed with diethyl ether (2 ¥ 5 mL) and dried under vacuum.
Yield: 213 mg, (76%), m.p. 183–184 ◦C (decomp.), El-
emental analysis, found% C, 40.12; H, 4.27; calcd. for
C24H31O10POs·0.75H2O, C, 40.36; H, 4.59; MS (ESI+): m/z: 725
[M + Na]+; [a]20D = 4 (c 0.25, CH2Cl2). 1H NMR (500.10 MHz,
CDCl3, 25 ◦C): d = 6.07 (d, J = 3.2 Hz, 1 H, H-1), 5.94 (brs, 1
H, H-Ar), 5.78 (brs, 1 H, H-Ar), 5.58 (brs, 2 H, H-Ar), 5.08 (m,
1 H, H-5), 4.71 (brs, 1 H, H-3), 4.62 (d, J = 3.2 Hz, 1 H, H-2),
4.49 (m, 1 H, H-6), 4.38 (m, 1 H, H-4), 4.32 (m, 1 H, H-6¢), 2.76
(m, 1 H, CH(CH3)2), 2.29 (s, 3 H,CH3), 1.65 (m, 4 H, C6H10), 1.53
(m, 6 H, C6H10), 1.29 (d, J = 6.4 Hz, 3 H, CH(CH3)2), 1.28 (d,
J = 6.5 Hz, 3H, CH(CH3)2) ppm; 13C{1H} NMR (125.75 MHz,
CDCl3, 25 ◦C): d = 165.0 (J = 6.0 Hz; C=O), 113.4 (C(CH3)2),
105.3 (C-1), 102.7 (C-Ar), 99.1 (C-Ar), 83.1 (J = 6.1 Hz; C-2),
81.5 (C-Ar), 80.9 (C-Ar), 80.1 (C-Ar), 78.7 (J = 7.8 Hz; C-3), 76.7
(J = 10.1 Hz; C-4), 74.7 (J = 3.8 Hz; C-5), 69.6 (J = 7.1 Hz; C-6),
36.5 (C6H10), 35.6 (C6H10), 31.2 (CH(CH3)2), 24.7 (C6H10), 23.8
(C6H10), 23.5 (C6H10), 22.7 (CH(CH3)2-Ar), 22.6 (CH(CH3)2-Ar),
18.2 (CH3-Ar) ppm; 31P{1H}NMR (202.44 MHz, CDCl3, 25 ◦C):
d = 94.6 ppm.
Hydrolysis and reactivity with 5¢-GMP
For hydrolysis studies, the compounds were dissolved in D2O
and the samples were analyzed by 31P{1H} NMR spectroscopy
once a day for 5 days. The 31P{1H} NMR spectra for the kinetic
This journal is © The Royal Society of Chemistry 2010 Dalton Trans., 2010, 39, 7345–7352 | 7347
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experiments were recorded on a Bruker Avance 400 instrument at
161.98 MHz. For GMP binding experiments, the complexes were
mixed at molar ratios of 1 : 2 (complex :GMP) in D2O and kept at
room temperature for 2 days.
Cytotoxicity in cancer cell lines
Cell lines and culture conditions. CH1 cells originate from an
ascites sample of a patient with a papillary cystadenocarcinoma
of the ovary and were a generous gift from Lloyd R. Kel-
land, CRC Centre for Cancer Therapeutics, Institute of Cancer
Research, Sutton, UK. SW480 (adenocarcinoma of the colon,
human), and A549 (non-small cell lung cancer, human) cells
were kindly provided by Brigitte Marian (Institute of Cancer
Research, Department of Medicine I, Medical University of
Vienna, Austria). All cell culture reagents were obtained from
Sigma-Aldrich Austria. Cells were grown in 75 cm2 culture ﬂasks
(Iwaki) as adherent monolayer cultures in Eagle’s Minimal Es-
sential Medium (MEM) supplemented with 10% heat-inactivated
foetal calf serum, 1 mM sodium pyruvate and 2 mM L-glutamine.
Cultures were maintained at 37 ◦C in a humidiﬁed atmosphere
containing 95% air and 5% CO2.
MTT assay conditions. Cytotoxicity was determined by the
colorimetric MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide, purchased from Fluka) microculture assay.
For this purpose, cells were harvested from culture ﬂasks by
trypsinization and seeded in 100 mL aliquots MEM supplemented
with 10% heat-inactivated foetal calf serum, 1 mM sodium
pyruvate, 4 mM L-glutamine and 1% non-essential amino acids
(100¥) into 96-well microculture plates (Iwaki). Cell densities of
1.5 ¥ 103 cells/well (CH1), 2.5 ¥ 103 cells/well (SW480) and 4 ¥
103 cells/well (A549) were chosen in order to ensure exponential
growth of untreated controls throughout the experiment. Cells
were allowed to settle and resume exponential growth for 24 h.
The test compounds were dissolved and serially diluted in the
same medium and added in 100 mL aliquots to the microcultures
(if necessary due to limited solubility, the maximum concentration
tested was added in 200 mL aliquots after removal of the medium),
and cells were exposed to the test compounds for 96 h. At
the end of the exposure period, all media were replaced by
100 mL/well RPMI1640 culture medium (supplemented with 10%
heat-inactivated foetal calf serum) plus 20 mL/well MTT solution
in phosphate-buffered saline (5 mg ml-1). After incubation for 4 h,
the supernatants were removed, and the formazan crystals formed
by vital cells were dissolved in 150 mL DMSO per well. Optical
densities at 550 nmweremeasuredwith amicroplate reader (Tecan
Spectra Classic), using a reference wavelength of 690 nm to correct
for unspeciﬁc absorption. The quantity of vital cells was expressed
in terms of T/C values by comparison to untreated control micro-
cultures, and 50% inhibitory concentrations (IC50) were calculated
from concentration-effect curves by interpolation. Evaluation is
based on means from at least three independent experiments, each
comprising at least three replicates per concentration level.
Results and discussion
In recent years, the tumour microenvironment has become one
of the focuses of targeted cancer chemotherapy. Carbohydrate
compounds have been extensively studied as they could potentially
exploit the alteredmetabolism associated with cancer cells, such as
increased glucose uptake as compared to healthy tissues. In previ-
ouswork, we linked carbohydrate-derived ligands to organometal-
lic RuII–arene moieties to afford RAPTA-C analogues
such as dichlorido(h6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene-a-D-glucofuranoside)ruthenium(II) 4Ru, which is
more cytotoxic than RAPTA-C, probably due to its higher
lipophilicity and, hence, increased uptake. The complexes were
shown to undergo aquation of a halido ligand in aqueous solution,
followed by hydrolysis of a P–O bond of the phosphite ligand, and
ﬁnally formation of dinuclear species.25 In order to investigate
the inﬂuence of the metal centre on hydrolysis and cytotoxicity,
we prepared similar compounds based on osmium, the heavier
homologue of ruthenium.
The organometallic OsII-chlorido complexes 3 and 4 were syn-
thesized in very good yield by reacting the dimer bis[dichlorido(h6-
p-cymene)osmium(II)] a in CH2Cl2 at 40 ◦C with 3,5,6-
bicyclophosphite-1,2-O-isopropylidene-a-D-glucofuranoside 1
and 3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-a-D-gluco-
furanoside 2, respectively (Scheme 1). In contrast, the
oxalato analogues 5 and 6 were prepared via a two step
synthesis, following a literature procedure.29 In the ﬁrst step,
[oxalato(h6-p-cymene)(H2O)osmium(II)] was formed by reacting
bis[dichlorido(h6-p-cymene)osmium(II)] with disilver oxalate
(Ag2C2O4). In the second step the active aqua species was
stirred for 2 h in CH3OH with the respective carbohydrate-based
phosphorus ligand and the compounds ultimately precipitated
from the reaction mixture. The reason for choosing this reaction
sequence was to avoid side reactions involving the silver ions and
the phosphorus ligand.
Scheme 1 Synthesis of the dichlorido– (3, 4) and oxalato–OsII (5, 6)
compounds of P-derived sugar ligands (1, 2).
All the complexes were fully characterized by 1D and 2D
NMR spectroscopy, ESI-MS, elemental analysis, and the solid
state structure of complex 3 was determined by single crystal
X-ray diffraction analysis. Upon coordination of the P-containing
ligands to the Os centre, a change in chemical shift of the 31P{1H}
NMR signals was observed from approximately 117 ppm to about
87 ppm in the case of the chlorido complexes and to 94 ppm
7348 | Dalton Trans., 2010, 39, 7345–7352 This journal is © The Royal Society of Chemistry 2010
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in the case of the oxalato complexes. For the analogous Ru
compounds low-ﬁeld shifts to about 130 ppm were observed.25
In the 13C{1H}NMR spectra of 5 and 6, the most indicative signal
for complex formation is found at 165.0 ppm, which corresponds
to the carboxylate moieties of the coordinated oxalato ligand. 1H
NMR spectra of oxalato complexes in CDCl3 gave two sets of
signals (two doublets) for the Ar-CH(CH3)2 protons, which is in
contrast to NMR in D2O where the methyl groups are observed
as a single doublet, since the inversion of the metal centre only
occurs in protic solvents.35 A similar observation was previously
reported for related complexes.36
X-Ray diffraction analysis of 3 demonstrated the presence
of piano-stool geometry (Fig. 2), as usually observed for such
metal–arene organometallics.11,14,36 Complex 3 crystallizes in the
orthorhombic space group P212121. The osmium–centroidarene
distance is 1.713 A˚ in 3 and the Os–Cl1, Os–Cl2, and Os–P bond
lengths are 2.4203(8), 2.4106(9) and 2.2411(9), respectively. The
Os–Cl bonds are slightly longer than the Ru–Cl bonds observed
in 3Ru, whereas the Os–P bond length is similar.25 As compared
Fig. 2 Molecular structure of 3. Selected bond lengths (A˚) and angles
(◦) are: Os–Cl1 2.4203(8), Os–Cl2 2.4106(9), Os–P 2.2411(9); P–Os–Cl2
88.51(3), P–Os–Cl1 88.74(3), Cl2–Os–Cl1 86.29(3).
to the RAPTA-C analogous Os compound, the Os–centroidarene
distance is slightly longer (1.698 A˚), whereas the Os–Cl and Os–P
bonds are shorter [2.4344(15), 2.4194(15); 2.3324(16) A˚].37
The hydrolysis of 3 was studied by 31P{1H}NMR spectroscopy.
Initially only a single peak is observed at 90.0 ppm which was
assigned to unmodiﬁed 3 (Fig. 3). After 24 h, two additional
peaks of equal relative intensity at 95.8 and 95.3 ppmappear due to
formation of diastereomers by exchange of a single chlorido ligand
with an aqua molecule (Scheme 2). These observations are similar
to those made for related ruthenium(II) compounds,12,25,38 as is the
next step in the hydrolysis mechanism which involves cleavage of
a P–O bond (after approximately 4 d; peak at d(31P) = 62.1 ppm,
Fig. 3). In contrast to the Ru compounds, the rate of hydrolysis is
very slow for the Os compounds, as also observed in other cases.39
Within 24 h only 5% of the complex undergo hydrolysis in the case
of Os complex, whereas for the Ru analogue more than 50% of the
initial complex was degraded. For the ruthenium(II) compounds
the formation of mono-aqua species and the hydrolysis of the P–
O bond of the phosphite was observed already after 12 h and
a dimeric species had formed within 24 h. The diaqua complex
was not observed in the NMR spectrum, probably because it
is converted immediately into the dimeric species. In contrast
to the Ru complexes, no dimeric species were detected for the
Os compound after 72 h. Since the dimer is believed to be not
cytotoxic,14,36 avoiding the formation of a dimeric species could
prove advantageous (see below). Forced hydrolysis of 3 by addition
of two equivalents of AgNO3 resulted in a release of both chlorido
ligands and formation of aqua species with hydrolyzed P–O bonds
(d(31P) = 99.1 and 97.9 for 3Ru and 62.2 ppm for 3).
Introduction of bidentate ligands has been demonstrated to
be an option to overcome the instability problem of titanocene
anticancer compounds and has also proven useful for platinum
drugs by leading to higher stability, reduced side-effects and
extending the range of treatable tumors.7,40 In order to study the
inﬂuence of chelating oxalato ligands on the hydrolysis behaviour,
5 and 6 were prepared (Scheme 1) and similar hydrolysis studies
Fig. 3 31P{1H}NMR spectra for the hydrolysis of 3Ru and 3 in D2O up to 72 h. Peak assignment: a, monoaqua complex; b, products obtained by cleavage
of the P–O bond; c, dimeric species.
This journal is © The Royal Society of Chemistry 2010 Dalton Trans., 2010, 39, 7345–7352 | 7349
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Scheme 2 Reaction scheme for the hydrolysis of 3 (charges/counter ions were omitted for clarity).
Table 2 In vitro anticancer activity in humanovarian cancer (CH1), colon
cancer (SW480) and non-small cell lung cancer (A549) cells (exposure time
96 h unless stated otherwise). Values are means ± standard deviations,
obtained from at least three independent experiments
IC50 values/mM
Compound CH1 SW480 A549
3 113 ± 24 n.d.a n.d.a
4 50 ± 6 215 ± 7 > 640
5 436 ± 72 > 640 > 640
6 764 ± 215 > 640 > 640
3Ru 60 ± 14b 361 ± 122b 498 ± 17bc
4Ru 29 ± 4b 150 ± 19b 223 ± 14ac
a Not determined. b From ref. 25. c Exposure time 72 h.
as for 3 were conducted. The exchange of the chlorido ligands by
oxalato stabilized the compounds and there were no hydrolysis
products identiﬁed during a week of incubation (after two weeks
a very small peak at 59.1 ppm was assigned to a P–O bond
hydrolysis product). A similar approachwas followed forRAPTA-
C and most notably such modiﬁcation did not alter the anticancer
activity of the compounds.29 In contrast, 5 and 6 are much less
active in in vitro anticancer assays than their Ru counterparts (see
below; Table 2).
In an attempt to study the reactivity of the compounds to 5¢-
GMP, 31P{1H}NMR studies were conducted on mixtures with 5¢-
GMP in 1 : 2 ratio inD2O.However, none of the complexes reacted
with 5¢-GMP within 48 h, whereas the Ru organometallics are
relatively reactive and form adducts via the N7 atoms of guanine.
Hydrolysis prior to reaction with biomolecular targets can be
considered an essential step for Ru and Pt compounds in their
modes of action.1,5 However, for the studied derivatives, although
hydrolysis is observed, no binding of Os(II) toN-donor ligands oc-
curs. This property has been noted for similar Os(II) complexes,18,21
butmight also be related to the insufﬁcient detection limit ofNMR
spectroscopy, since only a minor fraction of the Os compound was
found to hydrolyze within the experimental time.
Evaluation of the in vitro anticancer activity
The antiproliferative potential of 3–6 was determined in human
SW480 colon adenocarcinoma, CH1 ovarian cancer and A549
non-small cell lung cancer cells by means of the MTT assay, and
the obtained results are compared to those of the analogous Ru(II)
compounds (Table 2). Structure–activity relationships can best be
assessed in CH1 cells, the most sensitive of these cell lines, and
concentration–effect curves of 3, 4, 3Ru and 4Ru are depicted in
Fig. 4.
Among the series of Os derivatives, 4 is the most cytotoxic
in CH1 cells, followed by the chlorido species 3 and the oxalate
complexes 5 and 6. As in the case of the Ru compounds
with chlorido ligands, the Os analogue bearing the lipophilic
cyclohexylidene protection group, i.e., 4, is more cytotoxic than
the isopropylidene derivative. The Ru–chlorido compounds are
approximately twice as potent as their Os counterparts 3 and 4.
The Ru complexes exhibited activity in cisplatin-resistant A2780
cells, which suggests a mode of action different from that of DNA-
targeted agents, and furthermore selectivity for non-tumourigenic
cells was observed.25 A non-DNA-related mode of action is also
supported by the fact that the Ru analogues form inactive dimers
which are not detectable for the Os compounds. However, the Os
complexes still lack reactivity to 5¢-GMP and the cytotoxicity
is low. In general, the cytotoxicities of the tested Os and Ru
organometallics cover a broad range of IC50 values of 30–760 mM
in the most sensitive cell line CH1.
Such a low anticancer potency in vitro has often been ob-
served for osmium and ruthenium drug candidates, including
the clinically tested NAMI-A and certain organometallic RAPTA
compounds, especially when compared to platinum-based drugs.
Nevertheless, the Ru compounds exhibit excellent in vivo ac-
tivities, in particular against tumour metastases.12,41–43 Ru and
Pt complexes bearing carbohydrate ligands were shown to be
generally less cytotoxic than structural analogues,24 but they often
exhibit considerable activity in vivo, which makes them promising
compounds for further development.12,44
7350 | Dalton Trans., 2010, 39, 7345–7352 This journal is © The Royal Society of Chemistry 2010
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Fig. 4 Concentration–effect curves of Os and Ru carbohydrate complexes in CH1 cells.
Conclusions
RAPTA-type complexes are among the best studied and most
promising Ru–arene anticancer agents. In an attempt to confer
to the basic scaffold tumour-targeting properties, sugar moieties
had been linked to Ru complexes of this kind, which yielded com-
poundswith selectivity for tumourigenic cell lines. In this paper, we
report on the synthesis of Os analogues with carbohydrate-derived
phosphorus-containing ligands. These compounds exhibit slightly
higher IC50 values than their Ru counterparts. In contrast to the
Ru compounds, studies on the reactivity to 5¢-GMP showed that
the Os complexes do not react with this DNA model within 48 h,
which may account for their lower cytotoxicity.
In addition, the chlorido ligands were replaced by oxalate
groups, in order to increase the stability of the compounds. In
aquation studies, both the Os–chlorido and –oxalato complexes
were signiﬁcantly more stable than the Ru counterparts, as
demonstrated by 31P{1H}NMR spectroscopy, though structurally
similar species are formed, including a species in which an
intramolecular P–O bond break occurs upon replacement of a
chlorido ligand by an aqua moiety. These oxalato compounds
inhibit cancer cell growth with a much lower potency in vitro than
the chlorido analogues.
Acknowledgements
We thank theHigher EducationCommission of Pakistan, theAus-
trian Exchange Service (O¨AD), the Hochschuljubila¨umsstiftung
Vienna, the Theodor-Ko¨rner-Fonds, the FFG – Austrian Re-
search Promotion Agency (811591), the Austrian Council for
Research and Technology Development (IS526001), COST D39
andCM0902 and theAustrian Science Fund for ﬁnancial support.
This research was supported by a Marie Curie Intra European
Fellowship within the 7th European Community Framework
Programme project 220890-SuRuCo (A.A.N.). We gratefully ac-
knowledge Alexander Roller for collecting the X-ray diffraction
data, Michaela Hejl for performing the in vitro anticancer assays
and Prof. Markus Galanski for recording the 2D NMR spectra.
References
1 M. Galanski, M. A. Jakupec and B. K. Keppler, Curr. Med. Chem.,
2005, 12, 2075–2094.
2 P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L.
Elbling,M.Micksche, B. Keppler andW. Berger,Drug Resist. Updates,
2008, 11, 1–16.
3 P. J. Sadler, Dalton Transactions themed issue on Metal Anticancer
Compounds, Dalton Trans., 2009, 10629–10936.
4 Z. Guo and P. J. Sadler, Angew. Chem., Int. Ed., 1999, 38, 1512–1531.
5 C. G. Hartinger, S. Zorbas-Seifried, M. A. Jakupec, B. Kynast, H.
Zorbas and B. K. Keppler, J. Inorg. Biochem., 2006, 100, 891–904.
6 C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried, M. Groessl, A.
Egger, W. Berger, H. Zorbas, P. J. Dyson and B. K. Keppler, Chem.
Biodiversity, 2008, 5, 2140–2155.
7 C. G. Hartinger and P. J. Dyson, Chem. Soc. Rev., 2009, 38, 391–401.
8 J.M.Rademaker-Lakhai, D. VanDenBongard,D. Pluim, J. H. Beijnen
and J. H. M. Schellens, Clin. Cancer Res., 2004, 10, 3717–3727.
9 R. E. Morris, R. E. Aird, P. d. S. Murdoch, H. Chen, J. Cummings,
N. D. Hughes, S. Parsons, A. Parkin, G. Boyd, D. I. Jodrell and P. J.
Sadler, J. Med. Chem., 2001, 44, 3616–3621.
10 R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H.
Chen, P. J. Sadler and D. I. Jodrell, Br. J. Cancer, 2002, 86, 1652–1657.
11 W. F. Schmid, R. O. John, V. B. Arion, M. A. Jakupec and B. K.
Keppler, Organometallics, 2007, 26, 6643–6652.
12 C. Scolaro, A. Bergamo, L. Brescacin, R. Delﬁno, M. Cocchietto, G.
Laurenczy, T. J. Geldbach, G. Sava and P. J. Dyson, J. Med. Chem.,
2005, 48, 4161–4171.
13 M.G.Mendoza-Ferri, C. G.Hartinger, A. A.Nazarov, R. E. Eichinger,
M. A. Jakupec, K. Severin and B. K. Keppler, Organometallics, 2009,
28, 6260–6265.
14 W. Kandioller, C. G. Hartinger, A. A. Nazarov, C. Bartel, M. Skocic,
M. A. Jakupec, V. B. Arion and B. K. Keppler, Chem.–Eur. J., 2009,
15, 12283–12291.
15 M. G. Mendoza-Ferri, C. G. Hartinger, M. A. Mendoza, M. Groessl,
A. E. Egger, R. E. Eichinger, J. B. Mangrum, N. P. Farrell, M.
Maruszak, P. J. Bednarski, F. Klein, M. A. Jakupec, A. A. Nazarov, K.
Severin and B. K. Keppler, J. Med. Chem., 2009, 52, 916–925.
16 J. Maksomiska, D. S. Williams, G. E. Atilla-Gokcumen, K. S. M.
Smalley, P. J. Carroll, R. D. Webster, P. Filippakopoulos, S. Knapp,
M. Herlyn and E. Meggers, Chem.–Eur. J., 2008, 14, 4816–4822.
17 Y. K. Yan, M. Melchart, A. Habtemariam and P. J. Sadler, Chem.
Commun., 2005, 4764–4776.
18 A. F. A. Peacock, A. Habtemariam, R. Fernandez, V. Walland, F. P. A.
Fabbiani, S. Parsons, R. E. Aird, D. I. Jodrell and P. J. Sadler, J. Am.
Chem. Soc., 2006, 128, 1739–1748.
19 C. A. Vock, W. H. Ang, C. Scolaro, A. D. Phillips, L. Lagopoulos,
L. Juillerat-Jeanneret, G. Sava, R. Scopelliti and P. J. Dyson, J. Med.
Chem., 2007, 50, 2166–2175.
This journal is © The Royal Society of Chemistry 2010 Dalton Trans., 2010, 39, 7345–7352 | 7351
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
t W
ie
n 
on
 1
9 
O
ct
ob
er
 2
01
0
Pu
bl
ish
ed
 o
n 
02
 Ju
ly
 2
01
0 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C0
030
85F
View Online
36
20 A. Dorcier, W. H. Ang, S. Bolano, L. Gonsalvi, L. Juillerat-Jeannerat,
G. Laurenczy,M. Peruzzini, A. D. Phillips, F. Zanobini and P. J. Dyson,
Organometallics, 2006, 25, 4090–4096.
21 A. F. A. Peacock, S. Parsons and P. J. Sadler, J. Am. Chem. Soc., 2007,
129, 3348–3357.
22 S. H. van Rijt, A. J. Hebden, T. Amaresekera, R. J. Deeth, G. J.
Clarkson, S. Parsons, P. C. McGowan and P. J. Sadler, J. Med. Chem.,
2009, 52, 7753–7764.
23 S. H. van Rijt, A. F. A. Peacock, R. D. L. Johnstone, S. Parsons and
P. J. Sadler, Inorg. Chem., 2009, 48, 1753–1762.
24 C. G. Hartinger, A. A. Nazarov, S. M. Ashraf, P. J. Dyson and B. K.
Keppler, Curr. Med. Chem., 2008, 15, 2574–2591.
25 I. Berger, M. Hanif, A. A. Nazarov, C. G. Hartinger, R. O. John, M. L.
Kuznetsov, M. Groessl, F. Schmitt, O. Zava, F. Biba, V. B. Arion, M.
Galanski, M. A. Jakupec, L. Juillerat-Jeanneret, P. J. Dyson and B. K.
Keppler, Chem.–Eur. J., 2008, 14, 9046–9057.
26 R. A. Gatenby and R. J. Gillies, Nat. Rev. Cancer, 2004, 4, 891–899.
27 S. Stahl and H. Werner, Organometallics, 1990, 9, 1876–1881.
28 N. K. Kochetkov, E. E. Nifant’ev, M. P. Koroteev, Z. K. Zhane and
A. A. Borisenko, Carbohydr. Res., 1976, 47, 221–231.
29 W. H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeannerat
and P. J. Dyson, Inorg. Chem., 2006, 45, 9006–9013.
30 M. R. Pressprich and J. Chambers, Bruker Analytical X-ray systems,
Madison, Editon edn, 2004.
31 G. M. Sheldrick, University Go¨ttingen (Germany), Editon edn, 1997.
32 G. M. Sheldrick, University Go¨ttingen (Germany), Editon edn, 1997.
33 L. J. Farrugia, J. Appl. Crystallogr., 1997, 30, 565.
34 International Tables forX-rayCrystallography,KluwerAcademic Press,
Dordrecht, The Netherlands, 1992.
35 R. Lang, K. Polborn, T. Severin and K. Severin, Inorg. Chim. Acta,
1999, 294, 62–67.
36 A. F. A. Peacock, M. Melchart, R. J. Deeth, A. Habtemariam, S.
Parsons and P. J. Sadler, Chem.–Eur. J., 2007, 13, 2601–2613.
37 A. Dorcier, P. J. Dyson, C. Gossens, U. Rothlisberger, R. Scopelliti and
I. Tavernelli, Organometallics, 2005, 24, 2114–2123.
38 C. Scolaro, C. G. Hartinger, C. S. Allardyce, B. K. Keppler and P. J.
Dyson, J. Inorg. Biochem., 2008, 102, 1743–1748.
39 J. Reedijk, Platinum Met. Rev., 2008, 52, 2–11.
40 M.A. Jakupec,M.Galanski andB.K.Keppler,Rev.Physiol., Biochem.,
Pharmacol., 2003, 146, 1–53.
41 E. Alessio, G. Mestroni, A. Bergamo and G. Sava, Curr. Top. Med.
Chem., 2004, 4, 1525–1535.
42 A. Bergamo, A. Masi, P. J. Dyson and G. Sava, Int. J. Oncol., 2008, 33,
1281–1289.
43 S. Chatterjee, S. Kundu, A. Bhattacharyya, C. G. Hartinger and P. J.
Dyson, JBIC, J. Biol. Inorg. Chem., 2008, 13, 1149–1155.
44 I. Berger, A. A. Nazarov, C. G. Hartinger, M. Groessl, S.-M. Valiahdi,
M. A. Jakupec and B. K. Keppler, ChemMedChem, 2007, 2, 505–514.
7352 | Dalton Trans., 2010, 39, 7345–7352 This journal is © The Royal Society of Chemistry 2010
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
t W
ie
n 
on
 1
9 
O
ct
ob
er
 2
01
0
Pu
bl
ish
ed
 o
n 
02
 Ju
ly
 2
01
0 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C0
030
85F
View Online
37
2.3. From Hydrolytically Labile to Hydrolytically Stable Ru(II)-
Arene Anticancer Complexes with Carbohydrate-Derived Co-
ligands 
 
Muhammad Hanif, Samuel M. Meier, Wolfgang Kandioller, Anna Bytzek,  Michae-
la Hejl, Christian G. Hartinger, Alexey A. Nazarov, Vladimir B. Arion, Michael A. 
Jakupec, Paul J. Dyson, Bernhard K. Keppler 
 
Journal of Inorganic Biochemistry, 2010, in Press 
 
 
 
 
 
 
 
 
 
 
 
 
 
38
1 From hydrolytically labile to hydrolytically stable Ru(II)–arene anticancer complexes
2 with carbohydrate-derived co-ligands
3 Muhammad Hanif a, Samuel M. Meier a,c, Wolfgang Kandioller a, Anna Bytzek a, Michaela Hejl a,
4 Christian G. Hartinger a,c,⁎, Alexey A. Nazarov a,b,⁎, Vladimir B. Arion a,c, Michael A. Jakupec a,c,
5 Paul J. Dyson b, Bernhard K. Keppler a,c
6 a University of Vienna, Institute of Inorganic Chemistry, Waehringer Str. 42, A-1090 Vienna, Austria
7 b Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
8 c University of Vienna, Research Platform “Translational Cancer Therapy Research”, Waehringer Str. 42, A-1090 Vienna, Austria
9
10
a b s t r a c ta r t i c l e i n f o
11 Article history:
12 Received 13 August 2010
13 Received in revised form 30 September 2010
14 Accepted 6 October 2010
15 Available online xxxx
1678
19 Keywords:
20 Anticancer activity
21 Aquation
22 Bioorganometallic chemistry
23 Carbohydrate ligands
24 Ruthenium
25The synthesis, characterization, reactivity and in vitro anticancer activity of a series of RuII–arene complexes
26with carbohydrate-derived phosphite and biscarboxylato co-ligands are reported. The compounds were
27characterized by NMR spectroscopy and electrospray ionization (ESI) mass spectrometry, and the molecular
28structures of oxalato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-d-glucofuranoside)ru-
29thenium(II) and oxalato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-d-glucofurano-
30side)ruthenium(II) were determined by X-ray diffraction analysis. In contrast to their dichlorido
31counterparts, the biscarboxylato complexes did not exhibit signiﬁcant reactivity towards biomolecules,
32such as cysteine, methionine, ubiquitin or the DNAmodel 5′-GMP, and resist hydrolysis; no hydrolytic species
33were detected by 1 H and 31P{1 H} NMR spectroscopy over several days. These structural alterations led to a
34decrease in the tumor-inhibiting potency of the compounds in human cancer cell lines.
35© 2010 Published by Elsevier Inc.
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40 1. Introduction
41 Organometallic medicinal chemistry is an emerging research area
42 with considerable potential [1]. In recent years many examples of
43 organometallic compounds appeared that exhibit potent anticancer
44 activity [1–4], including compounds that selectively inhibit enzymes
45 [5–9], block receptors [2], or have been used to label peptides or other
46 biomolecules [10,11]. Indeed, titanocene dichloride, Cp2TiCl2, entered
47 clinical trials as an anticancer agent [12,13], and other compounds are
48 expected to follow.
49 One of the most investigated class of organometallic compounds
50 are based on the RuII–arene unit linked to ethylenediamine (en)
51 [14,15], 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (pta) [16], pyr
52 (id)ones [17–19] or bioactive groups [5,6,8,9,20]. For example, the so-
53 called RAPTA compounds are a large family of organometallic
54 compounds with general formula [RuII(η6-arene)(pta)Cl2] (for
55 RAPTA-C, see Fig. 1), which have been extensively investigated for
56 their tumor-inhibiting properties. In vivo studies on some RAPTA
57 compounds have shown excellent inhibition of metastases growth in
58CBA mice bearing the MCa mammary carcinoma while exhibiting
59selective, but mild cytotoxicity towards the TS/A tumorigenic cell line
60as opposed to the HBL-100 non-tumorigenic cell line in in vitro
61anticancer assays [16]. RAPTA complexes undergo aquation of the
62chloride ligand(s) in aqueous solution [21]. The extent of the aquation
63depends on the concentration of the complex in solution, the amount
64of chloride present and the pH. Hydrolysis was found to be suppressed
65at the high chloride concentration found in blood plasma
66(ca. 100 mM), but occurs at chloride concentrations typical of cell
67cytoplasm (ca. 4 mM), representing a possible activation pathway.
68In order to improve their efﬁcacy, a number of structural
69modiﬁcations have been made to the basic RAPTA framework such
70as introduction of H-bonding functionalities [22], change of the arene
71ligand [16] or the leaving group (Fig. 1) [23] and tethering to bioactive
72segments such as human serum albumin which resulted in a
73twentyfold increase in cytotoxicity with respect to prototype
74RAPTA-C [24].
75By replacing the ptamoietywith sugar-phosphite ligandswith similar
76hydrophilicity [25,26], RAPTA-like analogues were obtained, capable of
77targeting cancer cells by exploiting the increased glucose uptake resulting
78from overexpression of glucose transporters and glycolytic enzymes
79[25,27]. This concept led to the development of compounds with the
80general formula [RuII(η6-p-cymene)(3,5,6-bicyclophosphite-α-d-gluco-
81furanoside)Cl2]. The complexes showed moderate cytotoxicity, with
82certain selectivity for tumor cells over non-tumorigenic cells, and
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83 importantly activity in cisplatin-resistant cells [26]. The cytotoxicity
84 appears to be determined, to some extent, by lipophilicity, i.e., the most
85 lipophilic compoundwas themost cytotoxic. These compounds are prone
86 to aquation/hydrolysis similar to RAPTA compounds in that they undergo
87 aquation of theﬁrst halido ligand in aqueous solution, but additionally the
88 hydrolysis of a P–O bond of the phosphite ligand, and ultimately the
89 formation of inert dinuclear species takes place [26,28].
90 Use of anionic chelating ligands such as oxalate instead of halido
91 ligands has already been employed to overcome the problem of
92 solubility problems and stability in platinum compounds and with
93 titanocenes [1,3,29], and the replacement of the two chlorido ligands
94 in RAPTA-C by oxalate resulted in a complex which resists aquation
95 [23]. In this paper we describe the inﬂuence of the leaving group on
96 hydrolysis, binding to biomolecules, and cytotoxicity for a series of
97 carbohydrate–ruthenium(II)-arene complexes, with oxalato and
98 malonato leaving groups, and compare it to data obtained for
99 structurally similar Os compounds [30].
100 2. Experimental
101 All reactions were carried out in dry solvents under argon
102 atmosphere. Chemicals were obtained from commercial suppliers
103 and used as received. Ubiquitin from bovine red blood cells was
104 purchased from Sigma, L-cysteine from Fluka and L-methionine from
105 Sigma-Aldrich and used as obtained. MeOH (VWR Int., 20864.320,
106 HiPerSolv CHROMANORM), formic acid (Fluka) and milliQ H2O were
107 used as solvents for MS studies. For the microemulsion electrokinetic
108 chromatography studies sodium dodecyl sulfate (SDS), dodecano-
109 phenone, 1-butanol and sodium monohydrogenphosphate were
110 purchased from Sigma-Aldrich. Sodium hydroxide solution (0.1 M),
111 hydrochloric acid, heptane and sodium dihydrogenphosphate were
112 obtained from Fluka, and DMSO from Fisher Scientiﬁc. Methanol and
113 CH2Cl2 used in synthesis were dried using standard procedures.
114 Dichlorido(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropyli-
115 dene-α-d-glucofuranoside)ruthenium(II) 1 [26], the dimer bis
116 [dichlorido(η6-p-cymene)ruthenium(II)] {[RuII(cym)Cl(μ-Cl)]2 a
117 [31]}, 3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-d-glucofurano-
118 side I [32], 3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-d-
119 glucofuranoside II [32], 1,2-O-(2,2,2-trichloroethylidene)-α-d-
120 glucofuranose 3,5,6-bicyclophosphite III [33], disilver oxalate [23] and
121 oxalato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-
122 α-d-glucofuranoside)osmium(II) 2Os and oxalato(η6-p-cymene)
123 (3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-d-glucofuranoside)
124 osmium(II) 3Os [23] were synthesized using literature procedures.
125
1H, 13C{1H}and 31P{1 H}NMRspectrawere recorded at25 °ConaBruker
126 FT NMR spectrometer Avance III 500 MHz at 500.10 (1H), 125.75 (13C
127 {1H}) and 202.44 MHz (31P{1H}). The 31P NMR spectra were referenced
128 to 85% phosphoric acid. 2D NMR spectra were collected in a gradient-
129 enhancedmode. Speciﬁc optical rotationsweredetermined on a Perkin-
130 Elmer 341 polarimeter in a 10 cm cell at 20 °C. Melting points were
131 measured on a Büchi B-540 apparatus and are uncorrected. Elemental
132 analysis was determined by the Laboratory for Elemental Analysis,
133 Faculty of Chemistry, University of Vienna, on a Perkin-Elmer 2400 CHN
134 ElementalAnalyzer. Electrospray ionizationmass spectrawere recorded
135 on a Bruker esquire3000.
1362.1. General procedure for the synthesis of 2–6
137The dimer [(η6-cymene)RuCl(μ-Cl)]2 (122 mg, 0.20 mmol) and
138silver dicarboxylate (0.44 mmol) were stirred in water (25 mL) for
13912 h. The mixture was ﬁltered through a bed of Celite to remove the
140AgCl precipitate. The solvent was removed under vacuum, and the
141residue was redissolved in methanol (25 mL) and the carbohydrate
142ligand (0.40 mmol) was added. The reaction mixture was stirred for
1432 h, then the volume of the solution was reduced to 5 mL and diethyl
144ether (25 mL) was added. The slurry was cooled to 4 °C for 12 h to
145afford a yellow crystalline product that was isolated by ﬁltration,
146washed with diethyl ether (2×5 mL) and dried under vacuum.
147Oxalato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopropyli-
148dene-α-d-glucofuranoside)ruthenium(II) 2 was prepared following
149the general procedure, using silver oxalate (133 mg, 0.44 mmol) and
1501,2-O-isopropylidene-α-d-glucofuranose 3,5,6-bicyclophosphite
151(100 mg, 0.40 mmol). Crystals suitable for X-ray diffraction studies
152were grown by slow diffusion from diethyl ether and methanol. Yield:
153190 mg (83%), m.p. 175–177 °C (decomp.), Elemental analysis, found
154% C, 43.37; H, 4.91; calcd. for C21H27O10PRu·0.5H2O, C, 43.45; H, 4.86.MS
155(ESI+):m/z: 572.7 (573.0) [M+H]+, 595.1 (595.0) [M+Na]+; 1H NMR
156(500.10 MHz, CDCl3, 25 °C, d = doublet, m = multiplet, s = singlet,
157brs = broad singlet): δ=6.08 (d, J=4 Hz, 1H; H-1), 5.88 (d, J=6 Hz,
1581H;H–Ar), 5.86 (d, J=6 Hz, 1H;H–Ar), 5.74 (d, J=5 Hz, 1H;H–Ar), 5.71
159(d, J=5 Hz, 1H; H–Ar), 5.15–5.18 (m, 1H; H-5), 4.71 (brs, 1H; H-3),
1604.60 (d, J=4 Hz, 1H; H-2), 4.56 (brs, 1H; H-6), 4.34 (brs, 2H; H-4, H-6′),
1612.77–2.82 (m, 1H; CH(CH3)2), 2.22 (s, 3H; CH3), 1.46 (s, 3H; C(CH3)2),
1621.30 (s, 3H; C(CH3)2), 1.29 (d, J=7 Hz, 3H; CH(CH3)2), 1.28 (d, J=7 Hz,
1633H; CH(CH3)2)ppm; 13C{1H} NMR (125.75 MHz, CDCl3, 25 °C):
164δ=165.2 (J=4 Hz; C=O), 112.6 (C(CH3)2), 109.3 (C–Ar), 105.7 (C-1),
165105.0 (C–Ar), 89.8 (CH–Ar), 89.6 (CH–Ar), 89.0 (CH–Ar), 88.2 (CH–Ar),
16683.6 (J=5 Hz; C-2), 78.6 (J=8 Hz; C-3), 76.9 (J=6 Hz; C-4), 74.7
167(J=5 Hz; C-5), 69.3 (J=8 Hz; C-6), 31.2 (CH(CH3)2), 26.9 (C(CH3)2),
16826.2 (C(CH3)2), 22.5 (CH(CH3)2), 22.4 (CH(CH3)2), 18.3 (CH3) ppm;
169
31P{1H} NMR (202.44 MHz, CDCl3, 25 °C): δ=134.1 ppm.
170Oxalato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohex-
171ylidene-α-d-glucofuranoside)ruthenium(II) 3 was prepared follow-
172ing the general procedure, using silver oxalate (133 mg, 0.44 mmol) and
1731,2-O-cyclohexylidene-α-d-glucofuranose 3,5,6-bicyclophosphite
174(115 mg, 0.40 mmol). Crystals suitable for X-ray diffraction studies
175were grown by slow diffusion from diethyl ether and methanol. Yield:
176191 mg, (78%), m.p. 181–183 °C (decomp.), Elemental analysis, found
177% C, 46.24; H, 4.87; calcd. for C24H31O10PRu·0.5H2O, C, 46.45; H, 5.19.
178MS (ESI+): m/z: 612.8 (613.1) [M+H]+, 635.3 (635.1) [M+Na]+;
179
1HNMR (500.10 MHz, CDCl3, 25 °C): δ=6.08 (d, J=3 Hz, 1H, H-1), 5.87
180(d, J=6 Hz, 1H;H–Ar), 5.85 (d, J=6 Hz, 1H;H–Ar), 5.72 (d, J=5 Hz, 1H;
181H–Ar), 5.70 (d, J=5 Hz, 1H;H–Ar), 5.14–5.17 (m, 1H,H–5), 4.70 (brs 1H,
182H-3), 4.61 (d, J=3 Hz, 1H, H-2), 4.51–4.53 (m, 1H, H-6), 4.32 (brs, 2H,
183H-4, H-6′), 2.78–2.83 (m, 1H, CH(CH3)2), 2.22 (s, 3H,CH3), 1.59–1.65 (m,
1844H, C6H10), 1.51–1.55 (m, 6H, C6H10), 1.29 (d, J=7 Hz, 3H; CH(CH3)2),
1851.28 (d, J=7 Hz, 3H; CH(CH3)2)ppm; 13C{1H} NMR (125.75 MHz, CDCl3,
18625 °C): δ=165.1 (J=4 Hz; C=O), 113.3 (C(CH3)2), 109.3 (C–Ar), 105.3
187(C-1), 105.0 (C–Ar), 89.7 (C–Ar), 89.5 (C–Ar), 88.9 (C–Ar), 88.2 (C–Ar),
18883.1 (J=6 Hz; C-2), 78.7 (J=8 Hz; C-3), 76.8 (J=8 Hz; C-4), 74.7
189(J=6 Hz; C-5), 69.2 (J=6 Hz; C-6), 36.5(C6H10), 35.6 (C6H10), 31.1
Fig. 1. Structures of anticancer RAPTA complexes and an analogues carbohydrate-derived compound.
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190 (CH(CH3)2), 24.7 (C6H10), 23.8 (C6H10), 23.5 (C6H10), 22.5 (CH(CH3)2–Ar),
191 22.4 (CH(CH3)2–Ar), 18.3 (CH3–Ar)ppm; 31P{1H} NMR (202.44 MHz,
192 CDCl3, 25 °C): δ=134.1 ppm.
193 Oxalato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-(2,2,2-
194 trichloroethylidene-α-d-glucofuranoside)ruthenium(II) 4 was
195 prepared following the general procedure, using silver oxalate
196 (133 mg, 0.44 mmol) and 1,2-O-(2,2,2-trichloroethylidene)-α-d-glu-
197 cofuranose 3,5,6-bicyclophosphite (135 mg, 0.40 mmol). Yield:
198 177 mg (67%), m.p. 251–252 °C (decomp.), Elemental analysis,
199 found% C, 35.34; H, 3.26; calcd. for C20H22O10Cl3PRu·0.75H2O, C,
200 35.62; H, 3.51. MS (ESI+): m/z: 662.6 (662.9) [M+H]+; 1H NMR
201 (500.10 MHz, CDCl3, 25 °C): δ=6.29 (d, J=4 Hz, 1H; H-1), 6.14 (d,
202 J=5 Hz, 1H; H–Ar), 6.12 (d, J=5 Hz, 1H; H–Ar), 5.92 (d, J=6 Hz, 1H;
203 H–Ar), 5.90 (d, J=6 Hz, 1H; H–Ar), 5.57 (s, 1H, CHCCl3 ), 5.20–5.24
204 (m , 1H; H-5), 5.04 (d, J=3 Hz, 1H; H-3), 4.84 (d, J=3 Hz, 1H; H-2),
205 4.77–4.81 (m, 1H; H-6), 4.71 (brs, 1H; H-4), 4.06–4.10 (m, 1H; H-6′),
206 2.63–2.68 (m, 1H; CH(CH3)2), 2.07 (s, 3H; Ar–CH3), 1.20 (d, J=7 Hz,
207 6H; CH(CH3)2)ppm; 13C{1H} NMR (125.75 MHz, CDCl3, 25 °C):
208 δ=164.6 (J=6 Hz; C=O), 108.6 (C–Ar), 106.9 (C-1), 106.5 (CH–Ar),
209 104.8 (C–Ar), 97.4 (CCl3), 90.8 (CH–Ar), 89.0 (CH–Ar), 88.6 (CH–Ar),
210 86.0 (J=6 Hz; C-2), 78.6 (J=5 Hz; C-3), 77.9 (J=8 Hz; C-4), 74.4
211 (J=5 Hz; C-5), 69.1 (J=9 Hz; C-6), 31.1 (CH(CH3)2), 24.5 (CHCCl3),
212 22.5 (CH(CH3)2), 22.4 (CH(CH3)2), 18.1 (CH3) ppm; 31P{1H} NMR
213 (202.44 MHz, CDCl3, 25 °C): δ=135.0 ppm.
214 Malonato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-isopro-
215 pylidene-α-d-glucofuranoside)ruthenium(II) 5 was prepared fol-
216 lowing the general procedure, using silver malonate (140 mg,
217 0.44 mmol) and 1,2-O-isopropylidene-α-d-glucofuranose 3,5,6-bicy-
218 clophosphite (100 mg, 0.40 mmol). Yield: 168 mg (72%), m.p.N200 °C
219 (decomp.), Elemental analysis, found% C, 43.62; H, 5.05; calcd. for
220 C22H29O10PRu·H2O, C, 43.78; H, 5.18. MS (ESI+): m/z: 608.9 (609.0)
221 [M+Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ=6.09 (d, J=4 Hz,
222 1H; H-1), 5.81 (d, J=7 Hz, 1H; H–Ar), 5.80 (d, J=7 Hz, 1H; H–Ar),
223 5.68 (d, J=6 Hz, 2H; H–Ar), 5.64 (d, J=6 Hz, 2H; H–Ar), 5.17–5.20
224 (m, 1H; H-5), 4.73 (brs, 1H; H-3), 4.66 (d, J=3.5 Hz, 1H; H-2), 4.52–
225 4.56 (m, 1H; H-6), 4.33–4.34 (m, 2H; H-4 and H-6′), 3.41 (d, J=17 Hz,
226 1H, CH2COO), 3.20 (d, J=17 Hz, 1H, CH2COO), 2.80–2.86 (m, 1H; CH
227 (CH3)2), 2.19 (s, 3H; CH3), 1.49 (s, 3H; C(CH3)2), 1.32 (s, 3H; C(CH3)2),
228 1.26 (d, J=7 Hz, 3H; CH(CH3)2)ppm; 13C{1H} NMR (125.75 MHz,
229 CDCl3, 25 °C): δ=175.4 (J=10 Hz; C=O), 112.7 (C(CH3)2), 109.6
230 (C–Ar), 106.7 (C–Ar), 105.7 (C-1), 90.0 (C–Ar), 89.7 (C–Ar), 89.4
231 (C–Ar), 88.9 (C–Ar), 83.4 (J=5 Hz; C-2), 78.7 (J=8 Hz; C-3), 76.7
232 (J=10 Hz; C-4), 74.7 (J=5 Hz; C-5), 69.0 (J=9 Hz; C-6), 46.8
233 (CH2COO), 30.7 (CH(CH3)2), 26.8 (C(CH3)2), 26.1 (C(CH3)2), 22.2
234 (CH(CH3)2), 18.1 (CH3) ppm; 31P{1H} NMR (202.44 MHz, CDCl3,
235 25 °C): δ=137.4 ppm.
236 Malonato(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclo-
237 hexylidene-α-d-glucofuranoside)ruthenium(II) 6 was prepared
238 following the general procedure, using silver malonate (140 mg,
239 0.44 mmol) and 1,2-O-cyclohexylidene-α-d-glucofuranose 3,5,
240 6-bicyclophosphite (115 mg, 0.40 mmol). Yield: 185 mg (74%), m.p.N
241 200 °C (decomp.), Elemental analysis, found% C, 46.39; H, 5.75; calcd.
242 for C25H33O10PRu·H2O, C, 46.65; H, 5.48. MS (ESI+):m/z: 648.8 (649.1)
243 [M+Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ=6.09 (d, J=4 Hz,
244 1H; H-1), 5.80 (d, J=7 Hz, 1H; H–Ar), 5.79 (d, J=7 Hz, 1H; H–Ar), 5.67
245 (d, J=6 Hz, 2H; H–Ar), 5.62 (d, J=6 Hz, 2H; H–Ar), 5.16–5.19 (m, 1H;
246 H-5), 4.74 (brs, 1H; H-3), 4.65 (d, J=4 Hz, 1H; H-2), 4.50–4.54 (m, 1H;
247 H-6), 4.33 (brs, 2H; H-4 andH-6′), 3.40 (d, J=17 Hz, 1H, CH2COO), 3.20
248 (d, J=17 Hz, 1H, CH2COO), 2.81–2.86 (m, 1H; CH(CH3)2), 2.20 (s, 3H;
249 CH3), 1.64–1.67 (m, 4H, C6H10), 1.53–1.55 (m, 6H, C6H10), 1.26 (d,
250 J=7 Hz, 3H; CH(CH3)2), 1.25 (d, J=7 Hz, 3H; CH(CH3)2)ppm; 13C{1H}
251 NMR (125.75 MHz, CDCl3, 25 °C): δ=175.4 (J=9 Hz; C=O), 113.4
252 (C(CH3)2), 109.6 (C–Ar), 106.7 (C–Ar), 105.3 (C-1), 90.1 (C–Ar), 89.7
253 (C–Ar), 89.4 (C–Ar), 88.8 (C–Ar), 83.0 (J=5 Hz; C-2), 78.8 (J=8 Hz;
254 C-3), 76.7 (J=5 Hz; C-4), 74.7 (J=5 Hz; C-5), 68.9 (J=9 Hz; C-6), 46.8
255 (CH2COO), 36.4 (C6H10), 35.6 (C6H10), 30.7 (CH(CH3)2), 24.7 (C6H10),
25623.8 (C6H10), 23.4 (C6H10), 22.2 (CH(CH3)2–Ar), 22.4 (CH(CH3)2–Ar),
25718.1 (CH3–Ar) ppm; 31P{1H} NMR (202.44 MHz, CDCl3, 25 °C):
258δ=137.5 ppm.
2592.2. X-ray diffraction analysis
260X-ray diffraction measurements of 2 and 3 were performed on a
261Bruker X8 APEXII CCD diffractometer at 100 K. The crystals were
262positioned at 40 and 35 mm from the detector and 1386 and 1345
263frames, each for 10 and 80 s over 1°, were measured. The data were
264processed using the SAINT software package [34]. Crystal data, data
265collection parameters, and structure reﬁnement details are given in
266Table 1. The structures were solved by direct methods and reﬁned by
267full-matrix least-squares techniques. Non-hydrogen atoms were
268reﬁned with anisotropic displacement parameters. H atoms were
269inserted at calculated positions and reﬁned with a riding model. One
270of the four co-crystallized methanol molecules was reﬁned with 75%
271occupancy. The following computer programs were used: structure
272solution SHELXS-97, reﬁnement SHELXL-97 [35], molecular diagrams
273ORTEP-3 [36]. Crystallographic data for the structural analysis of 2 and
2743 has been deposited with the Cambridge Crystallographic Data
275Centre, CCDC 785120 and 785121, respectively. These data can be
276obtained free of charge from The Cambridge Crystallographic Data
277Centre via www.ccdc.cam.ac.uk/data_request/cif.
2782.3. Reactions with biomolecules
2792.3.1. NMR spectroscopy
280Solutions of 1 or 2 containing either Cys, Met (both 1:1) or GMP
281(1:2) were prepared in D2O (pH 4–5) and kept at room temperature
282for 5 days. The reaction progress was monitored by 1H and 31P NMR
283spectroscopy at 0.5, 48 and 120 h. ESI-MS. The complexes were
284incubated at 37 °C with Cys and Met at a molar ratio of 1:1 and with
285ubiquitin at 2:1 molar ratio in milliQ water (18.2 MΩ; Millipore
286Synergy 185 UV Ultrapure Water system; Molsheim, France). The
Table 1 t1:1
Crystal data and details of data collection for 2 and 3.
t1:2
t1:3Compound 2 3
t1:4Chemical formula C22H31O11PRu C25.88H38.50O11.88PRu
t1:5M (g mol−1) 603.51 671.61
t1:6Temperature (K) 100(2) 100(2)
t1:7Crystal size (mm) 0.20×0.10×0.03 0.25×0.08×0.04
t1:8Crystal color, habit yellow, plate orange, stick
t1:9Crystal system orthorhombic monoclinic
t1:10Space group P212121 P21
t1:11a (Å) 8.2719(7) 15.1978(9)
t1:12b (Å) 12.9548(14) 13.0153(7)
t1:13c (Å) 22.785(2) 15.7673(9)
t1:14V (Å3) 2441.7(4) 2964.0(3)
t1:15Z 4 4
t1:16Dc (g cm−3) 1.642 1.505
t1:17μ (cm−1) 7.67 6.42
t1:18F(000) 1240 1391
t1:19Θ range for data collection (°) 2.92 to 26.00 2.72 to 26.00
t1:20h range −10/10 −18/18
t1:21k range −15/15 −16/16
t1:22l range −28/28 −19/19
t1:23No. reﬂs. used in reﬁnement 4781 11628
t1:24No. parameters 319 731
t1:25Rint 0.1242 0.0775
t1:26R1 (obs.)a 0.0503 0.0374
t1:27wR2 (all data)b 0.1266 0.0837
t1:28Flack parameter 0.01(5) −0.05(2)
t1:29Sc 1.053 1.006
a Reﬁnement was by full-matrix least-squares (Fo2) for all reﬂections, R1=Σ||Fo|–|Fc||/
Σ|Fo|. t1:30
b wR2={Σ[w(Fo2–Fc2)2]/Σ[w(Fo2)2]}1/2. t1:31
c Goodness of ﬁt, S={Σ[w(Fo2–Fc2)2]/(n–p)}1/2. t1:32
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287 samples containing amino acids were diluted with MeOH, and the
288 protein incubation mixtures were diluted with H2O/MeOH/formic
289 acid (50:50:0.1). Mass spectra were recorded after 3, 6, 24, 72 h and
290 7 days at concentrations of 1–10 μM, using a Bruker esquire3000 ion
291 trap mass spectrometer with direct infusion at a ﬂow rate of 5 μl/min.
292 The experimental conditions were as follows: capillary 4.5 kV, end
293 plate offset 0.5 kV, skim1 45.5 V, skim2 6 V, cap exit offset 78.4 V and
294 dry temperature 200 °C. The spectra were recorded using ESI Compass
295 1.3 (Bruker) and DataAnalysis 4.0 software. Deconvolution was
296 obtained by the maximum entropy algorithm with a 0.1m/z-mass
297 step and an instrument peak width of 1.
298 2.4. Aquation studies
299 For hydrolysis studies, the compounds were dissolved in D2O and
300 the samples were analyzed by 31P{1H} NMR spectroscopy once a day
301 over 15 days. The 31P{1H} NMR spectra were recorded on a Bruker
302 Avance 400 instrument at 161.98 MHz.
303 2.5. Cytotoxicity studies
304 2.5.1. Cell lines and culture conditions
305 CH1 (ovarian carcinoma, human) cells were a gift from Lloyd R.
306 Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer
307 Research, Sutton, UK. SW480 (adenocarcinoma of the colon, human)
308 and A549 (non-small cell lung cancer, human) cells were provided by
309 Brigitte Marian (Institute of Cancer Research, Department of Medicine
310 I, Medical University of Vienna, Austria). All cell culture reagents were
311 purchased from Sigma-Aldrich. Cells were grown in 75 cm² culture
312 ﬂasks (Iwaki) as adherent monolayer cultures in Eagle's Minimal
313 Essential Medium (MEM) supplemented with 10% heat-inactivated
314 fetal calf serum, 1 mM sodium pyruvate and 2 mM l-glutamine at
315 37 °C under a humidiﬁed atmosphere containing 95% air and 5% CO2.
316 2.5.2. MTT assay conditions
317 Cytotoxicity was determined by the colorimetric MTT (3-(4,5-
318 dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Fluka)
319 microculture assay. For this purpose, cells were harvested from
320 culture ﬂasks by trypsinization and seeded in 100 μL aliquots of MEM
321 supplemented with 10% heat-inactivated fetal calf serum, 1 mM
322 sodium pyruvate, 4 mM l-glutamine and 1% non-essential amino acids
323 (100×) into 96-well microculture plates (Iwaki). The following cell
324 densities were chosen to ensure exponential growth of untreated
325 controls throughout the experiment: 1.5×103 cells/well (CH1),
326 2.5×103 cells/well (SW480) and 4×103 cells/well (A549). Cells
327 were allowed to settle and resume exponential growth for 24 h. The
328 test compounds were dissolved and serially diluted in the same
329 medium and added in aliquots of 100 μL/well. After exposure for 96 h,
330 all media were replaced by 100 μL/well RPMI1640 medium (supple-
331 mented with 10% heat-inactivated fetal calf serum) plus 20 μL/well
332 MTT in phosphate-buffered saline (5 mg/mL). After incubation for 4 h,
333 the supernatants were removed, and the formazan crystals formed by
334 viable cells were dissolved in 150 μL DMSO per well. Optical densities
335 at 550 nm were measured with a microplate reader (Tecan Spectra
336 Classic), using a reference wavelength of 690 nm to correct for
337 unspeciﬁc absorption. The quantity of viable cells was expressed as
338 percentages of untreated controls, and 50% inhibitory concentrations
339 (IC50) were calculated from concentration–effect curves by interpo-
340 lation. The results given are mean values from at least three or two
341 independent experiments in case of activity or inactivity, respectively,
342 each comprising three replicates per concentration level.
343 2.6. Microemulsion electrokinetic chromatography (MEEKC) studies
344 CE separations were carried out on an HP3D CE system (Agilent,
345 Waldbronn, Germany) equipped with an on-column diode-array
346detector and the analytes were detected by UV absorption at 200 nm.
347For all measurements, capillaries of 48.5 cm total length (40 cm
348effective length; 50 μm ID) were used (Polymicro Technologies,
349Phoenix, AZ, USA). Capillary and sample tray were thermostatted at
35025 °C. The sample injection was carried out by hydrodynamic
351injection at 10 mbar for 15 s with a separation voltage of 25 kV.
352New capillaries were conditioned with 0.1 M HCl, water, 0.1 M NaOH,
353and again with water (10 min each). The capillary was ﬂushed with
3540.1 M NaOH, water, and BGE for 5 min each before the ﬁrst run each
355run. Before each injection the capillary was purged with 0.1 M NaOH,
356water and the BGE for 2 min each.
357The following component ratios (wt.%) were used to establish a
358stable microemulsion: 91.22% sodium phosphate buffer (20 mM, pH
3597.4), 0.84% heptane, 1.47% SDS, and 6.48% 1-butanol. For the
360preparation of the MEEKC solutions, surfactant, alcohol, oil, and a
361small portion of buffer were mixed by sonication for 5 min. The
362residual buffer was then slowly added to the mixture. Afterwards, the
363solution was kept for 30 min at room temperature before use. The
364analytes were dissolved in the microemulsion to give concentrations
365between 0.45 and 0.6 mg/ml. DMSO and dodecanophenonewere used
366as markers for the electroosmotic ﬂow (EOF) and the microemulsion
367droplets, respectively: to 1 ml of the sample solution 1 μl DMSO and
36820 μl dodecanophenone (18 mg/ml in methanol) were added.
369The capacity factor, k, is deﬁned as the ratio nme/naq (nme=total
370number of moles of solute in the microemulsion phase, naq=total
371number of moles of solute in the aqueous phase) and this mass
372distribution coefﬁcient can be calculated according to Eq. (1)
373[to=migration time of an unretained substance (EOF marker),
374tme=migration time of the microemulsion, tR=solute migration
375time] [37,38].
k =
tR−t0
t0 1−tR

tme
  ð1Þ
3767
3783. Results and discussion
379In previous work, we prepared RAPTA-C analogues by linking
380various carbohydrate-derived ligands to RuII–arene scaffold, and some
381examples such as dichlorido(η6-p-cymene)(3,5,6-bicyclophosphite-
3821,2-O-isopropylidene-α-d-glucofuranoside)ruthenium(II) 1 were
383more anticancer active than RAPTA-C in in vitro assays. The complexes
384were found to exhibit aquation of the ﬁrst halido ligand in aqueous
385solution, followed by hydrolysis of a P–O bond of the phosphite ligand,
386and ﬁnally formation of dinuclear species [26]. In order to study the
387inﬂuence of chelating ligands on the hydrolysis, reactivity towards
388biomolecules and cytotoxicity of the complexes, we synthesized
389carbohydrate containing RuII–arene dicarboxylato compounds. This
390concept proved successful in case of RAPTA complexes [23], which
391undergo rapid hydrolysis in aqueous media, although they can be
392stabilized by high concentrations of NaCl [21]. These dicarboxylate
393species were found to be highly soluble and kinetically more stable
394than their RAPTA precursors with the two chlorido ligands and
395notably, the anticancer activitywasmaintained, as was their reactivity
396with biomolecules [23].
3973.1. Synthesis and characterization
398The preparation of the RuII–arene biscarboxylato complexes, 2–6,
399is summarized in Scheme 1, and follows a literature procedure [23]. In
400the ﬁrst step, [biscarboxylato(η6-p-cymene)(H2O)ruthenium(II)] was
401formed by reacting bis[dichlorido(η6-p-cymene)ruthenium(II)] with
402disilver oxalate or malonate (obtained by reacting 2.2 eq. of AgNO3
403with disodium oxalate and malonate) in water. In the second step the
404aqua species was stirred for 2 h in CH3OH with the respective
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405 carbohydrate-based phosphorus ligand. This reaction sequence avoids
406 side reactions involving the silver ions and the phosphorus ligand.
407 The complexes were characterized by 1D and 2D NMR spectros-
408 copy, ESI-MS, and elemental analysis (see Experimental for full
409 details). 31P NMR spectroscopy is very informative as coordination of
410 the P-containing sugar ligands to the metal center results in a
411 signiﬁcant change in frequency from 117 ppm to 134–137 ppm. These
412 values are in the same range as those observed for the analogous Ru
413 compounds with chlorido ligands [26]. In the 1H NMR spectra of
414 malonato Ru–arene complexes, the methylene protons of the malonic
415 acid become diastereotopic upon complexation and give two doublets
416 centered at about δ=3.4 and 3.2 ppm with a geminal coupling
417 constant 2J(H,H)=17 Hz, as expected for an AB system. The 13C{1H}
418 NMR spectra of 2–6 contain prominent signals at ca. 165 and 175 ppm
419 that correspond to coordinated carboxylates of oxalato and malonato
420 ligands, respectively.
421 Single crystals of 2 and 3 suitable for X-ray diffraction studies were
422 grown by slow diffusion of diethyl ether into a solution of the complex
423 in methanol. Their molecular structures are shown in Fig. 2, and as
424 expected, conﬁrm the piano-stool geometry typical of such systems
425 [5,18,23,39]. The ruthenium–centroidarene distances are 1.703 and
4261.704 Å in 2 and 3, which are similar to that observed in the dichlorido
427analogue (1.711 Å) [26]. Both 2 and 3 are solvated by methanol which
428forms H-bonds with a carbonyl oxygen of the oxalato ligand. The key
429binding parameters, such as Ru–P and Ru–O bond lengths, are similar
430to those of oxalo-RAPTA-C (see Table 2) [23].
4313.2. Aquatic stability
432In order to study the inﬂuence of chelating biscarboxylate ligands
433on the behaviour of carbohydrate-based RuII–arene complexes in
434aqueous solution, 2 and 5were dissolved in D2O and the reaction was
435monitored by 1H and 31P{1H} NMR spectroscopy over 15 days. As
436expected, the exchange of the chlorido ligands by biscarboxylato
437resulted in enhanced stability of the compounds. Both the oxalato and
438malonato derivatives are stable towards aquation over one week and
439no aquation products were identiﬁed. In the case of the dichlorido
440RuII–arene analogues mono aqua species are formed within a few
441hours followed by cleavage of the P–O(C5) bond of the sugar-derived
442phosphorous ligand, terminating in the formation of dinuclear species
443[26]. The same trends were basically conﬁrmed by ESI-MS, but in
444addition, a peak at m/z 564.88±0.02 that may be assigned to
445[(cym)2Ru2(μ-MeO)3]+ (19%, exact mass 565.08) was observed. This
446species presumably results from the exchange of the hydroxido
447ligands in [(cym)2Ru2(μ-OH)3]+ with the methanol added to assist
448the spraying/ionization process.
4493.3. Reactivity with biomolecules
450As shown above, in water the complexes are inert, but it has
451previously been shown that in the presence of other ligands (such as
452in biological media) reactions may occur more rapidly [23,26].
453Consequently, the reactivity of 1 and 2 with the sulfur-containing
454amino acids Cys and Met, with the small protein ubiquitin as well as
4555′-GMP as a DNA model were carried out in aqueous solution. In
456particular, the binding to proteinaceous targets appears to be of
457relevance to the mode of action of organometallic Ru(arene)
458complexes [9,40–44], although they are also known to have high
459afﬁnity to DNA [44,45].
460Analysis of samples containing 1 and Met by ESI-MS revealed
461adduct formation during the ﬁrst hours of incubation, with the
462formation of a signal at m/z 649.84±0.02 (relative intensity 76%,
463exact mass 650.11) assignable to the ion [1–2Cl+Met+OH]+
464(Table 3). With time the main peak observed in the spectrum is
Fig. 2.Molecular structures of 2 and one of the two crystallographically independent molecules of 3 (3A); thermal ellipsoids are drawn at 50% probability level and solvent molecules
were omitted for clarity.
a b
Scheme 1. Synthetic route to biscarboxylato RuII–arene compounds with sugar-derived
co-ligands.
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465 found at m/z 383.83±0.02 (100% after 72 h, exact mass 384.06),
466 which corresponds to[(cym)Ru(Met)–H]+.
467 Incubation of 1with Cys leads to deﬁned products only within the
468 ﬁrst 24 h where the most abundant signal at m/z 500.83±0.02
469 corresponds to [1−2Cl+OH]+, followed by m/z 355.90 (14%, exact
470 mass 356.04; [(cym)Ru(Cys)−H]+) andm/z 855.95 (37%, exact mass
471 856.06; [(cym)2Ru2(Cys)3−2 H+Na]+ and the hydrolysis products
472discussed before. Over time the intensities of those peaks decrease
473dramatically and after 72 h they are not assignable to deﬁned reaction
474products, probably due to Cys decomposing the RuII–arene complexes
475present in solution.
476In the spectrum of a solution containing 2 and Met recorded after
47724 h of reaction, there were only traces of Ru–Met adducts visible in
478themass spectrum (Table 3), indicating amuch lower reaction rate for
479the dicarboxylato species. After 72 h, a signal assignable to [(cym)Ru
480(Met)−H]+ (24%)was observed, which increases in relative intensity
481over 7 days of incubation to become the most abundant species,
482similar to the reaction of 1 with Met. In contrast to the reaction with
483Met, there is no signiﬁcant interaction of 2with Cys indicated by mass
484spectrometric methods over 7 days of incubation. These observations
485were also conﬁrmed by NMR spectroscopy.
486The reaction of 1 and 2 with the model protein Ub (8564.2±
4870.2 Da) was monitored over 7 days, and in the case of the dichlorido
488complex 1, a steady increase in relative intensity of the mono-adduct
489[(cym)Ru+Ub] at m/z 8797.4±0.6 Da was observed in the deconvo-
490luted mass spectrum (Fig. 3). The phospite ligand is lost during the
491binding process, as also observed for other RuII–arene complexes [28].
492Although 1 was present in a 2-fold excess no peaks corresponding to
493bis-adducts were observed. Furthermore, the protein appears to
494undergo degradation over time, as indicated by the appearance of, e.g.,
495the [y59+H]+ fragment (51% after 72 h). When incubating 2with Ub,
496no evidence for adduct formation was found during 7 days of
497incubation.
498The reactivity of 2with 5′-GMP was evaluated by means of 1H and
499
31P{1H} NMR spectroscopy and compared to 1. Samples containing
Table 2t2:1
Selected bond lengths (Å) and bond angles (°) of 1–3 and the structurally related compound OxaloRAPTA for comparison purposes.
t2:2
t2:3 1a 2 3c OxaloRAPTA-Cb
t2:4 A B
t2:5 Ru–O1 – 2.073 (4) 2.071 (3) 2.071 (3) 2.093 (2)
t2:6 Ru–O2 – 2.109 (4) 2.087 (3) 2.088 (3) 2.095−(1)
t2:7 Ru–P 2.2406 (11) 2.2491 (16) 2.2500 (11) 2.2492 (12) 2.310 (1)
t2:8 Ru-centroid 1.711 1.703 (3) 1.701 (2) 1.704 (2) 1.690
t2:9 O–Ru–O – 79.11 (17) 78.89 (11) 78.62 (12) 78.43 (7)
t2:10 O1–Ru–P – 85.95 (12) 86.25 (8) 85.40 (8) 82.83 (5)
t2:11 O2–Ru–P – 89.37 (14) 89.05 (9) 89.21 (9) 88.79 (5)
a,b)Taken from Refs. [26] and [23], respectively.
t2:12
c) There are two crystallographically independent molecules of 3 in the asymmetric unit.:13
Table 3t3:1
Relative abundance of selected adducts between 1 and 2 and Met, Cys and Ub
referenced to the most abundant species in the ESI mass spectra recorded after 24, 72
and 168 h of incubation.
t3:2
t3:3 Bioligand Compound Adduct Relative abundance / %
t3:4 24 h 72 h 168 h
t3:5 Met 1 [(cym)Ru(Met)−H]+ 37 100 100
t3:6 [1−2Cl+OH]+ 100 26 0
t3:7 2 [(cym)Ru(Met)−H]+ 3 24 100
t3:8 [2+H]+ 100 100 9
t3:9 Cys 1 [(cym)Ru(Cys)−H]+ 10 0 –a
t3:10 [1−2Cl+OH]+ 100 100 –a
t3:11 2 [(cym)Ru(Cys)−H]+ 0 4 0
t3:12 [2+H]+ 100 100 100
t3:13 Ub 1 [Ub+{Ru(cym)}]+ 66 100 100
t3:14 [Ub]+ 100 51 31
t3:15 [y58]+ 38 17 59
t3:16 2 [Ub+2]+ 0 0 0
t3:17 [Ub]+ 100 100 100
t3:18 [y58]+ 13 16 34
a Cysteine appears to decompose the complexes completely within 168 h.t3:19
Fig. 3. The reaction of 1 with Ub studied by ESI-MS over a period of 3 days. Upon adduct formation, the carbohydrate ligand of 1 is cleaved.
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500 molar ratios of 1:2 (metal complexes : 5′-GMP) were prepared in D2O
501 and analyzed after 0.5, 48 and 120 h. These studies reveal low
502 reactivity for 2 with 5′-GMP, whereas 1 and other dichlorido Ru
503 compounds are relatively reactive and form adducts via the N7 atoms
504 of guanine [26,46].
505 3.4. Evaluation of the in vitro anticancer activity
506 The antiproliferative potential of 2, 3, 5 and 6 (4 is not sufﬁciently
507 soluble in water to be included in the biological assay) was
508 determined in human SW480 colon adenocarcinoma, CH1 ovarian
509 cancer and A549 non-small cell lung cancer cells using the MTT assay,
510 and the obtained results are compared to those of the analogous
511 dichlorido compound 1 and the Os analogues of 2 and 3, i.e., 2Os and
512 3Os (Table 4) [30]. In general, only modest antiproliferative activity
513 was observed for this series of sugar compounds, which is not
514 unexpected considering recent literature reports on the tumor-
515 inhibiting properties of different carbohydrate–metal conjugates
516 [25]. Low in vitro cytotoxicity is common for many ruthenium drug
517 candidates, including NAMI-A and some RuII–arene compounds,
518 which nevertheless are often potent in vivo, e.g., certain RAPTA
519 complexes against tumor metastases [16,47,48].
520 In the series of compounds reported here, the replacement of the
521 labile chlorido ligands by chelating biscarboxylates signiﬁcantly alters
522 the biological activity of the compounds. The IC50 values in the CH1 and
523 SW480 cells are approximately 5–7 times lower for the biscarboxylato
524 complexes compared to their dichlorido counterparts [26], with the
525 malonato complexes 5 and 6 being somewhat more active than their
526 oxalato analogues 2 and 3, suggesting an inﬂuence of ligand stability on
527 cytotoxic potency (Fig. 4). In contrast, similar modiﬁcations in the
528 RAPTA-type complexes had only a minor effect on their tumor-
529 inhibiting potencies [23]. The variation of the phosphite ligand has a
530 minor inﬂuence on anticancer activity, althoughpotential binding to the
531 glucose receptor might by inﬂuenced by the substituents at the
532 carbohydrate-derived moiety.
533 In order to estimate the relative lipophilicity of the compounds,
534 being of relevance for the cellular uptake and therefore for the
535 intracellular concentration, microemulsion electrokinetic chromatog-
536 raphy (MEEKC) experiments were conducted and the capacity factors
537 log kwere determined for 2, 3, 4, 6 and the Os analogues of 2 and 3, i.e.,
538 2Os and 3Os (Table 4), using a literature method [25,49]. The
539 separation in MEEKC is not only based on the analytes electrophoretic
540 mobility but on their hydrophobic interactionwith themicroemulsion
541 droplets. The most active compound 6 was found to have the highest
542 lipophilicity whereas the log k values of the other compounds are in a
543 rather similar range, as are their IC50 values.
5444. Conclusions
545RAPTA-type complexes with their P-based pta ligand are among
546the best studied and most promising RuII–arene anticancer agents
547that appear to interfere with enzymatic targets and in vivo show
548selective antitumor activity. By maintaining the structural features
549around the Ru center, but modifying the carrier ligand, we have
550prepared closely related sugar-derived RuII–arene complexes. In order
551to study the role of the leaving group, the dichlorido ligands were
552replaced by the chelating biscarboxylates, i.e., oxalate and malonate.
553These structural modiﬁcations have a dramatic inﬂuence on the
554chemical and biological properties of the compounds. As expected,
555and in analogy to the RAPTA counterparts, hydrolysis is markedly
556inhibited. The reactivity of the organometallic species to the biological
557nucleophiles Met, Cys, Ub and 5′-GMP is signiﬁcantly reduced, and
558compared to the respective dichlorido complexes, essentially the
559same adducts are formed, but at a signiﬁcantly lowered rate. Since the
560introduction of the biscarboxylate ligands resulted in signiﬁcantly
561reduced in vitro anticancer activity in all tested cell lines, it appears
562that covalent binding to biological Q1targets is a prerequisite for the
563compound type to exhibit their desired biological properties.
564Acknowledgements
565We thank the Higher Education Commission of Pakistan, the
566Austrian Exchange Service (ÖAD), the Hochschuljubiläumsstiftung
567Vienna, the Theodor-Körner-Fonds, the FFG—Austrian Research
568Promotion Agency (811591), the Austrian Council for Research and
569Technology Development (IS526001), COST D39 and CM0902 and the
570Austrian Science Fund for the ﬁnancial support. This research was
571supported by a Marie Curie Intra European Fellowship within the
5727th European Community Framework Programme project 220890-
573SuRuCo (A.A.N.). We gratefully acknowledge Alexander Roller for
574collecting the X-ray diffraction data and Prof. Markus Galanski for
575recording the 2D NMR spectra.
576Appendix A. Supplementary data
577Supplementary data to this article can be found online at
578doi:10.1016/j.jinorgbio.2010.10.004.
579References
580[1] C.G. Hartinger, P.J. Dyson, Chem. Soc. Rev. 38 (2009) 391–401.
581[2] A. Nguyen, A. Vessieres, E.A. Hillard, S. Top, P. Pigeon, G. Jaouen, Chimia 61 (2007)
582716–724.
583[3] K. Strohfeldt, M. Tacke, Chem. Soc. Rev. 37 (2008) 1174–1187.
584[4] Dalton transactions themed issue on metal anticancer compounds, Dalton Trans.
585(2009) 10629–10936.
586[5] W.F. Schmid, R.O. John, V.B. Arion, M.A. Jakupec, B.K. Keppler, Organometallics 26
587(2007) 6643–6652.
Table 4t4:1
In vitro anticancer activity (mean IC50 values±standard deviations) of 2, 3, 5 and 6 in
human ovarian cancer (CH1), colon cancer (SW480) and non-small cell lung cancer
(A549) cells (exposure time 96 h), compared to 1, 2Os and 3Os, and the correlation to the
capacity factor log k.
t4:2
t4:3 Compound IC50 values / μM log k
t4:4 CH1 SW480 A549
t4:5 1a 60±14 361±122 – –
t4:6 2 425±43 N640 N640 −0.212
t4:7 3 354±31 N640 N640 −0.178
t4:8 2Osb 436±72 N640 N640 −0.386
t4:9 3Osb 764±215 N640 N640 0.296
t4:10 5 301±16 613±11 N640 –
t4:11 6 198±7 204±19 N640 2.124
a IC50 values taken from Ref. [26].t4:12
b IC50 values taken from Ref. [23].t4:13
Fig. 4. Concentration–effect curves of 3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-
d-glucofuranoside complexes 1 (dichlorido), 2 (oxalato) and 5 (malonato) in CH1 cells
(exposure time 96 h).
7M. Hanif et al. / Journal of Inorganic Biochemistry xxx (2010) xxx–xxx
Please cite this article as: M. Hanif, et al., From hydrolytically labile to hydrolytically stable Ru(II)–arene anticancer complexes with
carbohydrate-derived co-ligands, J. Inorg. Biochem. (2010), doi:10.1016/j.jinorgbio.2010.10.004
45
588 [6] W.H. Ang, A. De Luca, C. Chapuis-Bernasconi, L. Juillerat-Jeanneret, M. Lo Bello, P.J.
589 Dyson, ChemMedChem 2 (2007) 1799–1806.
590 [7] C.A. Vock, W.H. Ang, C. Scolaro, A.D. Phillips, L. Lagopoulos, L. Juillerat-Jeanneret,
591 G. Sava, R. Scopelliti, P.J. Dyson, J. Med. Chem. 50 (2007) 2166–2175.
592 [8] J. Maksomiska, D.S. Williams, G.E. Atilla-Gokcumen, K.S.M. Smalley, P.J. Carroll, R.D.
593 Webster, P. Filippakopoulos, S. Knapp,M. Herlyn, E. Meggers, Chem. Eur. J. 14 (2008)
594 4816–4822.
595 [9] W.H. Ang, L.J. Parker, A. De Luca, L. Juillerat-Jeanneret, C.J. Morton, M. Lo Bello, M.W.
596 Parker, P.J. Dyson, Angew. Chem. Int. Ed. 48 (2009) 3854–3857.
597 [10] N. Metzler-Nolte, Angew. Chem. Int. Ed. 40 (2001) 1040–1043.
598 [11] N. Metzler-Nolte, Chimia 61 (2007) 736–741.
599 [12] C.V. Christodoulou, D.R. Ferry, D.W. Fyfe, A. Young, J. Doran, T.M.T. Sheehan, A.
600 Eliopoulos, K. Hale, J. Baumgart, G. Sass, D.J. Kerr, J. Clin. Oncol. 16 (1998)
601 2761–2769.
602 [13] P. Köpf-Maier, Anticancer Res. 19 (1999) 493–504.
603 [14] R.E. Morris, R.E. Aird, P.d.S. Murdoch, H. Chen, J. Cummings, N.D. Hughes, S.
604 Parsons, A. Parkin, G. Boyd, D.I. Jodrell, P.J. Sadler, J. Med. Chem. 44 (2001)
605 3616–3621.
606 [15] R.E. Aird, J. Cummings, A.A. Ritchie, M. Muir, R.E. Morris, H. Chen, P.J. Sadler, D.I.
607 Jodrell, Br. J. Cancer 86 (2002) 1652–1657.
608 [16] C. Scolaro, A. Bergamo, L. Brescacin, R. Delﬁno, M. Cocchietto, G. Laurenczy, T.J.
609 Geldbach, G. Sava, P.J. Dyson, J. Med. Chem. 48 (2005) 4161–4171.
610 [17] M.G. Mendoza-Ferri, C.G. Hartinger, A.A. Nazarov, R.E. Eichinger, M.A. Jakupec, K.
611 Severin, B.K. Keppler, Organometallics 28 (2009) 6260–6265.
612 [18] W. Kandioller, C.G. Hartinger, A.A. Nazarov, C. Bartel, M. Skocic, M.A. Jakupec, V.B.
613 Arion, B.K. Keppler, Chem. Eur. J. 15 (2009) 12283–12291.
614 [19] M.G. Mendoza-Ferri, C.G. Hartinger, M.A. Mendoza, M. Groessl, A.E. Egger, R.E.
615 Eichinger, J.B. Mangrum, N.P. Farrell, M. Maruszak, P.J. Bednarski, F. Klein, M.A.
616 Jakupec, A.A. Nazarov, K. Severin, B.K. Keppler, J. Med. Chem. 52 (2009) 916–925.
617 [20] W.F. Schmid, R.O. John, G. Mühlgassner, P. Heffeter, M.A. Jakupec, M. Galanski, W.
618 Berger, V.B. Arion, B.K. Keppler, J. Med. Chem. 50 (2007) 6343–6355.
619 [21] C. Scolaro, C.G. Hartinger, C.S. Allardyce, B.K. Keppler, P.J. Dyson, J. Inorg. Biochem.
620 102 (2008) 1743–1748.
621 [22] C. Scolaro, T.J. Geldbach, S. Rochat, A. Dorcier, C. Gossens, A. Bergamo, M.
622 Cocchietto, I. Tavernelli, G. Sava, U. Rothlisberger, P.J. Dyson, Organometallics 25
623 (2006) 756–765.
624 [23] W.H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeannerat, P.J. Dyson,
625 Inorg. Chem. 45 (2006) 9006–9013.
626 [24] W.H. Ang, E. Daldini, L. Juillerat-Jeanneret, P.J. Dyson, Inorg. Chem. 46 (2007)
627 9048–9050.
628 [25] C.G. Hartinger, A.A. Nazarov, S.M. Ashraf, P.J. Dyson, B.K. Keppler, Curr. Med. Chem.
629 15 (2008) 2574–2591.
630 [26] I. Berger, M. Hanif, A.A. Nazarov, C.G. Hartinger, R.O. John, M.L. Kuznetsov, M.
631 Groessl, F. Schmitt, O. Zava, F. Biba, V.B. Arion, M. Galanski, M.A. Jakupec, L.
632 Juillerat-Jeanneret, P.J. Dyson, B.K. Keppler, Chem. Eur. J. 14 (2008) 9046–9057.
633[27] R.A. Gatenby, R.J. Gillies, Nat. Rev. Cancer 4 (2004) 891–899.
634[28] M. Hanif, H. Henke, S.M. Meier, S. Martic, M. Labib, W. Kandioller, M.A. Jakupec, V.B.
635Arion, H.-B. Kraatz, B.K. Keppler, C.G. Hartinger, Inorg. Chem. 49 (2010) 7953–7963.
636[29] R.W. Hay, S. Miller, Polyhedron 17 (1998) 2337–2343.
637[30] M. Hanif, A.A. Nazarov, C.G. Hartinger, W. Kandioller, M.A. Jakupec, V.B. Arion, P.J.
638Dyson, B.K. Keppler, Dalton Trans. 39 (2010) 7345–7352.
639[31] S. Stahl, H. Werner, Organometallics 9 (1990) 1876–1881.
640[32] N.K. Kochetkov, E.E. Nifant'ev, M.P. Koroteev, Z.K. Zhane, A.A. Borisenko,
641Carbohydr. Res. 47 (1976) 221–231.
642[33] M.P. Koroteev, S.B. Khrebtova, A.R. Bekker, N.M. Pugashova, V.K. Bel'skii, A.Y.
643Zotov, E.E. Nifant'ev, Zh. Obshch. Khim. 66 (1996) 1615–1628.
644[34] M.R. Pressprich, J. Chambers, SAINT + Integration Engine, Program for Crystal
645Structure Integration, Madison, 2004.
646[35] G.M. Sheldrick, Acta Crystallogr., Sect. A: Found. Crystallogr. 64 (2008) 112–122.
647[36] L.J. Farrugia, J. Appl. Crystallogr. 30 (1997) 565.
648[37] P.-E. Mahuzier, M.S. Aurora Prado, B.J. Clark, E.R.M. Kedor-Hackmann, K.D. Altria,
649LC GC Eur. Q216 (2003) 22–29.
650[38] A.K. Bytzek, M.R. Reithofer, M. Galanski, M. Groessl, B.K. Keppler, C.G. Hartinger,
651Electrophoresis 31 (2010) 1144–1150.
652[39] A.F.A. Peacock, M. Melchart, R.J. Deeth, A. Habtemariam, S. Parsons, P.J. Sadler,
653Chem. Eur. J. 13 (2007) 2601–2613.
654[40] A. Casini, C. Gabbiani, F. Sorrentino, M.P. Rigobello, A. Bindoli, T.J. Geldbach, A.
655Marrone, N. Re, C.G. Hartinger, P.J. Dyson, L. Messori, J. Med. Chem. 51 (2008)
6566773–6781.
657[41] A. Casini, C. Gabbiani, E. Michelucci, G. Pieraccini, G. Moneti, P.J. Dyson, L. Messori,
658J. Biol. Inorg. Chem. 14 (2009) 761–770.
659[42] A. Casini, A. Karotki, C. Gabbiani, F. Rugi, M. Vasak, L. Messori, P.J. Dyson,
660Metallomics 1 (2009) 434–441.
661[43] M. Groessl, M. Terenghi, A. Casini, L. Elviri, R. Lobinski, P.J. Dyson, J. Anal. At.
662Spectrom. 25 (2010) 305–313.
663[44] A.E. Egger, C.G. Hartinger, A.K. Renfrew, P.J. Dyson, J. Biol. Inorg. Chem. 15 (2010)
664919–927.
665[45] M. Groessl, Y.O. Tsybin, C.G. Hartinger, B.K. Keppler, P.J. Dyson, J. Biol. Inorg. Chem.
66615 (2010) 677–688.
667[46] A. Dorcier, C.G. Hartinger, R. Scopelliti, R.H. Fish, B.K. Keppler, P.J. Dyson, J. Inorg.
668Biochem. 102 (2008) 1066–1076.
669[47] M. Galanski, M.A. Jakupec, B.K. Keppler, Curr. Med. Chem. 12 (2005) 2075–2094.
670[48] P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, L. Elbling, M.
671Micksche, B. Keppler, W. Berger, Drug Res. Upd. 11 (2008) 1–16.
672[49] C. Rappel, M. Galanski, A. Yasemi, L. Habala, B.K. Keppler, Electrophoresis 26
673(2005) 878–884.
674
8 M. Hanif et al. / Journal of Inorganic Biochemistry xxx (2010) xxx–xxx
Please cite this article as: M. Hanif, et al., From hydrolytically labile to hydrolytically stable Ru(II)–arene anticancer complexes with
carbohydrate-derived co-ligands, J. Inorg. Biochem. (2010), doi:10.1016/j.jinorgbio.2010.10.004
46
  
2.4. The Arene Moiety as Anticancer Activity Determining Pa-
rameter in Organometallic Ru(II) Complexes with Carbohydrate 
Derived Ligands 
 
Results and Discussion  
RAPTA complexes are among the most extensively studied Ru–arene anticancer 
agents. In order to further improve the specificity and efficacy, RAPTA-C analogues 
were prepared by using carbohydrate derived moieties instead of pta. The resulting 
organometallic compounds exhibited selectivity for tumorigenic cell lines, and di-
chlorido(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-
glucofuranoside)ruthenium(II) 1, was found to be more cytotoxic  than RAPTA-C in 
in vitro assays.83,84 In order to investigate the influence of the nature of the arene 
ligand on the cytotoxicity, analogous  compounds with benzene, toluene and  biphe-
nyl arene ligand were prepared. 
The organometallic RuII-chlorido complexes 2-6 were synthesized in high yields by 
reacting 3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-glucofuranoside I or 
3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-glucofuranoside II with the re-
spective dimer bis[dichlorido(η6-arene)ruthenium(II)]  in CH2Cl2 (Fig. 13).  All the 
complexes were characterized by 1D and 2D NMR spectroscopy, ESI-MS, and ele-
mental analysis. On coordination of the P-containing ligands to the metal center,  the 
most significant change observed was a low field chemical shift of the 31P{1H} 
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NMR signals from ca. 117 to approximately 135 ppm, similar to reported analogous 
compounds.83 
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Figure 13. Synthesis of the dichlorido–RuII compounds 1-6 of P-derived sugar ligands (I, 
II). 
Stability in aqueous solution 
The hydrolysis of 2 and 3 was studied by 31P{1H} NMR spectroscopy.  For the tolu-
ene compound only a single peak is observed at 136.1 ppm after 1 h of dissolution, 
which was assigned to unhydrolyzed compound, indicating stability for this time 
period in aqueous solution. After 24 h, two additional peaks of equal relative inten-
sity at 137.4 and 136.8 ppm appear due to the formation of diastereomers by ex-
change of a single chlorido ligand with an aqua molecule. This was accompanied by 
the cleavage of a P–O bond as indicated by signals of equal relative intensity at 95.7 
and 94.5 ppm, while an additional signal at 94.7 ppm indicates P–O bond cleavage 
of unhydrolyzed complex. After 48 h, two additional signals appeared at 123.8 and 
122.4 ppm, potentially due to formation of dimeric species. The sequence of forma-
tion of hydrolytic species is similar to that observed for related ruthenium(II) com-
pounds.83 No further hydrolysis was observed for another 48 h, as the number and 
extent of hydrolysis products remained unchanged and account together for 30-40 
%.  
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Reaction with 9-EtG 
Complex 3 demonstrated rapid adduct formation with the DNA model 9-EtG via N7 
of the guanine moiety, as shown by 1H NMR spectroscopy. A low field shift from 
7.85 to 8.29 ppm was observed for H8 of guanine, indicating N7 binding. Immedi-
ately after mixing complex 3 with 9-EtG, a single peak was obtained at 135.9 ppm 
in the 31P{1H}- NMR for the unreacted compound. Within one hour, two additional 
signals at 136.6 and 137.2 ppm appeared due to the formation of diastereomers by 
exchange of one of the chlorido ligand with 9-EtG. However, after 24 h several spe-
cies were formed, including signals at 93.3 and 95.1 ppm indicative for cleavage of 
P-O bond. 
Evaluation of the in vitro cytotoxicity 
The tumor-inhibiting potential of 2–6 was determined in human SW480 colon ade-
nocarcinoma, CH1 ovarian cancer and A549 non-small cell lung cancer cells by 
means of the MTT assays (Table 1 ). Variation in the arene ligand of metal arene 
complexes has demonstrated a stronge influence on the antiproliferative activity. It 
appears that cytotoxicity is increased with both the size of the arene ligand and the 
lipophilicity of carbohydrate moiety in this series of Ru(II) complexes. The most 
lipophilic compound 6 with biphenyl arene was the most active with IC50 values in 
low micromolar range. The following order of cytotoxicity is observed with regard 
to variation of arene ligand with same sugar moiety: biphenyl > cymene > toluene > 
benzene. This is also observed when keeping the arene ligand same while changing 
the carbohydrates derived moiety, the compound having the most lipophilic ligand 
was the most cytotoxic. As we know, for a drug to exert its desired pharmacological 
effects, it must reach the target sites in sufficient concentration. Therefore, more 
lipophilic molecules penetrate through cell membranes more easily than those with 
less lipophilicity. This result in greater drug uptake and subsequently enhanced ac-
tivity. 
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Table 1. In vitro anticancer activity (mean IC50 values ± standard deviations) of 1-6 in hu-
man ovarian cancer (CH1), colon cancer (SW480) and non-small cell lung cancer (A549) 
cells (exposure time 96 h). 
IC50 values / µM Compound 
CH1 SW480 A549 
1 29 ± 4 a 150 ± 19 a 223 ± 14 a 
2 118 ± 36 129 ± 13 417 ± 68 
3 164 ± 47 276 ± 6 427 ± 163 
4 92 ± 22 99 ± 13 486 ± 55 
5 29 ± 3 26 ± 5 >160 
6 3.9 ± 0.3 5.3 ± 0.9 56 ± 9 
a) taken from ref.83 
 
Conclusions 
Organometallic compounds have gained an increasing importance in metallo-drug 
design. In particular, the M( η6-arene) moiety is versatile scaffold that can be modu-
lated to attribute desired properties to the molecule. A series of RuII( η6-arene) com-
plexes with carbohydrate-derived phosphorus-containing ligands was synthesized. 
These compounds exhibit IC50 values upto low micromolar range, depending on the 
lipophilicity of arene ligand with biphenyl containing compound the most active. In 
hydrolysis studies, the compounds form monoaqua species by exchange of chloride 
with water molecule, followed by cleavage of intramolecular P–O bond and forma-
tion of dinuclear species as demonstrated by 1H and 31P{1H} NMR spectroscopy. 
Adduct formation with DNA model 9-EtG was observed. 
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Experimental Section 
Materials: All reactions were carried out in dry solvents under an inert atmosphere. 
All chemicals were obtained from commercial suppliers, and were of analytical 
grade and used as received. RuCl3.xH2O was purchased from Johnson Matthey, 1-
methyl-1,4-cyclohexadiene from Aldrich, 1-isopropyl-4-methyl-1,3-cyclohexadiene 
(α-terpinene),  and 3-cyclohexadiene from Acros Organics. Methanol and CH2Cl2 
were dried using standard procedures. The dimer bis[dichlorido(η6-
biphenyl)ruthenium(II)],85 bis[dichlorido(η6-p-cymene)ruthenium(II)],86,87 
bis[dichlorido(η6-benzene)ruthenium(II)], bis[dichlorido(η6-toluene)ruthenium(II)], 
3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-glucofuranoside I,  3,5,6-
bicyclophosphite-1,2-O-cyclohexylidene-α-D-glucofuranoside88,89 II and dichlori-
do(η6-p-cymene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-
glucofuranose)ruthenium(II)83 1 were synthesized using literature procedures. 
Na2EDTA (p.a., Fisher Scientific), NaOH (Fluka), tris(hydroxymethyl)aminoethane 
(TAE) and glacial acetic acid (p.a., Acros) and MilliQ H2O (18.2 MΩ, Synergy 185 
UV Ultrapure, Millipore, France) were used for the preparation of TAE buffer for 
gel electrophoresis studies. Loading buffer (6x), pBR322 DNA (0.5 µg/µL) and 
GeneRulerTM 1kb DNA Ladder (0.5 µg/µL) were obtained from Fermentas.  1H, 
13C{1H} and 31P{1H} NMR spectra were recorded at 25 °C on a Bruker FT NMR 
spectrometer Avance III 500 MHz at 500.10 (1H), 125.75 (13C{1H}) and 202.44 
MHz (31P{1H}). 2D NMR spectra were collected in a gradient-enhanced mode. 
Melting points were measured on a Büchi B-540 apparatus and are uncorrected. 
Elemental analysis was determined by the Laboratory for Elemental Analysis, Fac-
                                                 
85
 Morris, R. E.; Sadler, P. J.; Chen, H.; Jodrell, D. Half-sandwich ruthenium(II) compounds compris-
ing nitrogen containing ligands for treatment of cancer. 2000-GB4144, 2001. 
86
 M. A. Bennett, T. N. Huang, T. W. Matheson, A. K. Smith, Inorg. Synth. 1982, 21, 74. 
87
 M. A. Bennett, A. K. Smith, J. Chem. Soc., Dalton Trans. 1974, 233. 
88
 N.K. Kochetkov, E.E. Nifant'ev, M.P. Koroteev, Z.K. Zhane, A.A. Borisenko, Carbohydr. Res. 47 
(1976) 221-231. 
89
 M.P. Koroteev, S.B. Khrebtova, A.R. Bekker, N.M. Pugashova, V.K. Bel'skii, A.Y. Zotov, E.E. 
Nifant'ev, Zh. Obshch. Khim. 66 (1996) 1615-1628 
51
ulty of Chemistry, University of Vienna, on a Perkin–Elmer 2400 CHN Elemental 
Analyzer. Electrospray ionization mass spectra were recorded on a Bruker es-
quire3000.  
General Procedure 
A mixture of bis[(η6-arene)dichloridoruthenium] (1 eq.) and phosphite ligand (2 eq.) 
in dry CH2Cl2 (25 mL) was stirred at 40 °C for 3 h. The solvent was reduced to 
about 3 mL under vacuum and diethyl ether (20 mL) was added resulting in orange 
or brown precipitate which were filtered, washed with diethyl ether (2×5 mL), and 
dried under vacuum. 
Dichlorido(η6-benzene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-
glucofuranose)ruthenium(II) 2  
The title compound was synthesized from 3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene-α-D-glucofuranose (58 mg, 0.2 mmol) and [(η6-benzene)RuCl(µ-
Cl)]2 (50 mg, 0.1 mmol) following the general procedure. 
Yield: 104 mg (96%); m.p. 295-297 °C (decomp); elemental analysis calcd. for 
C18H23Cl2O6PRu·0.5CH2Cl2: C 38.25, H 4.16; found: C 38.21, H 4.19%; MS (ESI+): 
m/z: 560.7 [M + Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 6.20 (brs, 1 H, H-
1), 5.89 (s, 6 H, H-Ar), 5.10-5.13 (m, 1 H, H-5), 4.83 (brs, 1 H, H-3), 4.75 (brs, 1 H, 
H-2), 4.48-4.50 (m, 1 H, H-6), 4.32-4.33 (m, 2 H, H-6’, H-4), 1.57-1.70 (m, 10 H, 
C6H10) ppm. 13C{1H} NMR (125.75 MHz, CDCl3, 25 °C): δ = 113.3 (Ccyc), 105.4 
(C-1), 91.2 (C-Ar), 83.4 (C-2), 79.5 (C-3), 75.7 (C-4), 75.2 (C-5), 71.5 (C-6), 36.5 
(C6H10), 35.8 (C6H10), 24.8 (C6H10), 23.9 (C6H10), 23.5 (C6H10) ppm. 31P{1H} NMR 
(202.44 MHz, CDCl3, 25 °C): δ = 132.7 ppm.  
Dichlorido(η6-toluene)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-
glucofuranose)ruthenium(II) 3  
The title compound was synthesized from 3,5,6-bicyclophosphite-1,2-O-
isopropylidene-α-D-glucofuranose (99 mg, 0.4 mmol) and [(η6-toluene)RuCl(µ-Cl)]2 
(106 mg, 0.2 mmol) following the general procedure. 
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Yield: 201 mg (97%); m.p. 180-181 °C (decomp); elemental analysis calcd. for 
C16H21Cl2O6PRu·0.25CH2Cl2: C 36.58, H 4.06; found: C 36.93, H 4.22%; MS 
(ESI+): m/z: 534.6 [M + Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 6.19 (d, J 
= 3 Hz, 1 H, H-1), 5.81-5.82 (m, 2 H, H-Ar), 5.58 (brs, 2 H, H-Ar), 5.52 (brs, 1 H, 
H-Ar) , 5.09-5.12 (m, 1 H, H-5), 4.81 (brs, 1 H, H-3), 4.74 (d, J = 2 Hz, 1 H, H-2), 
4.44-4.48 (m, 1 H, H-6), 4.32 (m, 2 H, H-6’, H-4), 2.34 (s, 3 H, Ar-CH3), 1.52 (s, 
3 H, C(CH3)2), 1.36 (s, 3 H, C(CH3)2) ppm. 13C{1H} NMR (125.75 MHz, CDCl3, 
25 °C): δ = 113.0 (C(CH3)2), 112.6 (C-Ar), 105.7 (C-1), 91.0 (C-Ar), 90.6 (C-Ar),  
83.7 (J = 6 Hz, C-2), 82.2 (C-Ar), 81.8 (C-Ar), 79.2 (J = 8 Hz, C-3), 77.2 (C-Ar), 
76.8 (J = 6 Hz, C-4), 74.8 (J = 5 Hz, C-5), 69.9 (J = 8 Hz, C-6), 26.9 (C(CH3)2), 26.3 
(C(CH3)2), 19.2 (Ar-CH3) ppm. 31P{1H} NMR (202.44 MHz, CDCl3, 25 °C): δ = 
134.5 ppm. 
Dichlorido(η6-toluene)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-D-
glucofuranose)ruthenium(II) 4  
The title compound was synthesized from 3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene-α-D-glucofuranose (58 mg, 0.2 mmol) and [(η6-toluene)RuCl(µ-
Cl)]2 (53 mg, 0.1 mmol) following the general procedure. 
Yield: 107 mg (95%); m.p. 282-283 °C (decomp); elemental analysis calcd. for 
C19H25Cl2O6PRu·0.15CH2Cl2: C 39.37, H 4.40; found: C 39.06, H 4.40%; MS 
(ESI+): m/z: 574.6 [M + Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 6.18 (d, J 
= 4 Hz, 1 H, H-1), 5.80-5.82 (m, 2 H, H-Ar), 5.58 (brs, 2 H, H-Ar), 5.50-5.51 (m, 
1 H, H-Ar), 5.08-5.12 (m, 1 H, H-5), 4.82 (brs, 1 H, H-3), 4.73 (brs, 1 H, H-2), 4.44-
4.48 (m, 1 H, H-6), 4.31 (m, 2 H, H-6’, H-4), 2.34 (s, 3 H, Ar-CH3), 1.67-1.70 (m, 
4 H, C6H10), 1.56-1.58 (m, 6 H, C6H10) ppm. 13C{1H} NMR (125.75 MHz, CDCl3, 
25 °C): δ = 113.7 (Ccyc),  112.7 (C-Ar), 105.3 (C-1), 91.1 (C-Ar), 90.7 (C-Ar), 83.4 
(J = 7 Hz, C-2), 82.3 (C-Ar), 81.6 (C-Ar), 79.4 (J = 8 Hz, C-3), 77.4 (C-Ar), 76.6 (J 
= 6 Hz, C-4), 74.9 (J = 5 Hz, C-5), 69.8 (J = 8 Hz, C-6), 36.9 (C6H10), 36.2 (C6H10), 
24.8 (C6H10), 24.2 (C6H10), 23.5 (C6H10), 19.2 (CH3) ppm. 31P{1H} NMR 
(202.44 MHz, CDCl3, 25 °C): δ = 134.4 ppm. 
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Dichlorido(η6-biphenyl)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-
glucofuranose)ruthenium(II) 5  
The title compound was synthesized from 3,5,6-bicyclophosphite-1,2-O-
isopropylidene-α-D-glucofuranose (99 mg, 0.4 mmol) and [(η6-biphenyl)RuCl(µ-
Cl)]2 (131 mg, 0.2 mmol) following the general procedure. 
Yield: 217 mg (91%); m.p. 178-179 °C (decomp); elemental analysis calcd. for 
C21H23Cl2O6PRu·0.25CH2Cl2: C 42.85, H 3.98; found: C 42.97, H 3.88%; MS 
(ESI+): m/z:: 596.6 [M + Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 7.69-7.71 
(m, 2 H, H-Ar), 7.49-7.50 (m, 3 H, H-Ar), 6.18-6.22 (m, 3 H, H-Ar), 5.99 (d, J = 
4 Hz, 1 H, H-1), 5.88 (brs, 2 H, H-Ar), 5.03-5.07 (m, 1 H, H-5), 4.72 (brs, 1 H, H-3), 
4.38-4.44 (m, 2 H, H-6’, H-2), 4.26 (brs, 1 H, H-4), 4.19 (brs, 1 H, H-6), 1.50 (s, 
3 H, C(CH3)2), 1.33 (s, 3 H, C(CH3)2) ppm. 13C{1H} NMR (125.75 MHz, CDCl3, 
25 °C): δ = 133.7 (C-Ar), 130.1 (C-Ar), 129.0 (C-Ar),  128.8 (C-Ar), 128.7 (C-Ar), 
127.3 (C-Ar), 112.5 (C(CH3)2),  108.3 (C-Ar), 105.7 (C-1), 91.2 (C-Ar), 90.8 (C-
Ar),  89.9 (C-Ar), 88.9 (C-Ar), 88.2 (C-Ar), 83.6 (J = 5 Hz, C-4), 79.1 (J = 8 Hz, C-
3), 76.8 (C-2),  74.9 (J = 5 Hz, C-5), 69.6 (C-6), 26.9 (C(CH3)2), 26.3 (C(CH3)2) 
ppm. 31P{1H} NMR (202.44 MHz, CDCl3, 25 °C): δ = 132.3 ppm.  
Dichlorido(η6-biphenyl)(3,5,6-bicyclophosphite-1,2-O-cyclohexylidene-α-
D-glucofuranose)ruthenium(II) 6  
The title compound was synthesized from 3,5,6-bicyclophosphite-1,2-O-
cyclohexylidene-α-D-glucofuranose (58 mg, 0.2 mmol) and [(η6-biphenyl)RuCl(µ-
Cl)]2 (65 mg, 0.1 mmol) following the general procedure. 
Yield: 119 mg (93%); m.p. 170-172 °C (decomp); elemental analysis calcd. for 
C24H27Cl2O6PRu·0.3CH2Cl2: C 45.61, H 4.35; found: C 45.27, H 4.38%; MS (ESI+): 
m/z: 636.7 [M + Na]+; 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 7.62-7.69 (m, 
2 H, H-Ar), 7.46-7.49 (m, 3 H, H-Ar), 6.17-6.20 (m, 2 H, H-Ar), 5.97-6.01 (m, 3 H, 
H-Ar, H-1), 5.87 (brs, 1 H, H-Ar), 5.03-5.05 (m, 1 H, H-5), 4.73 (brs, 1 H, H-3), 
4.43-4.46 (m, 2 H, H-6’, H-2), 4.26 (brs, 1 H, H-4), 4.18 (brs, 1 H, H-6), 1.65-1.67 
(m, 4 H, C6H10), 1.54-1.58 (m, 6 H, C6H10) ppm. 13C{1H} NMR (125.75 MHz, 
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CDCl3, 25 °C): δ = 133.6 (C-Ar), 130.1 (C-Ar), 129.0 (C-Ar),  128.8 (C-Ar), 128.6 
(C-Ar), 127.2 (C-Ar), 113.2 (Ccyc),  108.5 (C-Ar), 105.4 (C-1), 91.3 (C-Ar), 90.6 (C-
Ar),  90.0 (C-Ar), 89.0 (C-Ar), 88.3 (C-Ar), 83.2 (J = 6 Hz, C-4), 79.2 (J = 8 Hz, C-
3), 76.6 (C-2),  75.0 (J = 5 Hz, C-5), 70.0 (C-6), 36.5 (C6H10), 35.8 (C6H10), 24.8 
(C6H10), 23.9 (C6H10), 23.5 (C6H10) ppm. 31P{1H} NMR (202.44 MHz, CDCl3, 
25 °C): δ = 132.4 ppm.  
Hydrolysis and reactivity with 9-ethylguanine 
For hydrolysis studies, 2 and 3 were dissolved in D2O and the samples were ana-
lyzed by 1H and 31P{1H} NMR spectroscopy after 1, 24, 48 and 96 h. For 9-
ethylguanine (9-EtG) binding experiments, the complexes were mixed at molar ra-
tios of 1 : 1 and 1 : 2 (complex :9-EtG) in D2O and the reaction progress was moni-
tored by 1H and 31P{1H} NMR spectroscopy after 1, 24, and 96 h, while samples 
were kept at room temperature during this time period.  
Cytotoxicity in cancer cell lines 
Cell lines and culture conditions. CH1 cells originate from an ascites sample of a 
patient with a papillary cystadenocarcinoma of the ovary and were a generous gift 
from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer 
Research, Sutton, UK. SW480 (adenocarcinoma of the colon, human), and A549 
(non-small cell lung cancer, human) cells were kindly provided by Brigitte Marian 
(Institute of Cancer Research, Department of Medicine I, Medical University of 
Vienna, Austria). All cell culture reagents were obtained from Sigma-Aldrich 
Austria. Cells were grown in 75 cm² culture flasks (Iwaki) as adherent monolayer 
cultures in Eagle’s Minimal Essential Medium (MEM) supplemented with 10% 
heat-inactivated foetal calf serum, 1 mM sodium pyruvate and 2 mM L-glutamine. 
Cultures were maintained at 37 °C in a humidified atmosphere containing 95% air 
and 5% CO2. 
MTT assay conditions. Cytotoxicity was determined by the colorimetric MTT (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, purchased from 
Fluka) microculture assay. For this purpose, cells were harvested from culture flasks 
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by trypsinization and seeded in 100 µL aliquots MEM supplemented with 10% heat-
inactivated foetal calf serum, 1 mM sodium pyruvate, 4 mM L-glutamine and 1% 
non-essential amino acids (100×) into 96-well microculture plates (Iwaki). Cell den-
sities of 1.5 × 103 cells/well (CH1), 2.5 × 103 cells/well (SW480) and 
4 × 103 cells/well (A549) were chosen in order to ensure exponential growth of un-
treated controls throughout the experiment. Cells were allowed to settle and resume 
exponential growth for 24 h. The test compounds were dissolved and serially diluted 
in the same medium and added in 100 µL aliquots to the microcultures (if necessary 
due to limited solubility, the maximum concentration tested was added in 200 µL 
aliquots after removal of the medium), and cells were exposed to the test compounds 
for 96 hours. At the end of the exposure period, all media were replaced by 
100 µL/well RPMI1640 culture medium (supplemented with 10% heat-inactivated 
foetal calf serum) plus 20 µL/well MTT solution in phosphate-buffered saline 
(5 mg/ml). After incubation for 4 h, the supernatants were removed, and the forma-
zan crystals formed by vital cells were dissolved in 150 µL DMSO per well. Optical 
densities at 550 nm were measured with a microplate reader (Tecan Spectra Clas-
sic), using a reference wavelength of 690 nm to correct for unspecific absorption. 
The quantity of vital cells was expressed in terms of T/C values by comparison to 
untreated control microcultures, and 50% inhibitory concentrations (IC50) were cal-
culated from concentration-effect curves by interpolation. Evaluation is based on 
means from at least three independent experiments, each comprising at least three 
replicates per concentration level. 
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 2.5. Hydroxypyr(id)ones and their medicinal applications  
Hydroxypyrones have enjoyed growing interest in medicinal inorganic chemistry as 
a versatile class of chelating ligands.90 Pyrones can be converted to their N-
heterocyclic analogous pyridones by reaction with ammonia, primary amines, or 
bifunctional amines such as amino acids. In these reactions the pyrone ring –O– is 
replaced by –NR–, providing a great variety of potentially useful ligands and even 
for conjugating biologically active molecules.  Some 1-aryl derivatives can be syn-
thesized by direct heating aromatic amines with maltol in a sealed tube; however, 
the reaction completion takes a very long time and yields are often low. 91,92   
O
O
OH
a
O
O
OBn
b
N
O
OBn
R
c
N
O
OH
R
 
 
Figure 14. Synthetic strategy for conversion of pyrone to pyridone. a) BnBr, b) H2N-R, c) 
H2, Pd/C.  
It is often necessary to protect the hydroxyl group via benzylation to facilitate the 
reaction for high yields. Cleavage of the benzyl group via hydrogenation affords the 
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desired pyridones (Fig. 14).93,94There are three classes of hydroxypyridones namely, 
3-hydroxy-4-pyridone, 3-hydroxy-2-pyridone and 1-hydroxy-2-pyridone (Fig. 15). 
These are heterocyclic compounds with a hydroxyl group ortho to a ketone, and be-
have as {O,O} bidentates to form thermodynamically stable 5-membered chelate 
rings for metal-coordination similar to their pyrone analogues. In addition, the pyri-
done moiety contains a tertiary amino group which along with hydroxyl and ketone 
H-bonding functionalities, also contributes to enhance the solubility of the resulting 
complexes in comparison to pyrones.95 Moreover, the ease of N-functionalization of 
pyridones provides the option for the development of a variety of derivatives, 
namely bidentate,96,97,98 tetradentate,99,100 hexadentate chelators101 and tethering bioac-
tive or biological molecules including carbohydrates and amino acids.96  
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Figure 15. Examples for pyrone and pyridone ligands. 
2.5.1 Medicinal applications of hydroxypyr(id)ones 
Hydroxypyrones occur mostly as natural products such as maltol and kojic acid but 
many of them can be synthesized. Maltol is known for its biocompatibility and fa-
vorable toxicity profile and is used as food additive;102 whereas kojic acid is exten-
sively used as cosmetics additive and also inhibits the copper-containing enzyme 
tyrosinase that causes melanization in humans.103 In the last two decades, hy-
droxypyr(id)ones have found many applications in medicinal inorganic chemistry 
and they have been extensively investigated as metal chelators,90,101 magnetic reso-
nance imaging (MRI) contrast agents,104 matrix metalloprotein inhibitors,105 ,106 recep-
tors for Li+ or Na+,107,108 anthrax lethal factor inhibitors,109,110 antidiabetic,111 antivi-
ral,109 and antibacterial agents.109,112  
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2.5.2. Organometallic anticancer compounds of pyr(id)one ligands  
Sadler and co-workers reported Ru(arene) and Os(arene) compounds of maltol. 
These compounds were shown to be inactive in in vitro assays that can be attributed 
to their low stability and the formation of a hydroxide-bridged dimer under physio-
logical conditions.113 Keppler and coworkers have synthesized Ru(arene) complexes 
with modified pyrone ligands (Fig. 16), and some examples have shown potent anti-
cancer activity with IC50 values in the low micromolar range.114,115,116,117 The 
Ru(arene)(pyronato)(halido) complexes hydrolyze to their respective aqua species 
under physiological conditions. The aqua ligand can be rapidly replaced by biologi-
cal targets and test reactions with small biomolecules, such as the DNA model 5’-
GMP, were conducted.114-117 For the latter selective binding to the N7 of the guanine 
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moiety was shown and such adducts are stable in solution for more than 18 h, sug-
gesting DNA as a possible target for these organometallic Ru compounds.  
 
 
Figure 16. Structures of mono- (a,b), di- (c) and trinuclear (d) Ru/Os(arene)(pyr(id)one)X 
complexes with tumor-inhibiting properties.  
 
In addition to the substitution on the pyrone scaffold, the replacement of the car-
bonyl oxygen by a sulfur atom resulted in improved stability of the Ru complexes.115 
In contrast to the Ru(arene) complexes of O,O-chelating pyrones, in vitro anticancer 
activity assays revealed potent growth inhibition for their S,O-chelating thiopyrone 
analogues with IC50 values in the low µM range. Thus the stronger binding of 
thiopyrones to the ruthenium center explains the higher stability in aqueous solution 
compared to their pyrone counterparts. These complexes also react rapidly with 5’-
GMP to form mono-adducts, however, they show a significantly different behavior 
in presence of amino acids, forming stable complexes with Met and His, with the 
thiopyrone ligand remaining bound to the Ru center. This demonstrates again the 
higher stability of the thiopyrone complexes which might allow them to enter the 
cells to a higher degree in their unmodified form.114, 115 
Moreover, complexes based on 4-pyridonato ligands were reported and by linking 
pyridones di- and trinuclear Ru and Os(arene) compounds were obtained 
(Fig. 16).118,119,120,121 Out of the series of compounds, the dinuclear species proved to 
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be the most efficient in in vitro anticancer activity assays, in some cell lines being 
superior to platinum-based anticancer drugs (Fig. 16). The most potent dinuclear 
compound was 1,12-bis{chlorido[3-(oxo-κO)-2-methyl-4-pyridinonato-
κO4]cym)ruthenium(II)}dodecane (IC50 = 0.29 µM) which is an order of magnitude 
more active than cisplatin (IC50 = 4.5 µM) and equally active as oxaliplatin (IC50 = 
0.30 µM) in SW480 cells.118  The compounds show strong affinity for transferrin, but 
surprisingly no interaction with the smaller cellular proteins ubiquitin and cyto-
chrome c was detected. The compounds react rapidly with DNA and model nucleo-
tides, as observed by NMR spectroscopy, DNA precipitation, mass spectrometry, 
and gel electrophoresis. The anticancer activity of this compound class initially ap-
peared to be determined by their lipophilicity,118 however, DNA and protein interac-
tion studies revealed significant potential for DNA-protein and interduplex cross-
linking.122  
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Hydroxypyr(id)ones are versatile ligands for the synthesis of organometallic anticancer agents, equipping them with
fine-tunable pharmacological properties. Herein, we report on the preparation, mode of action, and in vitro anticancer
activity of RuII- and OsII-arene complexes with alkoxycarbonylmethyl-3-hydroxy-2-pyridone ligands. The hydrolysis
and binding to amino acids proceed quickly, as characterized by NMR spectroscopy and ESI mass spectrometry.
However, the reaction with amino acids causes cleavage of the pyridone ligands from the metal center because the
amino acids act as multidentate ligands. A similar behavior was also observed during the reactions with the model
proteins ubiquitin and cytochrome c, yielding mainly [protein þ M(η6-p-cymene)] adducts (M = Ru, Os). Notably the
ligand cleavage of the Os derivative was significantly slower than of its Ru analogue, which could explain its higher
activity in in vitro anticancer assays. Furthermore, the reaction of the compounds to 50-GMP was characterized and
coordination to the N7 of the guanine moiety was demonstrated by 1H NMR spectroscopy and X-ray diffraction
analysis. CDK2/Cyclin A protein kinase inhibition studies revealed potent activity of the Ru and Os complexes.
Introduction
Ruthenium-based coordination compounds and organo-
metallics are promising antitumor agents, and NAMI-A and
KP1019 have passed clinical phase I trials.1-6 Ruthenium
complexes benefit from low ligand exchange rates (similar to
platinum complexes), low systemic toxicity, a range of oxida-
tion states accessible under physiological conditions, some
physicochemical properties similar to iron, and affinity to
serum transport proteins.7-10 In recent years, the anticancer
activity of Ru drug candidates has often been compared to
that of their Os analogues; however, no clear-cut structure-
activity relationship could be derived. Organometallic
ruthenium(II)-arene and also their analogous osmium(II)-
arene compounds provide an option to fine-tune the chemical
reactivity and also pharmacological properties such as water
solubility, oral bioavailability, stability in plasma, pharma-
cokinetic behavior, etc., on the basis of the choice of ligands
and coordination geometry.5
One of the first concepts applied in the quest for organo-
metallic Ru anticancer drugs was to combine metal-arene
moieties with bioactive ligands as in the first organometallic
ruthenium species tested for anticancer activity, i.e., [Ru(η6-
C6H6)Cl2(metronidazole)], containing the common antiin-
fective agentmetronidazole.11 This strategy was also successful
with a variety of enzyme inhibitors such as paullones, ethacry-
nic acid, and staurosporine.12-14 However, the combination of
noncytotoxic ligands with metals also led to compounds with
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significant anticancer activity as demonstrated for pta, ethy-
lenediamine, and many other examples.4-6,15
Metal-arene complexes of the type [M(η6-arene)-
(XY)Cl]nþ (XY= a bidentate N,N-, N,O-, O,O- or S,O-
chelating ligand; n=0, 1) have shownpromising cytotoxicity
profiles. The coordination of simple bidentate N,N ligands
such as ethylenediamine to organometallic Ru(II)-arene
species resulted in compounds exhibiting high cytotoxicity
in cancer cells, including cisplatin-resistant cell lines.4 Mono-
functional covalent binding accompanied by a hydrogen
bond toDNAnucleobases is considered essential for themode
of action,16with the ultimate targets of bioorganometallics still
remaining unclear and controversially discussed.4,5,17 Com-
plexes bearing paullone-derived N,N-chelating ligands are
highly active in in vitro anticancer assays, regardless of
whether rutheniumor osmium is the centralmetal.13 The same
metal centers equipped with N,O- and O,O-chelating ligands
such as those derived from the amino acids glycine, L-alanine,
and L-proline, or with 8-oxyquinolinato, tropolonato, or
acetylacetonato give compounds which are moderately
cytotoxic,18 whereas with picolinato and picolinamide ligands
promising in vitro activities, also in cisplatin-resistant cells,
were observed.19-21
Mononuclear ruthenium-arene complexes with O,O-
bound maltol-derived ligands are not or are only marginally
cytotoxic.22,23 Switching from O,O- to S,O-donor systems
increases the anticancer activity in vitro,24 probably because
of higher stability in the presence of biomolecules.25 Ex-
changing pyrones by pyridones (HPs), for example in
dinuclear ruthenium-arene complexes with an adjustable
spacer length, results in high anticancer activity with the
potential to overcome drug resistance.26-30 Another class of
O,O-donor system ligands are hydroxypyr(id)ones, and their
metal complexes have demonstrated potential in different
research areas, including medicinal inorganic chemistry. They
have been studied extensively as metal chelators,31,32 mag-
netic resonance imaging (MRI) contrast media,33-41 matrix
metalloprotein inhibitors,42-44 receptors for Liþ or Naþ,45-47
anthrax lethal factor inhibitors,48,49 antidiabetic,50-53 antiviral,49
and antibacterial agents.48,49,54 We have reported a series of
mono- and polynuclear metal-arene complexes of 3-hydro-
xy-4-pyr(id)ones and investigated their tumor inhibiting
properties.23,24,26,27,29,55 In order to extend the structure-
activity relationships, a series of mononuclear metal(II)-
arene complexes of ruthenium and osmium withO,O-bound
alkoxycarbonylmethyl-3-hydroxy-2(1H)-pyridones were
synthesized and characterized with regard to stability toward
hydrolysis, biological activity, and interaction with DNA
model nucleobases such as 50-GMP and 9-ethylguanine and
with proteins in order to correlate affinity to biomolecules
with anticancer activity.
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Experimental Section
Materials and Methods. All reactions were carried out in dry
solvents under an inert atmosphere. Chemicals obtained from
commercial suppliers were used as received and were of analy-
tical grade; methanol and CH2Cl2 were dried using standard
procedures. OsO4 (99.8%; Caution! OsO4 is highly toxic and
volatile!56) and RuCl3 3 3H2O (40.4%) were purchased from
Johnson Matthey; ubiquitin from bovine red blood cells and
horse heart cytochrome c from Sigma; L-alanine and R-terpi-
nene from Acros; glycine and L-histidine from Merck; L-cy-
steine, 50-dGMP, 50-GMP, and N2H4 3 2HCl from Fluka; and L-
methionine from Sigma-Aldrich. The solvents for ESI-MS
studies were methanol (VWR Int., HiPerSolv CHROMA-
NORM), formic acid (Fluka), and Milli-Q H2O (18.2 MΩ,
Synergy 185 UVUltrapure, Millipore, France). The dimers bis-
[dichlorido(η6-p-cymene)ruthenium(II)],57,58 bis[dibromido(η6-
p-cymene)ruthenium(II)],28 bis[diiodido(η6-p-cymene)ruthe-
nium(II)],28 and bis[dichlorido(η6-p-cymene)osmium(II)],59
and the ligands 1-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-
pyridone a,60 1-[(methoxycarbonyl)methyl]-3-hydroxy-2-(1H)-
pyridone b,61 and 1-ethoxycarbonylmethyl-3-hydroxy-4-methyl-
2-(1H)-pyridone c62 were synthesized using literature procedures.
1H, 31P{1H}, and 13C{1H} NMR spectra were recorded at
25 C on a Bruker FT NMR spectrometer Avance III 500 MHz
at 500.10 (1H), 202.44 (31P{1H}), and 125.75 MHz (13C{1H}),
and 2DNMRdata were collected in a gradient-enhancedmode.
Melting points were measured on a B€uchi B-540 apparatus and
are uncorrected. Elemental analysis was done on a Perkin-
Elmer 2400 CHN elemental analyzer by the Laboratory for
Elemental Analysis, Faculty of Chemistry, University of Vienna.
Electrospray ionization mass spectra were recorded on a Bruker
esquire3000 ion trap instrument.
X-ray diffraction measurements of single crystals of 1a, 1b,
and 5a were performed on a Bruker X8 APEX II CCD diffrac-
tometer at 100 K. The crystals were positioned at 35 mm from
the detector and 1917, 1580, and 1446 frames for 30, 50, and 60 s
over 1 were measured for 1a, 1b, and 5a, respectively. The data
were processed using the SAINT Plus software package.63
Crystal data, data collection parameters, and structure refine-
ment details are given in Table 1. The structures were solved by
direct methods and refined by full-matrix least-squares techni-
ques. Non-hydrogen atoms were refined with anisotropic dis-
placement parameters. H atoms were inserted at calculated
positions and refined with a riding model. The isopropyl group
of the p-cymene moiety in 5a was found disordered. The
disorder was resolved with constrained anisotropic displace-
ment parameters and restrained bond distances using EADP
and SADI instructions of SHELX97, respectively. The site
occupation factors were refined to about 0.60:0.40. The following
software programs and tables were used: structure solution,
SHELXS-97;64,65 refinement, SHELXL-97;65,66 and molecular
diagrams, ORTEP-3.67
Synthesis. General Procedure. A solution of 3-hydroxy-
2-(1H)-pyridone (2.2 equiv) and NaOMe (3.5 equiv) in 20 mL
MeOH was stirred for about 30 min. A solution of [(η6-
cymene)MX(μ-X)]2 (1.0 equiv; M = Ru, Os; X = Cl, Br, I) in
5 mL CH2Cl2 was added, and the mixture was stirred for 4 h at
RT. The solvent was removed under reduced pressure. The
residue was redissolved in CH2Cl2, and filtered to remove un-
dissolved impurities. The filtrate was evaporated under vacuum.
Recrystallization from CH2Cl2 and diethyl ether gave the pure
product.
[Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-
KO-2-(1H)-pyridonato-KO}ruthenium(II)] (1a). The title com-
pound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hy-
droxy-2-(1H)-pyridone (130 mg, 0.33 mmol), NaOMe (38 mg,
0.70 mmol), and [(η6-p-cymene)RuCl(μ-Cl)]2 (92 mg, 0.15
mmol), following the general procedure. Crystals suitable for
X-ray diffraction analysis were grown by slow diffusion of
diethyl ether into a solution of 1a in CH2Cl2. Yield: 130 mg
(93%), mp 221-222 C dec. Elemental analysis: found C, 48.55;
H, 4.88; N, 2.94. Calcd for C19H24O4NClRu: C, 48.87; H, 5.18;
N, 2.99; MS (ESIþ) m/z 432.2 [M - Cl]þ. 1H NMR (500.10
MHz, CDCl3, 25 C): δ 6.67 (dd, 3J(H5,H6) = 8Hz, 4J(H4,H6) = 1
Hz, 1H,H-6Py), 6.40 (dd,
3J(H4,H5)=7Hz,
4J(H4,H6)=1Hz, 1H,
H-4Py), 6.26 (dd,
3J(H5,H6)= 7Hz,
3J(H4,H5)= 7Hz, 1H,H-5Py),
5.62 (d, 3J(H,H) = 6 Hz; 1H, Ar-H), 5.60 (d,
3J(H,H) = 6 Hz, 1H,
Ar-H), 5.38 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.34 (d,
3J(H,H) = 6
Hz, 1H,Ar-H), 5.11 (d, 2Jgem(H,H)= 17Hz, 1H,NCH2CO), 4.27
(m, 3H, NCH2CO, OCH2CH3), 2.93 (m, 1H, CH(CH3)2), 2.31
(s, 3H, Ar-CH3), 1.33 (m, 9H, (CH3)2CH-Ar, OCH2CH3) ppm.
13C{1H} NMR (125.75 MHz, CDCl3, 25 C): δ 167.0 (C-2),
166.3 (C-3), 160.9 (COOEt), 121.1 (C-4), 117.6 (C-6), 112.7 (C-
5), 99.7 (C-Ar), 94.4 (C-Ar), 81.4 (CH-Ar), 80.5 (CH-Ar), 79.3
(CH-Ar), 77.8 (CH-Ar), 61.9 (OCH2CH3), 51.3 (NCH2CO),
31.2 (CH(CH3)2), 22.5 (CH(CH3)2), 22.4 (CH(CH3)2), 18.5 (Ar-
CH3), 14.2 (OCH2CH3) ppm.
[Chlorido(η6-p-cymene){N-[(methoxycarbonyl)methyl]-3-oxo-
KO-2-(1H)-pyridonato-KO}ruthenium(II)] (1b). The title com-
pound was synthesized from N-[(methoxycarbonyl)methyl]-3-
hydroxy-2-(1H)-pyridone (40 mg, 0.22 mmol), NaOMe (19 mg,
0.35mmol) and [(η6-p-cymene)RuCl(μ-Cl)]2 (61mg, 0.10mmol),
following the general procedure. Crystals suitable for X-ray
diffraction analysis were grown by slow diffusion of diethyl
ether into a solution of 1b in CH2Cl2. Yield: 81 mg (90%), mp
>200 C dec. Elemental analysis: found C, 47.39; H, 4.63; N,
2.98. Calcd for C18H22NO4ClRu: C, 47.74; H, 4.89; N, 3.09; MS
(ESIþ) m/z 418.0 [M - Cl]þ. 1H NMR (500.10 MHz, CDCl3,
25 C): δ 6.67 (dd, 3J(H5,H6)=8Hz, 4J(H4,H6)= 1Hz, 1H,H-6Py),
6.40 (d, 3J(H4,H5) = 7Hz, 1H,H-4Py), 6.26 (dd,
3J(H5,H6) = 7Hz,
3J(H4,H5)=8Hz, 1H,H-5Py), 5.51 (d,
3J(H,H)= 6Hz; 1H,Ar-H),
5.50 (d, 3J(H,H) = 6 Hz; 1H, Ar-H), 5.31 (d,
3J(H,H) = 6 Hz, 1H,
Ar-H), 5.31 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.11 (d,
2Jgem(H,H) =
17 Hz, 1H, NCH2CO), 4.27 (d,
2Jgem(H,H) = 17 Hz, 1H,
NCH2CO), 3.81 (s, 3H, OCH3), 2.88 (m, 1H, CH(CH3)2), 2.29
(s, 3H, Ar-CH3), 1.34 (d,
3J(H,H) = 6.9Hz, 3H, CH(CH3)2), 1.30
(d, 3J(H,H) = 6.9 Hz, 3H, CH(CH3)2) ppm.
13C{1H} NMR
(125.75 MHz, CDCl3, 25 C): δ 167.3 (C-2), 166.2 (C-3), 160.7
(COOMe), 121.1 (C-4), 117.7 (C-6), 112.8 (C-5), 99.4 (C-Ar),
94.8 (C-Ar), 81.3 (CH-Ar), 80.5 (CH-Ar), 79.2 (CH-Ar), 77.3
(CH-Ar), 52.7 (COOCH3), 51.3 (NCH2CO), 31.1 (CH(CH3)2),
22.4 (CH(CH3)2), 22.3 (CH(CH3)2), 18.5 (Ar-CH3) ppm.
[Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-KO-
4-methyl-2(1H)-pyridonato-KO}ruthenium(II)] (1c). The title com-
pound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hy-
droxy-4-methyl-2(1H)-pyridone (85 mg, 0.40 mmol), NaOMe
(25 mg, 0.44 mmol), and [(η6-p-cymene)RuCl(μ-Cl)]2 (122 mg,
(56) Young, J. A. J. Chem. Educ. 2002, 79, 1064.
(57) Bennett, M. A.; Smith, A. K. J. Chem. Soc., Dalton Trans. 1974,
233–41.
(58) Bennett, M. A.; Huang, T. N.; Matheson, T. W.; Smith, A. K. Inorg.
Synth. 1982, 21, 74–8.
(59) Kiel, W. A.; Ball, R. G.; Graham, W. A. G. J. Organomet. Chem.
1990, 383, 481–96.
(60) Streater, M.; Taylor, P. D.; Hider, R. C.; Porter, J. J. Med. Chem.
1990, 33, 1749–55.
(61) Brown, E. J.; Whitwood, A. C.; Walton, P. H.; Duhme-Klair, A.-K.
Dalton Trans. 2004, 2458–2462.
(62) Fox, R. C.; Taylor, P. D. Synth. Commun. 1998, 28, 1563–1574.
(63) Pressprich, M. R.; Chambers, J. SAINT þ Integration Engine,
Program for Crystal Structure Integration; Bruker Analytical X-ray Systems:
Madison, WI, 2004.
(64) Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solu-
tion, University G€ottingen: G€ottingen, Germany, 1997.
(65) Sheldrick, G.M.Acta Crystallogr., Sect. A: Found. Crystallogr. 2008,
A64, 112–122.
(66) Sheldrick, G. M. SHELXL-97, Program for Crystal Structure Re-
finement; University G€ottingen; G€ottingen, Germany, 1997. (67) Farrugia, L. J. J. Appl. Crystallogr. 1997, 30, 565.
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0.20mmol), following the general procedure.Yield: 110mg (57%),
mp>200 C dec. Elemental analysis: found C, 49.60; H, 5.23; N,
2.89. Calcd for C20H26NO4ClRu: C, 49.95; H, 5.45; N, 2.91; MS
(ESIþ) m/z 446.0 [M - Cl]þ. 1H NMR (500.10 MHz, CDCl3,
25 C):δ6.34 (d, 3J(H5,H6)=7Hz, 1H,H-6Py), 6.18 (dd, 3J(H5,H6)=
7 Hz, 1H, H-5Py), 5.52 (d,
3J(H,H)=6 Hz, 1H, Ar-H), 5.49 (d,
3J(H,H)=6Hz, 1H, Ar-H), 5.25 (d,
3J(H,H)=6Hz, 1H, Ar-H), 5.24
(d, 3J(H,H)=6 Hz, 1H, Ar-H), 5.13 (d,
2Jgem(H,H)=17 Hz, 1H,
NCH2CO), 4.28 (m, 2H, OCH2CH3), 4.19 (d,
2Jgem(H,H)=17 Hz,
1H, NCH2CO), 2.89 (m, 1H, CH(CH3)2) 2.31 (s, 3H, Ar-CH3),
2.19 (s, 3H, Py-CH3), 1.34 (m, 9H, CH(CH3)2, OCH2CH3) ppm.
13C{1H} NMR (125.75MHz, CDCl3, 25 C): δ 167.2 (C-2), 164.3
(C-3), 158.2 (COOEt), 128.9 (C-4), 120.0 (C-6), 115.4 (C-5), 98.5
(C-Ar), 95.8 (C-Ar), 81.3 (CH-Ar), 80.5 (CH-Ar), 77.7 (CH-Ar),
77.1 (CH-Ar), 61.8 (OCH2CH3), 51.1 (NCH2CO), 31.1 (CH-
(CH3)2), 22.4 (CH(CH3)2), 22.3 (CH(CH3)2), 18.5 (Ar-CH3),
15.5 (Py-CH3), 14.2 (OCH2CH3) ppm.
[Bromido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-
KO-2-(1H)-pyridonato-KO}ruthenium(II)] (2a). The title com-
pound was synthesized from N-[(ethoxycarbonyl)methyl]-3-
hydroxy-2-(1H)-pyridone (43 mg, 0.22 mmol), NaOMe (19
mg, 0.35 mmol), and [(η6-p-cymene)RuBr(μ-Br)]2 (79 mg, 0.10
mmol), following the general procedure. Yield: 90 mg (88%),
mp 204-205 C dec. Elemental analysis: found C, 44.44; H,
4.69; N, 2,78. Calcd for C19H24NO4BrRu: C, 44.63; H, 4.73;
N, 2.74; MS (ESIþ) m/z 432.0 [M - Br]þ. 1H NMR (500.10
MHz, CDCl3, 25 C): δ 6.67 (dd, 3J(H5,H6) = 8 Hz, 4J(H4,H6) =
1 Hz, 1H, H-6Py), 6.40 (dd,
3J(H4,H5) = 7 Hz,
4J(H4,H6) = 1 Hz,
1H, H-4Py), 6.26 (dd,
3J(H5,H6) = 7 Hz,
3J(H4,H5) = 7 Hz, 1H,
H-5Py), 5.53 (d,
3J(H,H) = 6 Hz, 1H, Ar-H), 5.52 (d,
3J(H,H) =
6 Hz, 1H, Ar-H), 5.32 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.31 (d,
3J(H,H) = 6 Hz, 1H, Ar-H), 5.11 (d,
2Jgem(H,H) = 17 Hz, 1H,
NCH2CO), 4.27 (m, 3H, NCH2CO, OCH2CH3), 2.93 (m, 1H,
CH(CH3)2) 2.31 (s, 3H, Ar-CH3), 1.33 (m, 9H, CH(CH3)2,
OCH2CH3) ppm.
13C{1H}NMR (125.75MHz, CDCl3, 25 C):
δ 167.0 (C-2), 166.3 (C-3), 160.9 (COOEt), 121.1 (C-4), 117.6
(C-6), 112.7 (C-5), 99.7 (C-Ar), 94.4 (C-Ar), 81.4 (CH-Ar),
80.5 (CH-Ar), 79.3 (CH-Ar), 77.8 (CH-Ar), 61.9 (OCH2CH3),
51.3 (NCH2CO), 31.2 (CH(CH3)2), 22.5 (CH(CH3)2), 22.4
(CH(CH3)2), 18.5 (Ar-CH3), 14.2 (OCH2CH3) ppm.
[(η6-p-Cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-KO-2-(1H)-
pyridonato-KO}iodidoruthenium(II)] (3a). The title compound was
synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-
pyridone (43 mg, 0.22 mmol), NaOMe (19 mg, 0.35 mmol), and
[(η6-p-cymene)RuI(μ-I)]2 (98 mg, 0.10 mmol), following the gen-
eral procedure. Yield: 69 mg (62%), mp 214-215 C dec. Ele-
mental analysis: found C, 40.53; H, 4.26; N, 2.5. Calcd for
C19H24NO4IRu: C, 40.87; H, 4.33; N, 2.51; MS (ESI
þ) m/z
432.0 [M - I]þ. 1H NMR (500.10 MHz, CDCl3, 25 C): δ 6.66
(dd, 3J(H5,H6)=1Hz,
4J(H4,H6)=7Hz,1H,H-6Py), 6.41 (dd,
3J(H4,H5)=
7 Hz, 4J(H4,H6)=1 Hz, 1H, H-4Py), 6.26 (dd,
3J(H5,H6)=7 Hz,
3J(H4,H5)=8 Hz, 1H, H-5Py), 5.58 (d,
3J(H,H)=5 Hz, 1H, Ar-H),
5.54 (d, 3J(H,H)=5Hz, 1H,Ar-H), 5.38 (d,
3J(H,H)= 5Hz, 1H,Ar-
H), 5.31 (d, 3J(H,H)=5Hz, 1H, Ar-H), 5.02 (d,
2Jgem(H,H)=17Hz,
1H,NCH2CO), 4.28 (m, 3H,NCH2CO,OCH2CH3), 2.95 (m, 1H,
CH(CH3)2) 2.33 (s, 3H,Ar-CH3), 1.33 (m, 9H,CH(CH3)2, OCH2-
CH3) ppm.
13C{1H} NMR (125.75 MHz, CDCl3, 25 C): δ 167.3
(C-2), 166.7 (C-3), 161.7 (COOEt), 121.0 (C-4), 117.5 (C-6), 112.8
(C-5), 100.2 (C-Ar), 94.4 (C-Ar), 80.0 (CH-Ar), 79.4 (CH-Ar), 78.9
(CH-Ar), 77.0 (CH-Ar), 61.1 (OCH2CH3), 51.4 (NCH2CO), 31.4
(CH(CH3)2), 22.6 (CH(CH3)2), 22.5 (CH(CH3)2), 19.2 (Ar-CH3),
14.2 (OCH2CH3) ppm.
[Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-KO-
2-(1H)-pyridonato-KO}osmium(II)] (4a). The title compound was
synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-
pyridone (44 mg, 0.22 mmol), NaOMe (19 mg, 0.35 mmol), and
[(η6-p-cymene)OsCl(μ-Cl)]2 (79 mg, 0.10 mmol), following the
general procedure. Yield: 85 mg (76%), mp 222-223 C dec.
Elemental analysis: found C, 40.81; H, 4.14; N, 2.50. Calcd for
C19H24O4NClOs: C, 41.04; H, 4.35; N, 2.52; MS (ESI
þ)m/z 520.2
[M- Cl]þ. 1H NMR (500.10 MHz, CDCl3, 25 C): δ 6.68 (dd,
3J(H5,H6)=8Hz,
4J(H4,H6)=1Hz, 1H,H-6Py), 6.41 (dd,
3J(H4,H5)=
7 Hz, 4J(H4,H6)=1 Hz, 1H, H-4Py), 6.26 (dd,
3J(H5,H6)=7 Hz,
3J(H4,H5) = 7Hz, 1H, H-5Py), 5.51 (d,
3J(H,H) = 6 Hz, 1H, Ar-H),
5.50 (d, 3J(H,H)=6 Hz, 1H, Ar-H), 5.31 (d,
3J(H,H)=6 Hz, 1H,
Ar-H), 5.30 (d, 3J(H,H)=6Hz, 1H, Ar-H), 5.11 (d, 2Jgem(H,H)=17
Hz, 1H, NCH2CO), 4.27 (m, 3H,NCH2CO,OCH2CH3), 2.93 (m,
1H, CH(CH3)2), 2.31 (s, 3H, Ar-CH3), 1.33 (m, 9H, CH(CH3)2,
OCH2CH3) ppm.
13C{1H} NMR (125.75MHz, CDCl3, 25 C): δ
167.3 (C-2), 166.1 (C-3), 160.9 (COOEt), 121.4 (C-4), 117.6 (C-6),
Table 1. Crystal Data and Details of Data Collection for 1a, 1b, and 5aa
compound 1a 1b 5a
chemical formula C19H24ClNO4Ru C18H22ClNO4Ru C27H33F3N6O8Ru S
M (g mol-1) 466.91 452.89 759.72
temperature (K) 100(2) 100(2) 100(2)
crystal size (mm) 0.25  0.20  0.13 0.14  0.10  0.04 0.20  0.13  0.13
crystal color, habit orange, block orange, block orange, block
crystal system triclinic triclinic triclinic
space group P1 P1 P1
a (A˚) 9.5302(4) 9.4338(4) 11.6654(5)
b (A˚) 10.1465(4) 10.0892(4) 12.5639(9)
c (A˚) 10.5931(5) 10.2654(5) 12.6860(7)
V (A˚3) 960.63(7) 922.26(7) 1606.11(16)
Z 2 2 2
Dc (g cm
-3) 1.614 1.631 1.571
μ (mm-1) 0.979 1.017 0.627
F(000) 476 460 776
Θ range (deg) 2.64 to 30.12 2.64 to 30.08 2.51 to 30.11
h range -13/13 -13/13 -16/16
k range -14/14 -14/14 -17/17
l range -14/14 -14/14 -17/17
no. refls. 5610 5384 9411
no. parameters 237 227 425
Rint 0.0358 0.0736 0.0609
R1 (obs.) 0.0241 0.0356 0.0366
wR2 (all data) 0.0596 0.0802 0.0908
S 1.003 1.014 1.005
aRefinementwas by full-matrix least-squares (Fo
2) for all reflections,R1=
P
||Fo|- |Fc||/
P
|Fo|,wR2={
P
[w(Fo
2-Fc2)2]/
P
[w(Fo
2)2]}1/2. Goodness
of fit, S={
P
[w(Fo
2 - Fc2)2]/(n - p)}1/2.
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112.7 (C-5), 99.7 (C-Ar), 94.4 (C-Ar), 81.4 (CH-Ar), 80.5 (CH-Ar),
79.3 (CH-Ar), 77.8 (CH-Ar), 61.9 (OCH2CH3), 51.3 (NCH2CO),
31.2 (CH(CH3)2), 22.5 (CH(CH3)2), 22.4 (CH(CH3)2), 18.5
(Ar-CH3), 14.4 (OCH2CH3) ppm.
[(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-KO-2-(1H)-
pyridonato-KO}(9-ethylguanine-KN7)ruthenium(II)] trifluorometha-
nesulfonate (5a).Asolution ofAg(CF3SO3) (20mg, 0.077mmol) in
H2O (5 mL) was added to a solution of 1a (33 mg, 0.070 mmol) in
H2O (15 mL) and stirred for 2 h at RT under light protection. The
solution was filtered to remove AgCl, and 9-ethylguanine (14 mg,
0.077mmol; 9-EtG) was added to the filtrate and stirred for 24 h at
RT. The solvent was removed under reduced pressure, and the
product was recrystallized frommethanol and diethyl ether to give
crystals suitable forX-ray diffraction analysis. Yield: 36mg (67%),
mp >200 C dec. Elemental analysis: found C, 42.68; H, 4.12; N,
10.94. Calcd for C27H33N6O8F3SRu: C, 42.69; H, 4.38; N, 11.06;
MS (ESIþ) m/z 432.0 [M- 9EtG]þ (100%), 610.8 [M]þ (9%). 1H
NMR (500.10 MHz, DMSO-d4, 25 C): δ 10.77 (s, 1H, H-N1 of
9-EtG), 7.70 (s, 1H, H-8 of 9-EtG), 7.03 (dd, 3J(H5,H6) = 8 Hz,
4J(H4,H6)=1Hz, 1H,H-6Py), 6.79 (dd,
3J(H4,H5)=7Hz,
4J(H4,H6)=
1Hz, 1H,H-4Py), 6.65 (dd,
3J(H5,H6) = 7Hz,
3J(H4,H5) = 7Hz, 1H,
H-5Py), 6.41 (brs, 2H,H2N of 9-EtG), 5.85 (d,
3J(H,H) = 6Hz, 1H,
Ar-H), 5.77 (d, 3J(H,H) = 6Hz, 1H,Ar-H), 5.63 (d,
3J(H,H) = 6Hz,
1H,Ar-H), 5.58 (d, 3J(H,H)=6Hz, 1H,Ar-H), 5.17 (d,
2Jgem(H,H)=
17 Hz, 1H, NCH2CO), 5.04 (d,
2Jgem(H,H)=17 Hz, 1H, NCH2-
CO), 4.20 (m, 2H, OCH2CH3), 3.96 (m, 2H, NCH2CH3), 2.84 (m,
1H, CH(CH3)2), 2.26 (s, 3H, Ar-CH3), 1.33 (m, 3H, NCH2-
CH3)1.24 (m, 9H, CH(CH3)2, OCH2CH3) ppm.
13C{1H} NMR
(125.75 MHz, DMSO-d4, 25 C): δ 167.9 (C-2), 165.5 (C-3), 160.0
(COO), 157.3 (C6 of 9-EtG), 154.6 (C2 of 9-EtG), 151.4 (C4 of
9-EtG), 137.4 (C6 of 9-EtG), 129.3 (C-4), 123.5 (C-6), 117.8 (C-5),
117.2 (C5 of 9-EtG), 99.8 (C-Ar), 96.7 (C-Ar), 82.1 (CH-Ar), 81.8
(CH-Ar), 80.4 (CH-Ar), 79.6 (CH-Ar), 62.1 (OCH2CH3), 61.7
(NCH2CH3), 52.1 (NCH2CO), 30.99 (CH(CH3)2), 22.5 (CH-
(CH3)2), 22.4 (CH(CH3)2), 17.9 (Ar-CH3), 15.8 (NCH2CH3),
14.6 (OCH2CH3) ppm.
Hydrolysis Experiments. For hydrolysis studies, compounds
1a, 1b, and 4a (1-2 mg/mL) were dissolved in MeOD-d4/D2O
(5/95) solution, and the samples were analyzed by 1H NMR
spectroscopy. In order to force aquation of the complex, the
chlorido ligands were abstracted by addition of 2 equiv of
AgNO3 in D2O, and the solution was filtered to remove AgCl.
In both cases, 1H NMR spectra were recorded after 0.5, 24, 48,
72, and 120 h. To study a potential suppression of hydrolysis by
the presence of chloride, we dissolved 1a in 100 mM NaCl
solution in D2O (1-2 mg/mL), and a solution of 1a in D2O was
placed in a capillary in the same NMR tube for reference.
pKa Determination. pKa values were determined by dissolving
complexes 1a, 1b, and 4a inMeOD-d4/D2O (5/95) solution. The
pH values were measured directly in the NMR tubes with a pH
meter Eco Scan pH6 equipped with a glass microcombination
pH electrode (Orion 9826BN) and calibrated with standard
buffer solutions of pH 4.00, 7.00, and 10.00. The pH titration
was performed with NaOD (0.4-0.0004% in D2O) and DNO3
(0.4-0.0004% in D2O). The pH values were plotted against the
chemical shifts of the Arcym-H2/H6 protons of the arene ring in
the 1H NMR spectra, and the resulting curves were fitted using
the Henderson-Hasselbalch equation with Microsoft Office
Excel 2003, SP3 (Microsoft Corporation). The experimentally
obtained pKa* values were corrected with eq 1, in order to
convert the pKa* in D2O to the corresponding pKa values in
aqueous solutions.68
pKa ¼ 0:929 pKa þ 0:42 ð1Þ
Reaction with Biomolecules Monitored by NMR Spectro-
scopy. 50-GMPbinding experimentswere carried out by titrating
solutions of the complexes 1a, 1b, and 4a (1-2 mg/mL) in
MeOD-d4/D2O (5/95) with a 5
0-GMP solution (10 mg/mL
D2O) in 50 μL increments. The reaction was monitored by
1H
and 31P{1H} NMR spectroscopy until unreacted 50-GMP was
detected.
In order to investigate the reactivity of complexes with amino
acids, a solution of 1a (1 mg/mL) in MeOD-d4/D2O (5/95) was
treated with equimolar amounts of Gly, Ala, Cys, Met, and His
(pH of the solutions was in the range 5.5-7.1), and the 1HNMR
spectra were recorded after 5 min and 24 h.
Mass Spectrometry Studies on the Binding to Amino Acids and
Proteins. Stock solutions of 1a, 4a, Gly, Cys,Met, His, ubiquitin
(Ub), and cytochrome c (Cyt) (each 400 μM) were prepared in
MeOH/H2O = 10/90. Solutions of 1a and 4a were incubated
with the selected amino acid at a 1:1molar ratio for 1, 19, 24, and
48 h at 37 C. In order to follow the competitive reaction of 1a or
4a with amino acids, reaction mixtures with compound:Gly:
Met:His:Cys at a molar ratio of 1:1:1:1:1 were prepared and
incubated for 19 h. For the protein binding studies, 1a or 4a and
Ub or Cyt were mixed at 2:1 or 3:1 molar ratios, and aliquots
were taken after 1, 19, and 48 h.
The samples were analyzed at concentrations ranging from
10-30 μM. Therefore, they were diluted with MeOH in case
of the amino acid incubations and with MeOH/water/formic
acid = 50/50/0.1 for the analysis of the protein samples.
ESI mass spectra were recorded on a Bruker esquire3000 ion
trap mass spectrometer by direct infusion with a flow rate of
4 μL/min. The experimental conditions were as follows: Capil-
lary 4.5 kV, end plate offset 0.5 kV, skimmer 1 45.5 V, skimmer 2
6 V, cap exit offset 78.4 V, and dry temperature 200 C. The
spectra were recorded and processed usingESICompass 1.3 and
DataAnalysis 4.0 software (both Bruker, Bremen, Germany).
Deconvolution was obtained bymaximum entropy calculations
with a mass step of m/z 0.1 and an instrument peak width of 1.
CDK2/Cyclin A Protein Kinase Inhibition Assay. The CDK2
peptide substrate, HHASPRK, and CDK2/Cyclin A protein
complex were purchased from Enzo Life Sciences. Adenosine
50-[γ-ferrocene] triphosphate (Fc-ATP) was synthesized accord-
ing to the procedure published elsewhere.69 Gold rod electrodes
(99.99% purity) with surface area of 0.02 cm2 were obtained
from CH Instruments. All experiments were conducted in
aqueous conditions using ultrapure water (18.2 MΩ cm) from
a Millipore Milli-Q system.
Fabrication of Kinase Biosensor. The gold electrodes were
cleaned by polishing with slurry of 1 μm Al2O3 until a mirror
finish was obtained. After 5 min sonication inMilli-Q water, the
gold electrodes were rinsed with water and ethanol. The electro-
des were then cleaned electrochemically by cyclic voltammetry
(CV) in 0.5MH2SO4 in the range 0-1.2 V and then by cycling in
the negative potential range from-0.6 to-2.3 V. Next, the gold
electrodes were incubated with 2 mM lipoic acid NHS ester
solution in ethanol for 3 days at 273 K. After extensive washing
with freshly distilled ethanol, the gold electrodes were incubated
with a 0.1 mM peptide solution in Milli-Q water for 18 h at
273 K. Consequently, the modified electrodes were rinsed with
Milli-Q water and then incubated with 100 mM ethanolamine
solution in absolute ethanol for 1 h. Finally, the electrodes were
immersed in 10 mM dodecanethiol solution in ethanol for
20 min to block any unmodified gold surface.
Kinase-Catalyzed Phosphorylation Reaction. The peptide-
modified gold electrodes were immersed in the kinase assay
buffer based on 60 mM HEPES (pH 7.5), 3 mMMnCl2, 3 mM
MgCl2, 0.5 μg/μL of PEG 20000, 3 μM sodium ortho-vanadate,
1 μg/mL CDK2/Cylin A protein kinase, and 200 μM Fc-ATP.
The phosphorylation reaction was performed for 6 h at 37 C in
a heating block (VWR Scientific, USA). The modified gold
(68) Krezel, A.; Bal, W. J. Inorg. Biochem. 2004, 98, 161–166.
(69) Song, H.; Kerman, K.; Kraatz, H.-B. Chem. Commun. 2008, 502–
504.
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electrodes were washed five times using the kinase assay buffer
and 0.1 M phosphate buffer (pH 7.4) prior to the electrochemi-
cal measurement. For the inhibitor studies, the CDK2/Cyclin A
protein and compounds 1a, 1b, or 4a (1 mM, DMSO) were
added to the kinase buffer, while maintaining the working
concentration of the protein and inhibitor at 1 μg/mL and
20 μM, respectively. The DMSO concentration was maintained
at a low level (<2%). After 30 min, the kinase reaction was ini-
tiated by the addition of Fc-ATP and was followed by the
procedure outlined above.
Electrochemical Experiments. All electrochemical experi-
ments were carried out using a CH Instrument 660B system
potentiostat (Austin, TX) at a 100 mV/s scan rate unless other-
wise specified. The electrochemical measurements were per-
formed in 0.1 M phosphate buffer (pH 7.4). Typical electro-
chemical experimental set up included a three-electrode system:
a modified gold electrode as the working electrode, Ag/AgCl in
3 M KCl as the reference electrode, which was connected with
the electrolyte via a salt bridge, and platinum wire as the counter
electrode. For each electrode, CV was performed at a scan rate of
100 mV/s, and square-wave voltammetry (SWV) was recorded
from 0.2 to 0.6V, with an amplitude of 25mV at 20Hz frequency.
Cytotoxicity in Cancer Cell Lines. Cell Lines and Culture
Conditions. CH1 cells (adenocarcinoma of the ovary) were a
generous gift from Lloyd R. Kelland, CRC Centre for Cancer
Therapeutics, Institute of Cancer Research, Sutton, U.K. SW480
(adenocarcinoma of the colon, human) and A549 (nonsmall cell
lung cancer, human) cellswere kindlyprovidedbyBrigitteMarian
(Institute ofCancerResearch,Department ofMedicine I,Medical
University of Vienna, Austria). All cell culture reagents were
obtained from Sigma-Aldrich, Austria. Cells were grown in
75 cm2 culture flasks (Iwaki) as adherent monolayer cultures
in Eagle’s minimal essentialmedium (MEM) supplementedwith
10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate,
and 2 mM L-glutamine. Cultures were maintained at 37 C in a
humidified atmosphere containing 95% air and 5% CO2.
MTT Assay Conditions. Cytotoxicity was determined by the
colorimetric MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide, purchased from Fluka) microculture
assay. For this purpose, cells were harvested from culture flasks
by trypsinization and seeded in 100 μL aliquots MEM supple-
mented with 10% heat-inactivated fetal calf serum, 1 mM
sodium pyruvate, 4 mM L-glutamine, and 1% nonessential
amino acids (100  ) into 96 well microculture plates (Iwaki).
Cell densities of 1.5  103 cells/well (CH1), 2.5  103 cells/well
(SW480), and 4  103 cells/well (A549) were chosen in order to
ensure exponential growth of untreated controls throughout the
experiment. Cells were allowed to settle and resume exponential
growth for 24 h. The test compounds were dissolved in DMSO,
serially diluted in the same medium such that the maximum
DMSOcontent did not exceed 1%, and added in 100μLaliquots
to the microcultures (only the maximum concentration tested
was added in 200 μL aliquots after removal of the medium).
Cells were then exposed to the test compounds for 96 h. At the
end of exposure, all media were replaced by 100 μL/well
RPMI1640 culture medium (supplemented with 10% heat-
inactivated fetal calf serum) plus 20 μL/well MTT solution in
phosphate-buffered saline (5 mg/mL). After incubation for 4 h,
the supernatants were removed, and the formazan crystals
formed by viable cells were dissolved in 150 μLDMSO per well.
Optical densities at 550 nm were measured with a microplate
reader (Tecan Spectra Classic), using a reference wavelength of
690 nm to correct for unspecific absorption. The quantity of
vital cells was expressed in terms of T/C values by comparison to
untreated control microcultures, and 50% inhibitory concen-
trations (IC50) were calculated from concentration effect curves
by interpolation. Evaluation is based on means from three
independent experiments, each comprising three replicates per
concentration level.
Results and Discussion
Synthesis andCharacterization.Hydroxypyridones and
their derivatives are a versatile class of ligands and behave
asO,O-bidentates to form 5-membered chelate rings with
metals. These 6-membered N-heterocycles are readily
ionizable by deprotonation of the hydroxyl group, and
thereby, the zwitterionic “aromatic” character of the
molecule is introduced. They form stablemetal complexes
with a wide range of bi- or trivalent metals, including
Al, Fe, Ga, V, Mo, Zn, etc.70 In addition to those metals,
complexes of 3-hydroxy-4-pyr(id)ones of Ru have been
demonstrated to exhibit antitumor activity.23-29 How-
ever, no data for 3-hydroxy-2-pyrones have been re-
ported, a gap which we aim to fill with the present study
by synthesizing a series of ruthenium(II)- and osmium-
(II)-arene complexes of alkoxycarbonylmethyl-3-hydro-
xy-2-pyridones.
The bidentate ligand 1-[(ethoxycarbonyl)methyl]-3-hy-
droxy-2(1H)-pyridone a (Scheme 1) was synthesized
straightforwardly by N-alkylation of 2,3-dihydroxypyr-
idine with ethyl bromoacetate, acting also as solvent in
this reaction.60 Recrystallization from ethanol (96%)
gave rise to the pure compound (about 80% yield). In
addition, the simple N-alkylation of 2,3-dihydroxypyr-
idine with alkyl halides has been reported, but the syn-
thetic procedures require harsh conditions and often
result in poor yields.60 The methyl ester b was obtained
in excellent yield (99%) in a one-step procedure via acid-
catalyzed transesterification of 1-[(ethoxycarbonyl)-
methyl]-3-hydroxy-2-pyridone a.61 Alternatively, b is also
accessible in two steps, involving in the first step the
hydrolysis of ethyl ester a, followed by esterification of
the pyridone carboxylic acid.71 In order to introduce
regioselectively a methyl substituent at position 4 of the
hydroxypyridone scaffold, the Mannich reaction was
employed for mono aminomethylation and in a second
step, the Mannich base was further transformed to the
methyl-substituted N-[(ethoxycarbonyl)methyl]-3-hydroxy-
4-methyl-2-(1H)-pyridone c under palladium-catalyzed
transfer hydrogenolysis conditions.62
Ligands a, b, and cwere converted in methanol into the
corresponding complexes by activating the alkoxycarbo-
nylmethyl-3-hydroxy-2-pyridones with sodium meth-
oxide. The respective dimers [(η6-p-cymene)MX(μ-X)]2
Scheme 1. Synthetic Strategy to Ligands a, b, and c60-62,71
(70) Thompson, K. H.; Barta, C. A.; Orvig, C. Chem. Soc. Rev. 2006, 35,
545–556.
(71) Rai, B. L.; Khodr, H.; Hider, R. C. Tetrahedron 1999, 55, 1129–1142.
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(X = Cl, Br, I; M = Ru, Os; cym = η6-p-cymene) were
added to this solution at RT to yield the products
(57-93%) after recrystallization by slow diffusion of
diethyl ether into a concentrated solution of dichloro-
methane (Scheme 2).
The 1H NMR spectra of all complexes in CDCl3
contain doublets assigned to each of the four cym ring
protons with a coupling constant of about 6 Hz and two
doublets for the cym isopropyl methyl groups due to slow
epimerization of the chiral metal center and the presence
of nonequivalent aromatic protons. However, in the 1H
NMR spectra of 1a and 1b in D2O, conditions in which
the complex will hydrolyze quickly to the aqua species
(see below), only two doublets for the cym ring protons
and a doublet for the two methyl groups of the cym
isopropyl are observed.22 Upon coordination of hydro-
xypyridone to the ruthenium center, H4, H5, and H6
protons give three sets of signals (two set of doublets in
the case of 1c). In the case of 1c, the signal attributable to
the H4 of hydroxypyridone is no longer present, instead a
singlet at δ = 2.19 ppm appears, corresponding to the
methyl substituent, accompanied by loss of coupling of
H4 to H5 or H6.62
For all compounds, the methylene protons of the
alkoxycarbonylmethyl-3-hydroxy-2-pyridones become
diastereotopic upon complexation and show splitting of
their resonances, if analyzed in noncoordinating solvents.
The diastereotopic N-CH2-CO protons adjacent to the
pyridone ring give two doublets centered atδ=5.1 and 4.2
ppm with a geminal coupling constant 2J(H,H)=17 Hz as
expected for an AB system. Similar observations were re-
ported for complexes containing related hydroxypyri-
dones.46,61,72 If the 1H NMR spectra are recorded in D2O,
the same protons give a singlet atδ=4.8 ppm,which is com-
parable to the chemical shift in a, b, or c (δ=about 4.7 ppm).
Crystal structures of 1a and 1b were determined by
X-ray diffraction analysis. The compounds exhibit piano-
stool configuration as usually observed for such metal-
arene complexes.13,25,29 The alkoxycarbonylmethyl-3-hy-
droxy-2-pyridones act asO,O-chelating bidentate ligands
and form a five-membered chelate ring upon binding to
the ruthenium(II) center (Figure 1, selected bond lengths
and angles are given in Table 2). The ruthenium-
centroidarene distances are 1.6397(7) and 1.6427(12) A˚,
and the Ru__Cl bond lengths are 2.4186(4) and 2.4166(7)
A˚ in 1a and 1b, respectively. These parameters are very
similar to those observed for a dinuclear RuCl(cym)(3-
hydroxy-4-pyridone) complex.26
Stability in Aqueous Solution. The aquation of 1a, 1b,
and 4a was investigated by 1H NMR spectroscopy in
D2O/MeOD-d4 (95/5) because of limited water solubility.
Complexes 1a, 1b, and 4a hydrolyze rapidly upon dis-
solution in water by exchange of the chlorido ligand with
a neutral water molecule and exist predominantly as the
chargedmonoaqua species of the general formula [M(cym)-
(HP)(OH2)]
þ (see below). This result was confirmed by
obtaining similar NMR spectra when hydrolysis was
initiated by addition of equimolar amounts of AgNO3.
These data suggest immediate aquation after dissolution
in aqueous environment. Furthermore, addition of 100
mMNaCl appears not to suppress hydrolysis as shownby
1HNMRspectroscopy. Likewise, fast hydrolysis was also
observed for M(arene) complexes containing anionic
O,O-chelating ligands such as acac, maltolato, or other
hydroxypyrones in comparison to relative high stability
ofO,S-,O,N-, andN,N-chelate complexes. This might be
due to either the increased electron density at the metal
center or possible interactions between hydrogen atoms
of coordinated H2O and the oxygen atoms of the O,O-
chelating ligand, which in the case of acac was also
proposed by DFT calculations.4,24,73 When comparing
the hydrolysis behavior of Ru and Os analogues, the
Os compound 4a is less water soluble and hydrolyzes
Scheme 2. Synthesis of Complexes from Corresponding Ligands
Figure 1. ORTEP plots of 1a (top) and 1b (bottom); thermal ellipsoids
are drawn at 50% probability level.
(72) Grote, Z.; Bonazzi, S.; Scopelliti, R.; Severin, K. J. Am. Chem. Soc.
2006, 128, 10382–10383.
(73) Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, P. J. J. Inorg.
Biochem. 2007, 101, 1903–1912.
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significantly slower than the ruthenium analogue 1a
because of the higher lability of Ru than of Os complexes.
The aqua species [M(cym)(HP)(OH2)]
þ are stable for
more than five days, and in contrast to analogous hydro-
xypyrone complexes,22 no dimeric species of [(cym)2Ru2-
(μ-OH)3]þ are formed.23,74 The NMR data were
essentially confirmed by electrospray ionization mass
spectrometry (ESI-MS). Both 1a and 4a exhibit similar
behavior in solution, with the chlorido ligand being
released within an hour. This fact is supported by the
presence of base peaks assignable to [M(cym)(HP)]þ in
the MS spectra at m/z 432.3 and 522.3 for 1a and 4a,
respectively, and the peaks showing the characteristic
isotope pattern for thesemetal compounds. Furthermore,
transesterification to the methyl ester and hydrolysis of
the ester moiety occurred for 1a and 4a in presence of
methanol, however at low relative abundance (e.g., for 1a
at m/z 418.3 [10%] and 404.2 [5%]). These side products
were observed at increased relative abundance during the
protein binding experiments (see below) in the presence of
formic acid (Figure S1 of the Supporting Information).
The pKa values of 1a, 1b, and 4a were determined by
titrating the aqua species of the respective complexes with
NaOD to afford the corresponding hydroxido complex
and monitoring the deprotonation process by 1H NMR
spectroscopy (Table 3). The aqua species were generated
by dissolving the complexes in D2O containing 5%
MeOD-d4. The pKa values were determined by plotting
the chemical shifts of the proton signal of the arene ring
Arcym-H2/H6 against the pHvalue (e.g., from5.67 ppmat
pH 2.78 to 5.29 at pH 10.03 for 1a), and the inflection
points of the sigmoid curves give the pKa* values, which
were corrected using eq 1 in order to consider the differ-
ence between D2O and water and to yield the pKa. The
pKa values determined for 1a, 1b, and 4a are in a similar
range as those of the structurally related hydroxypyr-
(id)ones.22,25,29 As reported earlier, aqua ligands coordi-
nated to osmium are significantly more acidic than at
ruthenium centers.22,75 Note that pKa values strongly
depend on the first coordination sphere and can easily
be modified by replacingO,O-chelators by bidentateN,N
ligands, which leads to a significant decrease in the pKa
values.75,76
Amino Acids as Binding Partners for Hydroxypyridone
Complexes. Most metallodrugs are administered intrave-
nously, and hence, they encounter a number of reactive
biomolecules such as proteins in the bloodstream. Serum
proteins can play a divergent role either in delivery ofmetal-
based anticancer drugs to their cellular targets or in deacti-
vating themevenbefore reaching the target(s).9,77Therefore,
the reaction of 1a with the amino acids Gly, Ala, His, Met,
andCyswas investigated to gain insight into the reactivity to
biomolecules and potential metabolization. Histidine and
methionine aswell as cysteinehavebeen chosenbecause they
are known to undergo favorable binding interactions with
ruthenium(II) anticancer complexes, whereas Gly and Ala
served as nonselective references. For 1H NMR studies, the
amino acids were incubated with 1a at equimolar ratios in
D2O/MeOH-d4 (95/5), and the reaction was monitored for
24 h. It appears that the bidentate hydroxypyridone ligand
was replaced by the respective amino acid within 24 h as
signals assignable to the released hydroxypyridones ap-
peared in the 1H NMR spectra. Notably, Cys decomposes
the complex within minutes, probably due to the strong
trans-effect of the thiol functionality. A similar observation
has been reported for related pyrone-derived complexes.25
Similarly, the reaction of 1a with 1 equiv of Met and His
takes place immediately with quantitative release of the
pyridone ligand within 24 h, possibly due to the ability of
both amino acids to act as bidentate or tridentate chelating
ligands (with the thioether ofMet andN1orN3atomsof the
imidazole moiety of His as third donors in addition to NH2
and COOH). This hypothesis is supported by the mass
spectrum of the reaction between 1a and His in which the
peak at m/z 346.1, which appeared after 48 h, was assigned
to [Ru(cym)(His- CO2) - 2H]þ (1%). This indicatesN,N
chelationofHis to themetal center. The reactionofGlywith
1a was significantly slower than with all the other investi-
gated amino acids. In the 1H NMR spectra recorded after
24h, there appeared twodoublets atδ=3.11and 2.94ppm
with a geminal coupling constant of 2J(H,H)= 17Hz. These
signals were assigned to the Gly-CH2 protons, which
become diastereotopic upon coordination of Gly as an
N,O-chelating ligand to the Ru(II)-arene center forming a
five-membered ring. In analogy to related complexes,24,25
no ruthenium dimer signals appeared within 24 h in the
presence of amino acids (in 1H NMR spectra signals at
approximately 5.0 and 5.5 ppmwould be indicative for this
process).
In order to investigate the interaction of 1a with amino
acids (aa) by means of ESI-MS, 1a was incubated with
Table 2. Selected Bond Lengths (A˚) and Bond Angles (deg) for 1a, 1b, and 5a
1a 1b 5a
Ru-(OdC) 2.0716(12) 2.0686(16) 2.0711(15)
Ru-(O-C) 2.1294(12) 2.1323(17) 2.0941(15)
Ru-Cla 2.4186(4) 2.4166(7) 2.1227(17)
Ru(1)-centroid 1.6397(7) 1.6427(12) 1.6407(10)
O-Ru-O 78.75(5) 78.96(7) 79.82(6)
(CdO)-Ru-Cla 85.51(4) 84.73(5) 82.03(6)
(C-O)-Ru-Cla 84.51(3) 84.08(5) 82.60(6)
a In the case of 5a, the values for the Ru-N bond length and the
O-Ru-N angles are given.
Table 3. pKa Values of 1a, 1b, and 4a and Their in Vitro Anticancer Activity in
Human Ovarian Cancer (CH1), Colon Cancer (SW480), and Nonsmall Cell Lung
Cancer (A549) Cells (exposure time 96 h)a
IC50 values/μM
compound pKa CH1 SW480 A549
1a 8.97 242( 29 >320 >320
1b 9.46 232( 7 >320 >320
4a 7.70 129( 7 >320 >320
aValues aremeans( standard deviations obtained fromat least three
independent experiments.
(74) Berger, I.; Hanif, M.; Nazarov, A. A.; Hartinger, C. G.; John, R. O.;
Kuznetsov, M. L.; Groessl, M.; Schmitt, F.; Zava, O.; Biba, F.; Arion, V. B.;
Galanski, M.; Jakupec,M. A.; Juillerat-Jeanneret, L.; Dyson, P. J.; Keppler,
B. K. Chem.;Eur. J. 2008, 14, 9046–9057.
(75) Peacock, A. F. A.; Habtemariam, A.; Fernandez, R.; Walland, V.;
Fabbiani, F. P. A.; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. J. Am.
Chem. Soc. 2006, 128, 1739–1748.
(76) Fernandez, R.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler,
P. J. Chem.;Eur. J. 2004, 10, 5173–5179. (77) Hartinger, C.G.; Keppler, B.K.Electrophoresis 2007, 28, 3436–3446.
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one mol equiv of Gly, His, Met, or Cys at 37 C in water/
methanol (90/10). The samples were analyzed after 1, 24,
and 48 h, and the trend to replace the pyridone ligand is
already observablewithin1 h, however to different extents
and with differing kinetics. After 48 h incubation of 1a
with Met or His, the major products were identified as
[Ru(cym)(aa)-H]þ as were for Cys and Gly but at lower
relative abundance. To perform a competition experi-
ment, we incubated 1a with Gly, His, Cys, and Met at a
molar ratio of 1:1:1:1:1 for 19 h, and the following trend
for the formation of amino acid adducts was observed:
Met g His. Cys > Gly (Table S1 and Figure S2 of the
Supporting Information). The preference forMet andHis
might indicate enhanced stability of the formed adducts
as compared to their Gly and Cys counterparts. The
obvious feature of Cys, Met, and His as compared to
Gly is the side chain with soft donors that can be directly
involved in coordination to the metal center. Further-
more, when comparing Cys with His and Met, the side
chains of the latter two aa are more flexible to act as
N,O,S or N,O,N chelating ligands, whereas the Cys
complex is more constrained. These observations are also
supported by bis-aa adduct formation during the reaction
of 1a with Gly found at m/z 385.9 [Ru(cym)(Gly)2]
þ and
367.9 [Ru(cym)(Gly)2-H2O]
þ. In addition, the dinuclear
species [(cym)2Ru2(Gly) þ H2O]þwas detected at m/z
654.9 (5%). However, species containing both Gly and
the pyridone ligand were not observed. In analogy to the
1H NMR experiments, Cys appears to degrade 1a, which
might be a reason for the low relative abundance of Cys
adducts in themass spectrum, and several peaks appeared
in the range m/z 500-950, one of which was identified as
dimeric [(cym)2Ru2(Cys)2 þ H2O]þ at m/z 731.8.
The reactivity of the osmium analogue 4a toward
amino acids is similar to that of 1a as is the result of the
competition experiment (Met≈His>Cys.Gly). Again,
the pyridone ligand is replaced in each case by the
respective amino acid giving rise to [Os(cym)(aa) - H]þ
(aa=Met, His, Cys, Gly). Os has an even greater affinity
for softer ligands compared to Ru, but ligand exchange
rates are lower and replacement of the pyridone ligand is
thus slower. Interesting features were observed in the
mass spectrum of the reaction mixture containing His.
In analogy to 1a, a signal at m/z 480.3 [OsII(cym)(His) -
H]þ was observed which was partly overlapping with a
peak with the most abundant isotope at m/z 478.3. This
signal might be related to OsII/IV oxidation (occurring
probably during the ionization process in the ESI-MS
source), which requires double deprotonation to balance
the charge contributed by the metal center (Figure S3 of
the Supporting Information). Furthermore, again a de-
carboxylated species was observed at m/z 434.4 [OsIV-
(cym)(His-CO2) - 3H]þ (10%), and the peak at m/z
462.4 was assigned to [OsII(cym)(His - OH) - 2H]þ
(10%). In the reaction with Gly, 4a forms dinuclear
species not observed for 1a such as [(cym)Os2(μ-OMe)3]
þ
(m/z 743.4; 15%) and [(cym)Os2(μ-OMe)2(μ-OH)]
þ (m/z
729.3; 22%), probably becauseGly is only aweak binding
partner.
Reaction of 1a and 4a with Ubiquitin and Cytochrome c.
In order to estimate the binding to proteins as potential
targets in the bloodstream, we incubated 1a and 4a at
molar ratios of 2:1 with ubiquitin (Ub) and 3:1 with
cytochrome c (Cyt). The reaction mixtures were analyzed
with an ESI-ion trap-MS, and the data was deconvoluted
with themaximum entropy deconvolution algorithm. Ion
traps deliver spectra of relatively low resolution; however,
the identity of the formed species can be clearly identified
in this case. Such ESI-MS experiments have been success-
fully employed for a diversity of biomolecule binding
studies, in particular of metal complexes to DNA and
proteins, including the characterization of the formed
adducts and more sophisticated binding site charac-
terization.29,78-97
1a reacts quickly with Ub, and already after 1 h, the
peak at 8565 ( 2 Da assigned to unreacted ubiquitin has
vanished, giving rise to a signal at 8802 ( 2 Da (100%),
corresponding to the monoruthenated adduct [Ub þ
Ru(cym)]þ and a bisadduct [Ub þ 2 Ru(cym) - H]þ at
9035 ( 2 Da (8% after 48 h), again accompanied by loss
of the pyridone ligand. Various other signals appeared at
masses >9 kDa, stemming most probably from tertiary
adducts formed with solvent molecules, which were gone
after longer incubation, and as most intense signals re-
mained after 19 and 48 h peaks at m/z 8802 ( 2 and m/z
9035 ( 2 Da assigned to [Ub þ Ru(cym)]þ (100%) and
[Ub þ 2 Ru(cym) - H]þ (7 and 8%), respectively.
4a reacts with ubiquitin in a similarmanner as observed
for 1a but at a lower rate. Consequently, 4a binds to
ubiquitin to form [Ub þ Os(cym)] adducts (Figure 2).
After 19 h reaction time, the ubiquitin parent mass was
(78) Gibson, D.; Costello, C. E. Eur. Mass Spectrom. 1999, 5, 501–510.
(79) Peleg-Shulman, T.; Gibson, D. J. Am. Chem. Soc. 2001, 123, 3171–
3172.
(80) Peleg-Shulman, T.; Najajreh, Y.; Gibson, D. J. Inorg. Biochem. 2002,
91, 306–311.
(81) Balter, L.; Gibson, D. Rapid Commun. Mass Spectrom. 2005, 19,
3666–3672.
(82) Wang, F.; Bella, J.; Parkinson, J. A.; Sadler, P. J. J. Biol. Inorg.
Chem. 2005, 10, 147–155.
(83) Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Pellicani, R. Z.; Intini,
F. P.; Arnesano, F.; Natile, G.; Moneti, G.; Francese, S.; Messori, L.
Biochemistry 2007, 46, 12220–12230.
(84) Hartinger, C.G.; Ang,W.H.; Casini, A.;Messori, L.; Keppler, B.K.;
Dyson, P. J. J. Anal. At. Spectrom. 2007, 22, 960–967.
(85) Weidt, S. K.; Mackay, C. L.; Langridge-Smith, P. R. R.; Sadler, P. J.
Chem. Commun. 2007, 1719–1721.
(86) Hartinger, C. G.; Tsybin, Y. O.; Fuchser, J.; Dyson, P. J. Inorg.
Chem. 2008, 47, 17–19.
(87) Egger, A. E.; Hartinger, C. G.; Ben Hamidane, H.; Tsybin, Y. O.;
Keppler, B. K.; Dyson, P. J. Inorg. Chem. 2008, 47, 10626–10633.
(88) Hartinger, C. G.; Casini, A.; Duhot, C.; Tsybin, Y. O.; Messori, L.;
Dyson, P. J. J. Inorg. Biochem. 2008, 102, 2136–2141.
(89) Casini, A.; Guerri, A.; Gabbiani, C.; Messori, L. J. Inorg. Biochem.
2008, 102, 995–1006.
(90) Gabbiani, C.; Casini, A.; Mastrobuoni, G.; Kirshenbaum, N.;
Moshel, O.; Pieraccini, G.; Moneti, G.; Messori, L.; Gibson, D. J. Biol.
Inorg. Chem. 2008, 13, 755–764.
(91) Renfrew, A. K.; Phillips, A. D.; Egger, A. E.; Hartinger, C. G.;
Bosquain, S. S.; Nazarov, A. A.; Keppler, B. K.; Gonsalvi, L.; Peruzzini, M.;
Dyson, P. J. Organometallics 2009, 28, 1165–1172.
(92) Casini, A.; Gabbiani, C.; Michelucci, E.; Pieraccini, G.; Moneti, G.;
Dyson, P. J.; Messori, L. J. Biol. Inorg. Chem. 2009, 14, 761–770.
(93) Cubo, L.; Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.;
Jimenez-Barbero, J.; Navarro-Ranninger, C.; Quiroga, A. G. Chem.;Eur.
J. 2009, 15, 9139–9146.
(94) Groessl, M.; Terenghi, M.; Casini, A.; Elviri, L.; Lobinski, R.;
Dyson, P. J. J. Anal. At. Spectrom. 2010, 25, 305–313.
(95) Mura, P.; Camalli,M.; Casini, A.; Gabbiani, C.;Messori, L. J. Inorg.
Biochem. 2010, 104, 111–117.
(96) Groessl, M.; Tsybin, Y. O.; Hartinger, C. G.; Keppler, B. K.; Dyson,
P. J. J. Biol. Inorg. Chem. 2010, 15, 677-688.
(97) Egger, A. E.; Hartinger, C. G.; Renfrew, A. K.; Dyson, P. J. J. Biol.
Inorg. Chem. 2010, 15, 919-927.
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still present at 40% relative intensity, and in contrast to
1a, no bisadduct was observable within this time period.
Prolonging the reaction time to 48 h showed that the
intensity of the unreacted protein decreased to 19%
relative to the monoadduct. It appears as the reaction
proceeds by forming only a limited number of adducts,
whereas in the reaction of Ub with 1a a multitude of
species were detected. This might be related to the higher
stability of the Os compound as compared to that of the
Ru analogue.
In addition to the studies with Ub with potential His
and Met binding sites, the reaction with cytochrome c
(Cyt), a Cys containing heme protein, was monitored for
both 1a and 4a by ESI-MS. Within 1 h incubation, no
adducts were observed, but over the time course of the
reaction, a series of different species was detected. After
19 h, a monoruthenated Cyt adduct was observed at
12597 ( 1 Da at similar relative intensity as unreacted
Cyt (12363 ( 1 Da). Furthermore, a series of higher
adducts were detected, including the bisadduct at 12831 (
1 Da. As was the case for the reaction with ubiquitin, the
pyridone ligand of 1a is cleaved off during the reaction.
The reaction of Cyt with 4a revealed again higher stability
of the Os compound. After 1 h incubation, the Cyt peak is
the most abundant in the mass spectrum, with a mono-
adduct visible at 12686 ( 1 Da and possibly a series of
aqua species, e.g., a signal at 12732( 1Da was attributed
to a trisaqua adduct. It seems as these species are mainly
intermediates in the binding process and are converted
into the trifunctionally bonded [CytþOs(cym)] as can be
seen after an incubation time of 19 h, when the most
intense signal corresponds already to the monometalated
protein at 12686( 1Da (100%) versus Cyt (50%), and no
higher adducts were observed.
DNAas a Potential Target.BecauseDNA is thought to
be one of the important targets for metal-based anti-
cancer agents, the reactions of 1a, 1b, and 4awith 50-GMP
were investigated by 1H NMR spectroscopy in D2O/
MeOH (90/10), conditions under which immediately the
aqua species are formed (see above). The reaction oc-
curred in a quantitative manner within minutes, and the
resulting adducts were stable in solution for more than
48 h. Upon addition of the metal complex, the H8 signal
of 50-GMP shifts from δ=8.11 to 7.76 and 7.72 ppm due
to the formation of isomers.98 This change in chemical
shift indicates binding to the N7 of the guanine moiety
and implies that DNA may be a possible target for these
Ru(II)-arene complexes as proposed for related organo-
metallic ruthenium(II) compounds.22
In order to characterize the interaction of compound 1a
with guanine residues more in detail, 1a was reacted with
9-ethyl guanine (9-EtG) to yield 5a. The chlorido ligand
of 1awas abstractedbyadditionofAg(CF3SO3) (Scheme3),
AgCl was removed by filtration, and 9-ethylguanine was
added to the filtrate and stirred for 24 h to afford 5a. The
molecular structure of 5a was determined by X-ray diffrac-
tion analysis of a crystal grown frommethanol/diethyl ether
by the diffusion technique. This is the first example of a
crystal structure of a Ru(arene)[hydroxypyr(id)one] com-
plex bearing a 9-EtG moiety. As implied from the results of
the NMR studies, the 9-ethylguanine is coordinated to
ruthenium via itsN7 atom (Figure 3). The Ru-N7Gua bond
length in 5a is 2.1227(17) A˚ and hence slightly shorter than
that observed for a 9-EtG adduct of a Ph2acac-Ru(cymene)
complex [2.140(3) and 2.126(3) A˚], whereas theRu-Obond
lengths are rather similar (for key bond lengths and angles
see Table 2).73
Two molecules of 5a are linked by hydrogen bonds
between N3 and NH2 of neighboring guanines to form a
planar structure between the Ru centers, whereas in other
cases a noncoplanar arrangement was observed.99 In 5a,
both HP ligands point on different sides of the plane,
whereas in a structure of a complex bearing Ph2acac, both
ligands are on the same side of the plane.73 Furthermore,
N1-H and NH2 of 9-EtG are involved in hydrogen
bonding to two oxygen atoms of the CF3SO3
- counterion
(Figure 3 and Figure S4 of the Supporting Information).
Evaluation of the in Vitro Anticancer Activity andCDK2
Inhibition. The antiproliferative activity of 1a, 1b, and 4a
was determined in human SW480 colon adenocarcinoma,
CH1 ovarian cancer, and A549 nonsmall cell lung cancer
cells by means of the MTT assay (Table 3); 1c, 2a, and 3a
Figure 2. Time course for the reaction of 4a with Ub. Inset shows the
relative changes in the signal intensities for Ub and its Os(cym) adduct.
Scheme 3. Replacement of the Chlorido Ligand by 9-EtG; Counter-
ion CF3SO3
- Has Been Omitted for Clarity
(98) Dorcier, A.; Hartinger, C. G.; Scopelliti, R.; Fish, R. H.; Keppler,
B. K.; Dyson, P. J. J. Inorg. Biochem. 2008, 102, 1066–1076.
(99) Chen, H.; Parkinson, J. A.; Parsons, S.; Coxall, R. A.; Gould, R. O.;
Sadler, P. J. J. Am. Chem. Soc. 2002, 124, 3064–3082.
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were not sufficiently soluble in aqueous dilutions of
DMSO stocks to a maximum DMSO content of 1% to
be included in the biological assays. The ruthenium com-
plexes 1a and 1b showed low anticancer activity in the
most sensitive cell line with IC50 values of 242 and 232
μM, respectively, while that of the osmium complex 4a is
nearly 2 times lower (129 μM). This is one of the relatively
few known examples that an osmium complex is more
cytotoxic than its ruthenium analogue.
In an attempt to determine a possible CDK2/Cyclin A
kinase inhibition of the Ru and Os complexes, a substrate
peptide (HHASPRK) was immobilized onto an Au sur-
face and Fc-ATP was employed as a cosubstrate in the
kinase phosphorylation reaction assay.69,100 Following the
kinase-catalyzed phosphorylation reaction on the surface
in the presence of the Fc-ATP bioconjugate, the electro-
chemical response was measured by cyclic voltammetry
(CV) and square-wave voltammetry (SWV). The organo-
metallic species do not exhibit redox activity in the region
of interest, which makes the electrochemical peptide
biosensor a valuable probe for inhibitor screening. The
Ru and Os complexes inhibit the kinase activity at a
concentration of 20 μM to a comparable extent as the
known inhibitor R-roscovitine (Figures S6-S8 of the
Supporting Information), which is currently undergoing
clinical trials.101 These data might indicate an interesting
mode of action for this type of complexes, though the in
vitro anticancer activity is only moderate. However, in
vitro anticancer potency appears not to be a prerequisite
in particular for ruthenium drug candidates, considering
that NAMI-A failed the National Cancer Institute
screening but entered clinical trials, and RAPTA
compounds are excellent inhibitors of metastasis in
vivo.102-105 These facts support the requirement of im-
proved biological tools with higher predictability in order
to establish correlations between in vitro anticancer
activity, target modulation, and efficacy in humans.
Conclusions
Organometallic compounds have emerged to an exten-
sively studied class of anticancer chemotherapy drug candi-
dates. Of particular interest are Ru(arene) and Os(arene)
compounds, and on the basis of these scaffolds a series of
compounds with a diversity of modes of action has been
designed. Herein, we present Ru and Os complexes with
hydroxypyridones, a compound family that can act as
versatile ligands because of many options for derivatization,
leading to compoundswith particular chemical reactivity and
biological properties.A series ofRu- andOs-(η6-p-cymene)
compounds was synthesized and characterized by standard
methods. NMR studies revealed that the compounds hydro-
lyze quickly to the respective aqua species with pKa values in
the range 7.7-9.5 and the Os compound at the lower end of
this scale. Those aqua species are stable for several days
but react quickly, however to a different extent with the
amino acids Met, Cys, His, Gly, and Ala, and formM(η6-p-
cymene)(amino acid) adducts upon loss of the hydroxypyr-
idone ligand. The same types of adducts were observed in the
reactions with ubiquitin and cytochrome c as determined by
electrospray ionizationmass spectrometry. In general, the Os
complex 4a appearedmore stable than its Ru counterpart 1a,
indicated by a lower number of different adducts formed
initially after incubation with the proteins. Longer reaction
times lead in both cases to the formation of definedmono- or
even bisadducts of the type [protein þ M(η6-p-cymene)]. In
contrast to amino acids and proteins, 50-GMP and 9-ethyl-
guanine, employed as DNAmodels, did not induce cleavage
of the metal-hydroxypyridone bond but coordinate mono-
dentately via their N7 atoms to the metal center. In vitro
anticancer activity assays in a series of human tumor cell lines
revealed only low potency to inhibit the growth of tumor cells
but potent CDK2/Cyclin A protein kinase inhibition by the
Ru and Os complexes (similar to the drug candidate
roscovitine). It appears as in this particular case (compare
introduction) the reactivity of the compounds to biomole-
cules determines their in vitro anticancer activity, though a
broader panel of complexes with different substitution pat-
tern is required to draw definite conclusions.
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Figure 3. Part of the crystal structure of 5a showing the coordinated
9-EtG pairing and short contacts to CF3SO3
- counteranion via inter-
molecular hydrogen-bonding interactions N10-H 3 3 3N3
i [N10 3 3 3N3
i
3.032 A˚, N10-H 3 3 3N3
i 178.2], N1-H 3 3 3O8
ii [N1 3 3 3O8
ii 2.909 A˚,
N1-H 3 3 3O8
ii 177.2], and N10-H 3 3 3O6
ii [N10 3 3 3O6
ii 3.006 A˚,
N10-H 3 3 3O6
ii 169.1]. Atoms marked with i and ii are at symmetry
positions -x, -y þ 2, -z þ 1, and -x þ 1, -y þ 1, -z þ 1.
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Figure S1. Electrospray ionization mass spectra for transesterification and hydrolysis of the ester 
moieties of (a) 1a and (b) 4a in presence of methanol and formic acid. 
 
Table S1. In competitive experiments, 1a and 4a were incubated with Gly, His, Cys and Met at a molar 
ratio of 1 : 1 : 1 : 1 : 1 for 19 h and reaction mixtures were analyzed by ESI-MS (all m/z values contain 
standard deviations of ± 0.1). 
Species  
Relative abundance (%) m/z 
1a 4a 1a 4a 
Met adduct 100 100 384.0 474.3 
His adduct 66 96 390.0 480.3 
Cys adduct 8 57 356.0 446.3 
Gly adduct 1 0 310.0 400.2 
1a 8 - 432.3 - 
4a - 0 - 522.3 
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Figure S2. ESI mass spectrum for the competitive reaction of 1a with Gly, His, Met and Cys.  
 
 
 
Figure S3. Redox processes observed in the mass spectrum of 4a/His.  
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Figure S4. ORTEP plot of 5a at 50% probability level. 
 
 
 
 
Figure S5. Concentration–effect curves of 1a, 1b and 4a in CH1 ovarian cancer cells in the MTT assay 
(96 h exposure). Values are the means ± standard deviations from three independent experiments. 
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Figure S6. Cyclic voltammograms (A) and square-wave voltammograms (B) of 100 µM substrate 
peptide-modified Au surface electrodes for detection of CDK2/Cyclin A kinase (1 µg/ml) 
phosphorylation reactions. (a) in the presence of roscovitine (20 µM) and (b) in the absence of 
roscovitine. Measurements were taken in 0.1 M phosphate buffer solution (pH 7.4) versus Ag/AgCl as 
reference electrode and Pt wire as counter electrode at 100 mV/s. 
 
 
A 
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Figure S7. Plot of anodic and cathodic current density vs. scan rate in CDK2/Cyclin A kinase assay. 
 
 
Figure S8. Plot for dependence of integrated current density in CDK2/Cyclin A kinase assays as a 
function of inhibitor type (inhibitor concentration = 20 µM in kinase buffer, 100 mV/s, 0.1 M phosphate 
buffer pH 7.4, triplicate measurements). 
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2.7 Tuning the Anticancer Activity of Ruthenium(II)–Arene 
Complexes of 3-Hydroxy-2-pyridone-Derived Ligands 
Results and Discussion 
As already discussed (see section 2.5), hydroxypyr(id)ones are are versatile mole-
cules and a number of modifications or substitutions are possible on heterocyclic 
backbone of pyr(id)ones for fine-tuning the chemical and biological properties. 
Therefore, a series of alkoxycarbonylmethyl-3-hydroxy-2(1H)-pyridones and their 
mononuclear metal(II)–arene complexes was prepared (Fig. 17).  
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H2CO/C2H5OH
N
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O
O
N N
X X
R2
R1
R2
R1
Heterocyclic
Amine
2a) R1 = H, R2 = H, X = O
2b) R1 = H, R2 = H, X = S
2c) R1 = H, R2 = H, X = CH2
2d) R1 = H, R2 = CH3, X = CH2
2e) R1 = CH3, R2 = CH3, X = O
2f) R1 = H, R2 = H, X = N(CH3)
2g) R1 = H, R2 = H, X = N(C6H5)
1a
CH3OH/CH2Cl2
NaOCH3
3a) R1 = H, R2 = H, X = O
3b) R1 = H, R2 = H, X = S
3c) R1 = H, R2 = H, X = CH2
3d) R1 = H, R2 = CH3, X = CH2
3e) R1 = CH3, R2 = CH3, X = O
3f) R1 = H, R2 = H, X = N(CH3)
3g) R1 = H, R2 = H, X = N(C6H5)
 
Figure 17. Synthetic strategy to 3-hydroxy-2-pyridone ligands and their RuII(arene) com-
plexes. 
 
The ligands (2a-g) were synthesized in high yields (76-91%) by Mannich reaction.  
The presence of an ortho directing group hydroxy group at position 3 of pyridone 
scaffold provides a strategy to introduce a substituent regioselectively at position 4. 
The Mannich reaction of N-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-pyridone 
1a with formaldehyde and hetrocyclic secondary amines in ethanol/methanol resul-
ted in 4-aminomethyl substituted products which were purified by recrystallization 
from ethanol (96%). The tertiary nitrogen of 4-aminomethyl substituted products is 
not a very good ligand for transition metals and it was thus expected to enhance the 
solubility of the resulting complexes without coordinating to the metal ion. All the 
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ligands were characterized by NMR spectroscopy, ESI-MS and elemental analysis. 
In the 1H NMR spectra the H-4 signal disappeared and in the 13C NMR  spectra an 
additional quaternary carbon signal was observed for C-4 which further corroborates 
the substitution at position 4.   
Subsequently, activation of 2a-g with sodium methoxide and reaction with the [(η6-
cymene)RuCl2] in methanol gave the Ru-arene complexes 3a-g in reasonable yield 
54-76% (Scheme 1).  
 All the complexes were characterized by 1D and 2D NMR spectroscopy, ESI-MS, 
elemental analysis, and the solid state structure of 3c was determined by single crys-
tal X-ray diffraction analysis. After complexation, the methylene protons of the al-
koxycarbonylmethyl-3-hydroxy-2-pyridones become diastereotopic and show split-
ting of their resonances, if analyzed in non-coordinating solvents by 1H NMR 
spectroscopy. The diastereotopic N–CH2–CO protons adjacent to the pyridone ring 
give two doublets centered at δ = ca. 5.1 and ca. 4.2 ppm with a geminal coupling 
constant 2J(H,H) = 17 Hz. If the 1H NMR spectra are recorded in D2O, the same pro-
tons give a singlet at δ = 4.8 ppm which is comparable to the unbound ligands (δ = 
ca. 4.7 ppm). Similar observations were reported for complexes containing related 
hydroxypyridones.123  
The molecular structure of 3c was determined by X-ray diffraction analysis. The 
compound crystallizes in the triclinic P-1 space group and exhibits the typical piano-
stool configuration as usually observed for such metal–arene complexes (Table 2).19 
The 3-hydroxy-2-pyridone acts as an O,O-chelating bidentate ligand and forms a 
five-membered chelate ring upon binding to the ruthenium(II) center (Figure 18). 
The ruthenium–centroidarene distance is 1.646 Å, and the Ru__Cl1, Ru__O1, and 
Ru__O2 bond lengths are 2.4287(6), 2.0834(15) and 2.1142(15) respectively. These 
parameters are very similar to those observed for RuCl(cym)(3-hydroxy-2-pyridone) 
complexes.123  
                                                 
123
 Hanif, Muhammad; Henke, Helena; Meier, Samuel M.; Martic, Sanela; Labib, Mahmoud; Kandi-
oller, Wolfgang; Jakupec, Michael A.; Arion, Vladimir B.; Kraatz, Heinz-Bernhard; Keppler, Bern-
hard K.; Hartinger, Christian G.,Inorganic Chemistry 2010),  49(17),  7953-7963. 
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 Table 2. Crystal data and details of data collection for 3c. 
 
Compound 3c 
Chemical formula C25H35N2O4ClRu 
M (g mol-1) 564.07 
Temperature (K) 100(2) 
Crystal size (mm) 0.30 x 0.20 x 0.08 
Crystal color, habit red, block 
Crystal system triclinic 
Space group P-1 
a (Å) 10.5181(4) 
b (Å) 10.7150(4) 
c (Å) 11.9231(5) 
V (Å3) 1212.84(8) 
Z 2 
Dc (g cm-3) 1.545 
µ (cm-1) 7.91 
F(000) 584 
Θ range for data collection (°) 2.28 to 30.01 
h range -14/14 
k range -15/15 
l range -16/16 
No. refls. used in refinement 7018 
No. Parameters 299 
Rint 0.0815 
R1 (obs.) a) 0.0369 
wR2 (all data) b) 0.0876 
Flack parameter 0.01(5) 
S c) 1.058 
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 Figure 18. Molecular structure of 3c. 
 
Stability in aqueous solution 
The aquation of 3a, 3b and 3c was investigated by 1H NMR spectroscopy in 
D2O/MeOD-d4 (95/5) and 0.02 M phosphate buffer (pH 7.4, 100 mM NaCl)/MeOD-
d4 (95/5), Methanol was used to increase the solubility. The complexes hydrolyze 
within minutes upon dissolution in water by exchange of the chlorido ligand with a 
water molecule and exist predominantly as cationic monoaqua species. The aqua 
species [M(cym)(HP)(OH2)]+ in case of 3a and 3c are stable for about 24 h, after 
which the dimeric species [(cym)2Ru2(µ-OH)3]+ started to form, similarly to the 
analogous hydroxypyrone complexes.124,125 The NMR data were confirmed by elec-
trospray ionization mass spectrometry (ESI-MS). Complexes 3a and 3b exhibit 
similar behavior in solution with the chlorido ligand being released within half an 
hour and the resulting complexes [M – Cl]+, where M = 3a (m/z 531.2 ± 0.1, macc. = 
m/z 531.1) or 3b (m/z 547.10 ± 0.1, macc. = m/z 547.1), remain the most intense sig-
nals for 24 h, the peaks showing the characteristic isotope pattern for the ruthenium 
                                                 
124
 A. F. A. Peacock, M. Melchart, R. J. Deeth, A. Habtemariam, S. Parsons and P. J. Sadler, Chem. 
Eur. J., 2007, 13, 2601-2613. 
125
 W. Kandioller, C. G. Hartinger, A. A. Nazarov, J. Kasser, R. John, M. A. Jakupec, V. B. Arion, P. 
J. Dyson and B. K. Keppler, J. Organomet. Chem., 2009, 694, 922-929. 
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compounds. Both complexes slowly are converted into a methoxy-bridged dinuclear 
ruthenium(II) species, which is observable at m/z 565.0 ± 0.1 (macc. = m/z 565.1) 
with relative abundances of 36 and 29% for 3a and 3b, respectively. Additionally, 
transesterification of the ethyl ester to the methyl derivative was observed as well as 
formation of the carboxylic acid. Interestingly, these reactions occur to a larger de-
gree in 3b where the signal corresponding to the methyl ester was found quite abun-
dant (35%, m/z 533.1 ± 0.1, macc. = m/z 533.1). 
The pKa values of 3a and 3c were determined by titration of the respective aqua 
complexes with NaOD to afford the corresponding hydroxido complex, and the de-
protonation process was monitored by 1H NMR spectroscopy. The aqua species 
were generated by dissolving the complexes in D2O/MeOD-d4 (95/5). The pKa val-
ues were determined by plotting the chemical shifts of the proton signal of the arene 
ring Arcym-H2/H6 against the pD value and the inflection points of the sigmoid 
curves give the pKa* values which were corrected using Eq. (1), in order to consider 
the difference between D2O and water and to yield the pKa. The pKa values deter-
mined for 3a and 3c are 9.30 and 8.86, respectively and are in a similar range as 
those of structurally related hydroxypyr(id)ones.123-125  
 
Biomolecules as Binding Partners  
In order to evaluate their reactivity to and behavior in presence of potential biologi-
cal binding partners, 3a and 3b were exposed to the amino acids (aa) His, Met and 
Cys and to the proteins Ub and Tf. His, Met and Cys have been chosen because they 
are known to coordinate preferably to soft metal centers often present in metal-based 
anticancer compounds. Ub serves as a model protein to characterize the adducts in 
proteinaceous environment by mass spectrometry at sufficient resolution and mass 
accuracy and Tf is used as an example of higher molecular weight (serum) proteins. 
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 Figure 19. ESI-mass spectra of complexes 3a and 3b incubated with Met at a ratio of 1 : 1 
for 3 and 24 h at 37 °C. In both cases, the adduct [Ru(cym)(Met) – H]+ is selectively formed 
but at different rates. 
 
The interaction of 3a and 3b with aa was investigated by incubating the complexes 
with one equivalent of His, Met, or Cys at 37 °C in water/methanol (90/10). The 
samples were analyzed after 0.5, 1, 3, 6 and 24 h. As already observed in previous 
studies,123 Ru(II)-arene complexes containing hydroxypyridone ligands react very 
selectively with His or Met forming a complex-amino acid adduct of general for-
mula [Ru(cym)(aa) – H]+ accompanied by cleavage of the pyridone ligand, whereas 
Cys seems to decompose both complexes 3a and 3b, presumably due to the trans 
effect of the thiol group. In the case of the reaction between 3a and His, the metal-
amino acid-adduct [Ru(cym)(His) – H]+ (m/z 390.0 ± 0.1) was already the most 
abundant ion in the spectrum after the first 3 h of incubation. In the course of the 
reaction, a methoxide species [Ru2(cym)2(OMe)3]+ (23% after 6 h, 0% after 24 h), 
formed presumably from an intermediate during the spraying process, was also 
completely converted into the His adduct. Complex 3a reacted with Met to form 
selectively [Ru(cym)(Met) – H]+ (m/z 384.0 ± 0.1) but at a considerably lower rate 
than 3b. Replacing the morpholine-derivatized ligand by a thiomorpholine hy-
droxypyridone resulted in much faster kinetics when incubated with amino acid. 
Consequently, 3b reacted quantitatively with both His and Met within 3 h forming 
the respective adduct and decomposed in the presence of Cys within the same time 
period (Fig. 19).  
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Reaction of 3a and 3b with Ubiquitin and apo-Transferrin 
In order to estimate the binding to proteins as potential targets in the bloodstream, 
3a and 3b were incubated at molar ratios of 2 : 1 with ubiquitin (Ub) and 4 : 1 with 
apo-transferrin (Tf). The reaction mixtures were analyzed by ESI-ion trap-MS, and 
the data was treated with the maximum entropy deconvolution algorithm. Ion traps 
deliver spectra of relatively low resolution; however, the identity of the formed spe-
cies was unambiguous in this case. 
Ru(II) complexes of unsubstituted hydroxypyridone were found to react quickly 
with Ub accompanied by ligand cleavage.123 A similar observation was made for 3a 
and 3b which undergo the same process upon binding to the protein. The reaction of 
complex 3a occurred quickly. After 3 h, the Ub peak at 8565 ± 5 Da had vanished, 
giving rise to a signal at 8803 ± 3 Da (100%), corresponding to the monoruthenated 
adduct [Ub + Ru(cym)]+. The bis-adduct [Ub + 2 Ru(cym)]+ (8%) was also observ-
able after 6 h though in low amounts. In contrast to the observations during the reac-
tions with amino acids, complex 3b reacted with Ub in a similar manner but at a 
lower rate (Fig. 20). Consequently, unreacted Ub was still found at 10% abundance 
after 3 h relative to the singly ruthenated adduct at 8803 ± 3 Da. Mono-adduct for-
mation was completed after 6 h of incubation.  
 
Figure 20. Deconvoluted ESI-mass spectra of Ub incubated with 3a and 3b at a ratio of 1 : 
2 for 1 h at 37 °C. Protein adducts are formed via ligand loss and 3a (16% unreacted Ub) 
exhibits faster kinetics compared to 3b (36% unreacted Ub). 
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The reactivity of 3a and 3b towards apo-transferrin was investigated as a model for 
serum protein binding. Again, 3b reacted at a considerable lower rate with apo-Tf 
than 3a which can clearly be seen in the deconvoluted spectra recorded after 24 h of 
incubation despite the similar hydrolysis behavior (Fig. 21). With regard to the reac-
tivity towards Ub where both complexes formed a mono-adduct quantitatively 
within 6 h hours, there is still unreacted Tf in considerable amounts present after 24 
h of incubation. The excess of possible binding partners might thus have resulted in 
the non-selective formation of several multi-adducts. This in turn is an indication 
that 3a and 3c exhibit no selective affinity to bind into the binding pockets and that 
the complexes might prefer surface N- or S-donor containing amino acids.  
 
 
Figure 21. Deconvoluted ESI-MS spectra of Tf incubated with 3a and 3b at a molar ratio of 
1 : 2 for 24 h at 37°C in 30mM bicarbonate buffer. Protein adducts are formed via ligand 
loss and 3a exhibits faster kinetics compared to 3b. 
 
Reactivity with 5’-GMP  
The reactions of 3a, 3b and 3c with 5’-GMP were investigated by 1H NMR 
spectroscopy in D2O/MeOH (90/10), conditions under which immediately the aqua 
species are formed. The reaction occurred in a quantitative manner within minutes 
and the resulting adducts were stable in solution for more than 48 h. Upon addition 
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of the metal complex, the H8 signal of 5’-GMP shifts from δ = 8.11 to ca. 7.74 ppm. 
This change in chemical shift indicates binding to the N7 of the guanine moiety and 
implies that DNA may be a possible target for these Ru(II)–arene complexes. 
Evaluation of the in vitro anticancer activity  
The antiproliferative activity of 3a-3g was determined in human SW480 colon ade-
nocarcinoma, CH1 ovarian cancer and A549 non-small cell lung cancer cells by 
means of the MTT assay (Table 3). The ruthenium complexes 3b and 3c exhibit 
potent anticancer activity in all three tested cancer cell lines with IC50 values in the 
low micromolar range (e.g., in CH1 cell line IC50 values for 3b and 3c are 3.2 ± 0.3 
and 3.4 ± 0.2 µM, respectively). Notably, despite minor structural differences be-
tween 3a and 3b, a remarkable difference in their tumor-inhibiting properties was 
observed, with 3b being two orders of magnitude more cytotoxic than 3a.  The 
lower reactivity of 3b towards Ub and Tfs as compared to 3a gives a clue on its 
higher potency in in vitro anticancer tests.  
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 Table 3. In vitro anticancer activity (mean IC50 values ± standard deviations) of 3a-3g in 
human ovarian cancer (CH1), colon cancer (SW480) and non-small cell lung cancer (A549) 
cells (exposure time 96 h). 
 
IC50 values / µM Compound 
CH1 SW480 A549 
3a 229 ± 17 219 ± 7 487 ± 46 
3b 3.2 ± 0.3 6.1 ± 0.3 6.2 ± 0.3 
3c 3.4 ± 0.2 6.3 ± 0.1 6.0 ± 0.4 
3d 28 ± 7 94 ± 16 364 ± 60 
3e 56 ± 6 163 ± 16 > 640 
3f 126 ± 45 279 ± 54 461 ± 24 
3g 12 ± 1 68 ± 15 125 ± 34 
 
Conclusions 
Bioorganometallic chemistry is an emerging area of research and Ru(arene) com-
plexes have been intensively investigated as anticancer chemotherapeutics. A series 
of 3-hydroxy-2-pyridones are prepared. The hydroxypyridones were then converted 
into [Ru(arene)(hydroxypyridone)Cl]  complexes which were characterized chemi-
cally and biologically. The compounds hydrolyze quickly in aqueous solution to the 
respective aqua species as demonstrated by NMR studies. Those aqua species are 
stable for 48 h but react quickly, however to a different extent, with the amino acids 
Met, Cys, His and Gly and form M(η6-p-cymene)(amino acid) adducts upon release 
of the hydroxypyridone ligand. The same behavior in adduct formation was ob-
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served in reactions with ubiquitin and transferrin as  determined by electrospray 
ionization mass spectrometry. In vitro anticancer activity assays in human tumor cell 
lines revealed promising anticancer activity with IC50 values in the low micromolar 
range. A remarkable difference in reactivity with biomolecules and anticancer activ-
ity was found between Ru(arene) complexes of morpholino and thiomorpholino de-
rivatives, despite minor structural differences, the latter being two orders of magni-
tude more cytotoxic. The Ru(arene) complex with the thiomorpholino moiety reacts 
slowly with proteins such as Ub and Tf as determined by ESI-MS. Moreover, com-
plexes react with DNA model 5’-GMP via their N7 atoms of guanine without cleav-
age of the metal–hydroxypyridone bond.  
Experimental 
Materials and methods 
All reactions were carried out in dry solvents under an inert atmosphere. All chemi-
cals were obtained from commercial suppliers and used as received and were of ana-
lytical grade. Methanol and CH2Cl2 were dried using standard procedures. 
RuCl3·xH2O (40.4%) were purchased from Johnson Matthey, ubiquitin (bovine red 
blood cells) and human apo-transferrin from Sigma, α-terpinene from Acros, glycine 
and L-histidine from Merck, L-cysteine and 5’-GMP from Fluka, and L-methionine 
from Sigma-Aldrich. The solvents for ESI-MS studies were methanol (VWR Int., 
HiPerSolv CHROMANORM), formic acid (Fluka) and milliQ H2O (18.2 MΩ, Syn-
ergy 185 UV Ultrapure, Millipore, France). The dimer bis[dichlorido(η6-p-
cymene)ruthenium(II)]126,127 and 1-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-
pyridinone128 1a were synthesized using literature procedures.  
1H, 31P{1H} and 13C{1H} NMR spectra were recorded at 25 °C on a Bruker FT 
NMR spectrometer Avance III 500 MHz at 500.10 (1H), 125.75 MHz (13C{1H}) and 
202.44 MHz (31P{1H}). 2D NMR data were collected in a gradient-enhanced mode. 
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 M. A. Bennett, T. N. Huang, T. W. Matheson and A. K. Smith, Inorg. Synth., 1982, 21, 74-78. 
127
 M. A. Bennett and A. K. Smith, J. Chem. Soc., Dalton Trans., 1974, 233-241. 
128
 M. Streater, P. D. Taylor, R. C. Hider and J. Porter, J. Med. Chem., 1990, 33, 1749-1755. 
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Melting points were measured on a Büchi B-540 apparatus and are uncorrected. 
Elemental analysis was done on a Perkin–Elmer 2400 CHN Elemental Analyzer by 
the Laboratory for Elemental Analysis, Faculty of Chemistry, University of Vienna. 
Electrospray ionization mass spectra were recorded on a Bruker esquire3000 ion trap 
instrument.  
X-ray diffraction measurements of 3c were performed on a Bruker X8 APEXII 
CCD diffractometer at 100 K. The crystal was positioned at 35 mm from the detec-
tor and 1522 frames for 5 sec over 1° were measured. The data were processed us-
ing the SAINT software package.129 Crystal data, data collection parameters, and 
structure refinement details are given in Table 2.  
The structure was solved by direct methods and refined by full-matrix least-squares 
techniques. Non-hydrogen atoms were refined with anisotropic displacement pa-
rameters. H atoms were inserted at calculated positions and refined with a riding 
model. The following computer programs were used: structure solution, SHELXS-
97; refinement, SHELXL-97;130 molecular diagrams, ORTEP-3;131 computer, Pen-
tium IV; scattering factors.132 
Synthesis  
General procedure for ligands 
Compounds 2a-g were synthesized following a slightly modified literature proce-
dure.133 Aqueous formaldehyde (35%, 1.5 eq) and heterocyclic amine (1.2 eq) were 
stirred for 30 minutes with cooling (ice bath). The formed Mannich base was added 
dropwise to a suspension of 1-ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 
1a (1 eq) in ethanol (96%). Stirring was continued at RT until a clear solution was 
                                                 
129
 M. R. Pressprich and J. Chambers, Bruker Analytical X-ray systems, Madison, 2004. 
130
 G. M. Sheldrick, Acta Crystallogr., Sect. A: Found. Crystallogr., 2008, A64, 112-122. 
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132
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obtained after 8-24 h. The volume of the solvent was reduced to half of its original 
volume and kept at 4 °C overnight. The white precipitate formed was filtered and 
washed with cold ethanol (2×5 mL). Recrystallization from 96% ethanol gave the 
product as a white crystalline solid in high yield. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-morpholinomethyl-2(1H)-pyridone 
(2a)  
2a was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.980 g, 11.40 mmol), morpholine (0.800 g, 9.12 mmol) and 1-
ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.6 mmol). Yield: 
1.94 g (86%), m.p. 157–159 °C (decomp.), Elemental analysis found: C 56.37; H 
6.89; N 9.18; calcd. for C14H20N2O5: C 56.75; H 6.80; N 9.45%. MS (ESI+): m/z: 
297.1 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 25 °C): δ = 7.12 (d, 3J(H,H) = 7 
Hz, 1H, H6), 6.22 (d, 3J(H,H) = 7 Hz, 1H, H5), 4.71 (s, 2H, NCH2CO), 4.14 (q, 3J(H,H) 
= 7 Hz, 2H, CH3CH2O), 3.59 (t, 3J(H,H) = 4 Hz, 4H, Hmor), 3.38 (s, 2H, CH2N  ), 3.35 
(t, 3J(H,H) = 4 Hz, 4H, Hmor), 1.21 (t, 3J(H,H) =7 Hz, 3H, CH3CH2O) ppm. 13C{1H} 
NMR (125.75 MHz, DMSO-d6, 25 °C): δ = 168.5 (COOEt), 158.7 (C2), 144.6 (C3), 
128.2 (C6), 125.5 (C4), 107.1 (C5), 66.7 (Cmor), 61.4 (OCH2CH3), 55.8 (CH2N), 
53.7 (Cmor), 50.7 (NCH2CO), 14.5 (OCH2CH3 ) ppm. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-thiomorpholinomethyl-2(1H)-
pyridone (2b)  
2b was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.977 g, 11.40 mmol), thiomorpholine (0.941 g, 9.12 mmol) and 1-
ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.60 mmol). Yield: 
1.971 g (83%), m.p. 152–154 °C (decomp.), Elemental analysis, found: C 53.77; H 
6.13; N 8.78; calcd. for C14H20O4N2S: C 53.83; H 6.45; N 8.97%. MS (ESI+): m/z: 
313.0 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 25 °C): δ = 7.12 (d, 3J(H,H) = 7 
Hz, 1H, H6), 6.20 (d, 3J(H,H) = 7 Hz, 1H, H5), 4.70 (s, 2H, NCH2CO), 4.14 (q, 3J(H,H) 
= 7 Hz, 2H, CH3CH2O), 3.39 (s, 2H, CH2N  ), 2.64 (m, 8H, Hthiomor), 1.21 (t, 3J(H,H) = 
7 Hz, 3H, CH3CH2O) ppm. 13C{1H} NMR (125.75 MHz, DMSO-d6, 25 °C): δ = 
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168.4 (COOEt), 158.8 (C2), 144.4 (C3), 128.3 (C6), 125.6 (C4), 107.3 (C5), 65.8 
(Cthiomor), 61.5 (OCH2CH3), 55.6 (CH2N), 53.4 (Cthiomor), 50.6 (NCH2CO), 14.5 
(OCH2CH3 ) ppm. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-piperidinomethyl-2(1H)-pyridone 
(2c)  
2c was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.977 g, 11.40 mmol), piperidine (0.776 g, 9.12 mmol) and 1-
ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.60 mmol). Yield: 
1.767 g (79%), m.p. 132–133 °C (decomp.), Elemental analysis, found : C 61.20; H 
7.44; N 9.36; calcd. for C15H22O4N2: C 61.21; H 7.53; N 9.52%. MS (ESI+): m/z: 
295.2 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 25 °C): δ = 7.07 (d, 3J(H,H) = 7 
Hz, 1H, H6), 6.17 (d, 3J(H,H) = 7 Hz, 1H, H5), 4.71 (s, 2H, NCH2CO), 4.14 (q, 3J(H,H) 
= 7 Hz, 2H, CH3CH2O), 3.37 (s, 2H, CH2N), 2.37 (brs, 4H, Hpip), 1.50-1.53 (m, 4H, 
Hpip), 1.40-1.41  (m, 2H, Hpip),  1.21 (t, 3J(H,H) =7 Hz, 3H, CH3CH2O) ppm. 13C{1H} 
NMR (125.75 MHz, DMSO-d6, 25 °C): δ = 168.6 (COOEt), 157.7 (C2), 144.8 (C3), 
128.1 (C6), 125.9 (C4), 106.8 (C5), 61.4 (OCH2CH3), 56.7 (CH2N), 54.4 (Cpip), 50.6 
(NCH2CO), 26.0 (Cpip), 24.2 (Cpip), 14.5 (OCH2CH3) ppm. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-(3-methylpiperidinomethyl-2(1H)-
pyridinone (2d) 
2d was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.977 g, 11.40 mmol), 3-methylpiperidine (0.904 g, 9.12 mmol) and 
1-ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.60 mmol). 
Yield: 1.855 g (78%), m.p. 119–121 °C (decomp.), Elemental analysis, found: C 
61.86; H 7.69; N 8.83; calcd. for C16H24O4N2·0.1H2O: C 61.96; H 7.86; N 9.03%. 
MS (ESI+): m/z: 309.1 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 25 °C): δ = 
7.10 (d, 3J(H,H) = 7 Hz, 1H, H6), 6.16 (d, 3J(H,H) = 7 Hz, 1H, H5), 4.69 (s, 2H, 
NCH2CO), 4.15 (q, 3J(H,H) = 7 Hz, 2H, CH3CH2O), 3.38 (s, 2H, CH2N  ), 2.71-2.75 
(m, 2H, Hpip), 1.90-1.94 (m, 2H, Hpip), 1.59-1.66 (m, 4H, Hpip), 1.45-1.50 (m, 1H, 
Hpip),    1.21 (t, 3J(H,H) = 7 Hz, 3H, CH3CH2O), 0.83 (d, 3J(H,H) = 6 Hz, 3H, CH3) 
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ppm. 13C{1H} NMR (125.75 MHz, DMSO-d6, 25 °C): δ = 168.8 (COOEt), 157.7 
(C2), 144.8 (C3), 128.2 (C6), 125.9 (C4), 106.8 (C5), 61.7 (Cpip), 61.4 (OCH2CH3), 
56.5 (CH2N), 53.9 (Cpip), 50.6 (NCH2CO), 32.8 (Cpip), 31.2 (Cpip), 25.4 (Cpip), 19.9 
(CH3 )  14.5 (OCH2CH3 ) ppm. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-(2,6-dimethylmorpholinomethyl-
2(1H)-pyridinone (2e)  
2e was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.977 g, 11.40 mmol), 2,6-dimethylmorpholine (1.050 g, 9.12 mmol) 
and 1-ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.60 mmol). 
Yield: 1.873 g (76%), m.p. 158–159 °C (decomp.), Elemental analysis, found: C 
59.38; H 7.44; N 8.60; calcd. for C16H24O5N2: C 59.24; H 7.7.46; N 8.64%. MS 
(ESI+): m/z: 347.0  [M + Na]+, 325.1 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 
25 °C): δ = 7.11 (d, 3J(H,H) = 7 Hz, 1H, H6), 6.20 (d, 3J(H,H) = 7 Hz, 1H, H5), 4.70 (s, 
2H, NCH2CO), 4.15 (q, 3J(H,H) = 7 Hz, 2H, CH3CH2O), 3.55-3.59 (m, 2H, Hmor), 
3.37 (s, 2H, CH2N), 2.68 (d, 3J(H,H) = 10 Hz, 2H, Hmor), 1.70 (t, 3J(H,H) = 10 Hz, 2H, 
Hmor), 1.21 (t, 3J(H,H) = 7 Hz, 3H, CH3CH2O), 1.04 (d, 3J(H,H) = 6 Hz, 6H, CH3)  ppm. 
13C{1H} NMR (125.75 MHz, DMSO-d6, 25 °C): δ = 168.5 (COOEt), 157.8 (C2), 
144.6 (C3), 128.2 (C6), 125.4 (C4), 107.1 (C5), 71.5 (Cmor), 61.4 (OCH2CH3), 59.4 
(CH2N), 55.3 (Cmor), 50.7 (NCH2CO), 19.4 (CH3), 14.5 (OCH2CH3) ppm. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-(N-methylpiperazinomethyl-
2(1H)-pyridinone (2f) 
2f was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.977 g, 11.40 mmol), 1-methylpiperazine (0.913 g, 9.12 mmol) and 
1-ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.60 mmol). 
Yield: 2.138 g (91%), m.p. 150–152 °C (decomp.), Elemental analysis, found: C 
58.11; H 7.44; N 13.57; calcd. for C15H23O4N3: C 58.24; H 7.49; N 13.58%. MS 
(ESI+): m/z: 310.1 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 25 °C): δ = 7.11 (d, 
3J(H,H) = 7 Hz, 1H, H6), 6.18 (d, 3J(H,H) = 7 Hz, 1H, H5), 4.71 (s, 2H, NCH2CO), 4.15 
(q, 3J(H,H) = 7 Hz, 2H, CH3CH2O), 3.39 (s, 2H, CH2N), 2.37-2.41 (m, 8H, Hpipz), 2.17 
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(s, 3H, NCH3),  1.21 (t, 3J(H,H) = 7 Hz, 3H, CH3CH2O) ppm. 13C{1H} NMR (125.75 
MHz, DMSO-d6, 25 °C): δ = 168.5 (COOEt), 157.8 (C2), 144.6 (C3), 128.2 (C6), 
125.7 (C4), 106.9 (C5), 61.4 (OCH2CH3), 55.6 (CH2N), 55.1 (Cpipz), 53.0 (Cpipz), 
50.6 (NCH2CO), 46.1 (NCH3),  14.5 (OCH2CH3 ) ppm. 
1-Ethoxycarbonylmethyl-3-hydroxy-4-(N-phenylpiperazinomethyl-2(1H)-
pyridinone (2g)  
2g was prepared by following the general procedure, using aqueous formaldehyde 
(35% in water, 0.977 g, 11.40 mmol), 1-phenylpiperazine (1.480 g, 9.12 mmol) and 
1-ethoxycarbonylmethyl-3-hydroxy-2(1H)-pyridinone 1a (1.500 g, 7.60 mmol). 
Yield: 2.512 g (89%), m.p. 161–162 °C (decomp.), Elemental analysis, found: C 
64.53; H 6.86; N 11.39; calcd. for C20H25O4N3: C 64.67; H 6.78; N 11.31%. MS 
(ESI+): m/z: 372.1 [M + H]+; 1H NMR (500.10 MHz, DMSO-d6, 25 °C): δ = 7.20-
7.23 (m, 2H, ph), 7.14 (d, 3J(H,H) = 7 Hz, 1H, H-6), 6.92-6.94 (m, 2H, ph), 6.76-6.79 
(m, 1H, ph),   6.25 (d, 3J(H,H) = 7 Hz, 1H, H-5), 4.72 (s, 2H, NCH2CO), 4.16 (q, 
3J(H,H) = 7 Hz, 2H, CH3CH2O), 3.46 (s, 2H, CH2N), 3.15 (t, 3J(H,H) = 5 Hz, 4H, Hpipz), 
2.56 (t, 3J(H,H) = 5 Hz, 4H, Hpipz),1.22 (t, 3J(H,H) =7 Hz, 3H, CH3CH2O) ppm. 13C{1H} 
NMR (125.75 MHz, DMSO-d6, 25 °C): δ = 168.5 (COOEt), 157.8 (C-2), 151.5 (C-
ph),  144.6 (C-3), 129.4 (C-ph),  128.2 (C-6), 125.7 (C-4), 119.3 (C-ph), 115.9 (C-
ph), 107.1 (C-5), 61.4 (OOCH2CH3), 55.4 (CH2N), 53.2 (Cpipzn),  50.7 (NCH2CO), 
48.7 (Cpipzn), 14.5 (OOCH2CH3) ppm.  
General procedure for synthesis of complexs 3a-g:  
A solution of 2a-g (2.2 eq.) and NaOMe (3.5 eq.) in 20 ml MeOH was stirred for 
about 30 min. A solution of [(η6-cymene)RuCl(µ-Cl)]2 (1.0 eq.) in 5 ml CH2Cl2 was 
added and the mixture was stirred for 2-3 h at RT. The solvent was removed under 
reduced pressure and the residue was redissolved in CH2Cl2, filtered to remove in-
soluble impurities and the filtrate was evaporated under vacuum. Recrystallization 
from CH2Cl2 and diethyl ether gave the pure product.  
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[Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-(4-
morpholinomethyl)-2-(1H)-pyridonato-κO}ruthenium(II)] (3a)  
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
(4-morpholinomethyl)-2-(1H)-pyridone (130 mg, 0.44 mmol), NaOMe (38 mg, 0.70 
mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) following the general 
procedure. Yield: 152 mg (67%), m.p. 214–216 °C (decomp.), Elemental analysis 
found C 51.16; H 5.85; N 4.75; calculated for C24H33ClN2O5Ru: C 50.92; H 5.88; N 
4.95%; MS (ESI+): m/z 531.2 [M – Cl]+. 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 
6.52 (brs, 1H, H6), 6.38 (d, 3J(H,H) = 7 Hz, 1H, H5), 5.52 (d, 3J(H,H) = 6 Hz; 1H, Ar-
H), 5.49 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.24 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.23 (d, 
3J(H,H) = 6 Hz, 1H, Ar-H), 5.10 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 4.27-4.30 (m, 2H, 
OCH2CH3), 4.22 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 3.75 (s, 2H, NCH2), 3.67-3.73 
(m, 4H, Hmor),  2.86-2.91 (m, 1H, CH(CH3)2), 2.53-2.60 (m, 4H, Hmor), 2.30 (s, 3H, 
Ar-CH3), 1.33-1.36 (m, 9H, (CH3)2CH-Ar, OCH2CH3) ppm. 13C{1H} NMR (125.75 
MHz, CDCl3, 25 °C): δ = 167.0 (COOEt), 166.4 (C3), 165.3 (C2), 120.3 (C4), 113.9 
(C6), 105.7 (C5), 98.4 (C-Ar), 95.8 (C-Ar), 81.0 (C-Ar), 80.5 (C-Ar), 77.6 (C-Ar), 
77.2 (C-Ar), 67.0 (Cmor), 66.8 (Cmor), 61.9 (OCH2CH3), 55.2 (CH2N), 53.6 (Cmor), 
51.2 (NCH2CO), 31.1 (CH(CH3)2), 22.5 (CH(CH3)2), 22.3 (CH(CH3)2), 18.5 (Ar-
CH3), 14.2 (OCH2CH3) ppm. 
 [Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-(4-
thiomorpholinomethyl)-2-(1H)-pyridonato-κO}ruthenium(II)] (3b) 
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
(4-thiomorpholinomethyl)-2-(1H)-pyridone (137 mg, 0.44 mmol), NaOMe (38 mg, 
0.70 mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) following the 
general procedure. Yield: 135 mg (58%), m.p. >200 °C (decomp.), Elemental 
analysis found: C 49.35; H 5.62; N 4.65; calculated for C24H33O4N2SClRu: C 49.52; 
H 5.71; N 4.81%; MS (ESI+): m/z 547.2 [M – Cl]+. 1H NMR (500.10 MHz, CDCl3, 
25 °C): δ = 6.51 (brs, 1H, H6), 6.39 (d, 3J(H,H) = 7 Hz, 1H, H5), 5.52 (d, 3J(H,H) = 6 
Hz; 1H, Ar-H), 5.50 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.23 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 
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5.22 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.11 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 4.28-4.30 
(m, 2H, OCH2CH3), 4.23 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 3.73 (s, 2H, NCH2), 
3.68-3.72 (m, 4H, Hmor),  2.87-2.91 (m, 1H, CH(CH3)2), 2.54-2.59 (m, 4H, Hmor), 
2.31 (s, 3H, Ar-CH3), 1.32-1.36 (m, 9H, (CH3)2CH-Ar, OCH2CH3) ppm. 13C{1H} 
NMR (125.75 MHz, CDCl3, 25 °C): δ = 167.2 (COOEt), 166.7 (C3), 165.4 (C2), 
120.1 (C4), 113.8 (C6), 105.9 (C5), 98.6 (C-Ar), 95.5 (C-Ar), 81.1 (C-Ar), 80.6 (C-
Ar), 77.8 (C-Ar), 77.1 (C-Ar), 67.3 (Cmor), 66.7 (Cmor), 61.9 (OCH2CH3), 55.3 
(CH2N), 53.7 (Cmor), 51.3 (NCH2CO), 31.0 (CH(CH3)2), 22.4 (CH(CH3)2), 22.3 
(CH(CH3)2), 18.5 (Ar-CH3), 14.2 (OCH2CH3) ppm. 
 [Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-(4-
piperidinomethyl)-2-(1H)-pyridonato-κO}ruthenium(II)] (3c)  
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
(4-piperidinomethyl)-2-(1H)-pyridone (129 mg, 0.44 mmol), NaOMe (38 mg, 0.70 
mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) following the general 
procedure. Yield: 140 mg (62%), m.p. 215–217 °C (decomp.), Elemental analysis 
found: C 52.87; H 6.01; N 4.96; calculated for C25H35O4N2ClRu: C 53.23; H 6.25; N 
4.97%; MS (ESI+): m/z 565.1 [M + H]+. 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 
6.56 (brs, 1H, H6), 6.37 (d, 3J(H,H) = 7 Hz, 1H, H5), 5.52 (d, 3J(H,H) = 6 Hz; 1H, Ar-
H), 5.50 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.24 (d, 3J(H,H) = 6 Hz, 2H, Ar-H), 5.07 (d, 
2J(H,H) = 17 Hz, 1H, NCH2CO), 4.28-4.30 (m, 2H, OCH2CH3), 4.25 (d, 2J(H,H) = 17 
Hz, 1H, NCH2CO), 3.82 (s, 2H, NCH2), 3.67-3.69 (m, 2H, Hpip),  2.85-2.91 (m, 1H, 
CH(CH3)2), 2.57 (brs, 4H, Hpip), 2.30 (s, 3H, Ar-CH3), 1.66 (brs, 4H, Hpip),  1.32-
1.34 (m, 9H, (CH3)2CH-Ar, OCH2CH3) ppm. 13C{1H} NMR (125.75 MHz, CDCl3, 
25 °C): δ = 167.4 (COOEt), 166.9 (C3), 162.3 (C2), 129.0 (C4), 126.3 (C6), 120.2 
(C5), 98.4 (C-Ar), 95.7 (C-Ar), 80.9 (C-Ar), 80.5 (C-Ar), 77.6 (C-Ar), 77.2 (C-Ar), 
61.9 (OCH2CH3), 54.6 (CH2N), 52.7 (Cpip), 51.3 (NCH2CO), 51.1 (Cpip),  31.1 
(CH(CH3)2), 26.0 (Cpip), 24.2 (Cpip),  22.4 (CH(CH3)2), 22.3 (CH(CH3)2), 18.5 (Ar-
CH3), 14.2 (OCH2CH3) ppm. 
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 [Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-[4-(3-
methylpiperidino)methyl]-2-(1H)-pyridonato-κO}ruthenium(II)] (3d) 
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
[4-(3-methylpiperidino)methyl]-2-(1H)-pyridone (136 mg, 0.44 mmol), NaOMe (38 
mg, 0.70 mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) following 
the general procedure. Yield: 141 mg (61%), m.p. 127–129 °C (decomp.), Elemental 
analysis found: C 53.79; H 6.17; N 4.90; calculated for C26H37O4N2ClRu: C 54.02; 
H 6.45; N 4.84%; MS (ESI+): m/z 543.2 [M – Cl]+. 1H NMR (500.10 MHz, CDCl3, 
25 °C): δ = 6.45 (brs, 1H, H-6), 6.37 (d, 3J(H,H) = 6 Hz, 1H, H-5), 5.52 (d, 3J(H,H) = 6 
Hz; 1H, Ar-H), 5.49 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.24 (d, 3J(H,H) = 6 Hz, 2H, Ar-H), 
5.09 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 4.24-4.29 (m, 3H, OCH2CH3, NCH2CO), 
3.81 (s, 2H, NCH2), 2.85-2.89 (m, 1H, CH(CH3)2), 2.82-2.83 (brs, 4H, Hpip), 2.29 (s, 
3H, Ar-CH3), 1.97-1.99 (m, 4H, Hpip), 1.61-1.69 (m, 1H, Hpip),  1.31-1.34 (m, 9H, 
(CH3)2CH-Ar, OCH2CH3), 0.86 (s, 3H, Pip-CH3),  ppm. 13C{1H} NMR (125.75 
MHz, CDCl3, 25 °C): δ = 168.0 (COOEt), 166.7 (C3), 162.5 (C2), 128.4 (C4), 126.0 
(C6), 119.2 (C5), 98.5 (C-Ar), 95.3 (C-Ar), 80.6 (C-Ar), 80.2 (C-Ar), 77.8 (C-Ar), 
77.2 (C-Ar), 62.1 (Cpip), 61.5 (OCH2CH3), 55.4 (CH2N), 53.4 (Cpip), 51.5 
(NCH2CO), 52.4 (Cpip),  31.2 (CH(CH3)2), 26.3 (Cpip), 24.5 (Cpip),  22.4 (CH(CH3)2), 
22.3 (CH(CH3)2), 18.5 (Ar-CH3), 14.2 (OCH2CH3) ppm. 
 
[Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-[4-(2,6-
dimethylmorpholino)methyl]-2-(1H)-pyridonato-κO}ruthenium(II)] (3e)  
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
[4-(2,6-dimethylmorpholino)methyl]-2-(1H)-pyridone (143 mg, 0.44 mmol), 
NaOMe (38 mg, 0.70 mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) 
following the general procedure. Yield: 128 mg (54%), m.p. 176–178 °C (decomp.), 
Elemental analysis found: C 52.27; H 6.05; N 4.71; calculated for C26H37O5N2ClRu: 
C 52.56; H 6.28; N 4.72%;: MS (ESI+): m/z 559.2 [M – Cl]+. 1H NMR (500.10 
MHz, CDCl3, 25 °C): δ = 6.54 (brs, 1H, H6), 6.37 (d, 3J(H,H) = 7 Hz, 1H, H5), 5.51 
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(d, 3J(H,H) = 6 Hz; 1H, Ar-H), 5.49 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.25 (d, 3J(H,H) = 6 
Hz, 1H, Ar-H), 5.23 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.09 (d, 2J(H,H) = 17 Hz, 1H, 
NCH2CO), 4.26-4.29 (m, 2H, OCH2CH3), 4.23 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 
3.73 (s, 2H, NCH2), 3.63-3.69 (m, 4H, Hmor),  2.87-2.92 (m, 1H, CH(CH3)2), 2.54-
2.58 (m, 2H, Hmor), 2.32 (s, 3H, Ar-CH3), 1.34-1.37 (m, 9H, (CH3)2CH-Ar, 
OCH2CH3), 1.06 (d, 3J(H,H) = 6 Hz, 6H, CH3) ppm. 13C{1H} NMR (125.75 MHz, 
CDCl3, 25 °C): δ = 168.4 (COOEt), 167.0 (C3), 165.4 (C2), 121.3 (C4), 114.2 (C6), 
106.8 (C5), 98.6 (C-Ar), 95.4 (C-Ar), 81.3 (C-Ar), 80.6 (C-Ar), 77.8 (C-Ar), 77.1 
(C-Ar), 69.2 (Cmor), 61.7 (OCH2CH3), 56.2 (CH2N), 53.4 (Cmor), 51.3 (NCH2CO), 
31.2 (CH(CH3)2), 22.5 (CH(CH3)2), 22.3 (CH(CH3)2), 18.5 (Ar-CH3), 14.2 
(OCH2CH3) ppm. 
[Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-[4-(N-
methylpiperazino)methyl]-2-(1H)-pyridonato-κO}ruthenium(II)] (3f)  
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
[4-(N-methylpiperazino)methyl]-2-(1H)-pyridone (136 mg, 0.44 mmol), NaOMe (38 
mg, 0.70 mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) following 
the general procedure. Yield: 134 mg (56%), m.p. 187–189 °C (decomp.), Elemental 
analysis found: C 50.69; H 5.92; N 7.23; calculated for 
C25H36O4N3ClRu·0.25CH2Cl2: C 50.52; H 6.13; N 7.00%; MS (ESI+): m/z 544.2 [M 
– Cl]+. 1H NMR (500.10 MHz, CDCl3, 25 °C): δ = 6.44 (d, 3J(H,H) = 7 Hz, 1H, H6), 
6.37 (d, 3J(H,H) = 7 Hz, 1H, H5), 5.51 (d, 3J(H,H) = 6 Hz; 1H, Ar-H), 5.48 (d, 3J(H,H) = 
6 Hz, 2H, Ar-H), 5.09 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 4.20-4.29 (m, 3H, 
OCH2CH3, NCH2CO), 3.82 (s, 2H, NCH2), 3.64-3.67 (m, 4H, Hpipz),  2.86-2.92 (m, 
1H, CH(CH3)2), 2.46-2.54 (m, 4H, Hpipz), 2.33 (s, 3H, NCH3), 2.29 (s, 3H, Ar-CH3), 
1.31-1.35 (m, 9H, (CH3)2CH-Ar, OCH2CH3) ppm. 13C{1H} NMR (125.75 MHz, 
CDCl3, 25 °C): δ = 166.7 (COOEt), 165.6 (C3), 164.8 (C2), 120.6 (C4), 114.4 (C6), 
106.3 (C5), 98.5 (C-Ar), 95.6 (C-Ar), 81.2 (C-Ar), 80.7 (C-Ar), 77.4 (C-Ar), 77.1 
(C-Ar),  61.9 (OCH2CH3), 55.8 (CH2N), 55.2 (Cpipz),  53.7 (Cpipz), 51.3 (NCH2CO), 
47.1 (CH3N),  31.0 (CH(CH3)2), 22.4 (CH(CH3)2), 22.3 (CH(CH3)2), 18.4 (Ar-CH3), 
14.2 (OCH2CH3) ppm. 
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 [Chlorido(η6-p-cymene){N-[(ethoxycarbonyl)methyl]-3-oxo-κO-[4-(N-
phenylpiperazino)methyl]-2-(1H)-pyridonato-κO}ruthenium(II)] (3g)  
The title compound was synthesized from N-[(ethoxycarbonyl)methyl]-3-hydroxy-
[4-(N-phenylpiperazino)methyl]-2-(1H)-pyridone (163 mg, 0.44 mmol), NaOMe (38 
mg, 0.70 mmol) and [(η6-p-cymene)RuCl(µ-Cl)]2 (122 mg, 0.20 mmol) following 
the general procedure. Yield: 195 mg (76%), m.p. 168–170 °C (decomp.), Elemental 
analysis found: C 55.86; H 5.76; N 6.60; calculated for C30H38O4N3ClRu: C 56.20; 
H 5.97; N 6.55%; MS (ESI+): m/z 606.0 [M – Cl]+. 1H NMR (500.10 MHz, CDCl3, 
25 °C): δ = 7.25-7.29 (m, 2H, Ph), 6.93-6.95 (m, 2H, Ph), 6.84-6.87 (m, 1H, Ph),   
6.51 (d, 3J(H,H) = 6 Hz, 1H, H6), 6.39 (d, 3J(H,H) = 7 Hz, 1H, H5), 5.52 (d, 3J(H,H) = 6 
Hz; 1H, Ar-H), 5.50 (d, 3J(H,H) = 6 Hz, 1H, Ar-H), 5.25 (d, 3J(H,H) = 6 Hz, 2H, Ar-H), 
5.11 (d, 2J(H,H) = 17 Hz, 1H, NCH2CO), 4.27-4.30 (m, 2H, OCH2CH3), 4.22 (d, 
2J(H,H) = 17 Hz, 1H, NCH2CO),  3.84 (s, 2H, NCH2), 3.21 (brs, 4H, Hpipz), 2.86-2.92 
(m, 1H, CH(CH3)2), 2.70 (brs, 4H, Hpipz), 2.30 (s, 3H, Ar-CH3), 1.33-1.36 (m, 9H, 
(CH3)2CH-Ar, OCH2CH3) ppm. 13C{1H} NMR (125.75 MHz, CDCl3, 25 °C): δ = 
167.1 (COOEt), 165.2 (C3), 158.9 (C2), 151.4 (C-NPh), 129.1 (C4), 120.3 (C6), 
119.5 (C-NPh), 116.0 (C5), 113.8 (C-NPh),  98.4 (C-Ar), 95.8 (C-Ar), 80.8 (C-Ar), 
80.5 (C-Ar), 77.5 (C-Ar), 77.2 (C-Ar), 61.9 (OCH2CH3), 55.0 (Cpipz), 53.2(CH2N), 
51.2 (NCH2CO), 49.1 (Cpipz), 31.1 (CH(CH3)2), 22.5 (CH(CH3)2), 22.4 (CH(CH3)2), 
18.5 (Ar-CH3), 14.2 (OCH2CH3) ppm. 
Stability in aqueous solution 
For hydrolysis studies, 3a, 3b and 3c (1–2 mg/mL) were dissolved in D2O/MeOD-d4 
(95/5) or 0.02 M phosphate buffer (pH 7.40, 100 mM NaCl)/MeOD-d4 (95/5) and 
the samples were analyzed by 1H NMR spectroscopy. The 1H NMR spectra were 
recorded after 0.5, 24, 48, 72 and 120 h. 
pKa determination 
pKa values were determined by dissolving 3a and 3c in MeOD-d4/D2O (5/95) solu-
tion. The pH values were measured directly in the NMR tubes with an Eco Scan 
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pH6 pH meter equipped with a glass-micro combination pH electrode (Orion 
9826BN) and calibrated with standard buffer solutions of pH 4.00, 7.00 and 10.00. 
The pH titration was performed with NaOD (0.4–0.0004% in D2O) and DNO3 (0.4–
0.0004% in D2O). The pH values were plotted against the chemical shifts of the Ar-
cym-H2/H6 protons of the arene ring in the 1H NMR spectra and the resulting curves 
were fitted using the Henderson-Hasselbalch equation with Microsoft® Office Excel 
2003, SP3 (Microsoft Corporation). The experimentally obtained pKa* values were 
corrected with Eq. (1), in order to convert the pKa* in D2O to the corresponding pKa 
values in aqueous solutions.134  
pKa = 0.929 pKa* + 0.42     (1) 
Reaction with biomolecules monitored by NMR spectroscopy 
5’-GMP binding experiments were carried out by titrating solutions of 3a, 3b and 3c 
(1–2 mg/mL) in 0.02 M phosphate buffer (pH 7.4, 4 mM NaCl)/MeOD-d4 (95/5) 
with a 5’-GMP solution (10 mg/mL D2O) in 50 µL increments. The reaction was 
monitored by 1H and 31P{1H} NMR spectroscopy until unreacted 5’-GMP was de-
tected. 
In order to investigate the reactivity of complexes with amino acids, solutions of 3a, 
3b and 3c (1 mg/mL) in 0.02 M phosphate buffer (pH 7.40, 100 mM NaCl)/MeOD-
d4 (95/5)  were treated with equimolar amounts of Gly, Cys, Met and His and the 1H 
NMR spectra were recorded after 5 min and 24 h. 
Mass Spectrometry Studies on the Binding to Amino Acids and Pro-
teins 
Stock solutions of 3a, 3b, Cys, Met, His, ubiquitin (Ub) (each 400 µM) were pre-
pared in MeOH/H2O (90/10), and apo-transferrin (Tf) was dissolved in 50 mM am-
monium bicarbonate buffer. Solutions of 3a and 3b were incubated with the amino 
acids at a 1 : 1 molar ratio at 37 °C and ESI-MS spectra were measured after 0.5, 1, 
3, 6 and 24 h. For the protein binding studies, 3a or 3b and Ub or Tf were mixed at 
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2 : 1 molar ratios, and aliquots were taken after 0.5, 1, 2, 3, 6 and/or 24 h. The sam-
ples were analyzed at concentrations ranging from 10-30 µM. Therefore, they were 
diluted with MeOH in case of the amino acids, with MeOH/water/formic acid 
(50/50/0.1) for the analysis of the Ub samples and with MeOH/water/formic acid 
(10/90/2) for the analysis of Tf samples. ESI-mass spectra were recorded on a 
Bruker esquire3000 ion trap mass spectrometer by direct infusion with a flow rate of 4 
µL/min. The experimental conditions were as follows: Capillary 4.5 kV, end plate 
offset 0.5 kV, skimmer 1 43.2 V, skimmer 2 6 V, octopole 2.62 V, cap exit offset 
77.2 V, and dry temperature 200 °C. For Tf samples skimmer 1 was adjusted to 71.0 
V, skimmer 2 to 20.0 V octopole to 2.78 V, capillary exit offset to 120.0 V and Trap 
Drive to 73.0 V. The spectra were recorded and processed using ESI Compass 1.3 
and DataAnalysis 4.0 software (both Bruker, Bremen, Germany). Deconvolution 
was obtained by the maximum entropy deconvolution algorithm with a mass step of 
m/z 0.1 and an instrument peak width of 0.5-4. 
Cytotoxicity in cancer cell lines 
Cell lines and culture conditions. CH1 cells (adenocarcinoma of the ovary) were a 
generous gift from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute 
of Cancer Research, Sutton, UK. SW480 (adenocarcinoma of the colon, human), 
and A549 (non-small cell lung cancer, human) cells were kindly provided by 
Brigitte Marian (Institute of Cancer Research, Department of Medicine I, Medical 
University of Vienna, Austria). All cell culture reagents were obtained from Sigma-
Aldrich Austria. Cells were grown in 75 cm² culture flasks (Iwaki) as adherent 
monolayer cultures in Eagle’s Minimal Essential Medium (MEM) supplemented 
with 10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate and 2 mM L-
glutamine. Cultures were maintained at 37 °C in a humidified atmosphere containing 
95% air and 5% CO2. 
MTT assay conditions. Cytotoxicity was determined by the colorimetric MTT (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, purchased from 
Fluka) microculture assay. For this purpose, cells were harvested from culture flasks 
by trypsinization and seeded in 100 µL aliquots MEM supplemented with 10% heat-
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inactivated fetal calf serum, 1 mM sodium pyruvate, 4 mM L-glutamine and 1% 
non-essential amino acids (100×) into 96-well microculture plates (Iwaki). Cell den-
sities of 1.5 × 103 cells/well (CH1), 2.5 × 103 cells/well (SW480) and 
4 × 103 cells/well (A549) were chosen in order to ensure exponential growth of un-
treated controls throughout the experiment. Cells were allowed to settle and resume 
exponential growth for 24 h. The test compounds were dissolved and serially diluted 
in the same medium and added in 100 µL aliquots to the microcultures (if necessary 
due to limited solubility, the maximum concentration tested was added in 200 µL 
aliquots after removal of the medium), and cells were exposed to the test compounds 
for 96 h. At the end of exposure, all media were replaced by 100 µL/well RPMI1640 
culture medium (supplemented with 10% heat-inactivated fetal calf serum) plus 
20 µL/well MTT solution in phosphate-buffered saline (5 mg/ml). After incubation 
for 4 h, the supernatants were removed, and the formazan crystals formed by viable 
cells were dissolved in 150 µL DMSO per well. Optical densities at 550 nm were 
measured with a microplate reader (Tecan Spectra Classic), using a reference wave-
length of 690 nm to correct for unspecific absorption. The quantity of vital cells was 
expressed in terms of T/C values by comparison to untreated control microcultures, 
and 50% inhibitory concentrations (IC50) were calculated from concentration-effect 
curves by interpolation. Evaluation is based on means from three independent ex-
periments, each comprising three replicates per concentration level. 
 
104
105
 3. Conclusions and outlook 
Bioorganometallic chemistry is a relatively new but a fervent area of research. It 
offers possibilities for the design and development of metal based drugs for specific 
therapeutic needs that are not readily accessible to organic compounds. In recent 
years, Ru(II)- and Os(II)-arene complexes have become the focus of interest and 
some examples appear to be promising anticancer drug candidates. The metal-arene 
motif is an excellent scaffold, with potential to fine-tune the anticancer activity and 
other drug-like properties such as stability and solubility. Moreover, conjugation of 
the metal-arene fragment to bioactive species (e.g.ethacrynic acid, tamoxifen, 
staurosporine or aspirin) or simple biomolecules (e.g.sugars or amino acids) can 
result in enhanced activity as well as specificity.  
In this thesis, different strategies were employed, including coordination of bio-
molecules to the metal-arene unit, with the aim to improve pharmacological proper-
ties such as bioavailability, lipophilicity, solubility and anticancer activity. Cancer 
cells usually display enhanced glucose uptake under hypoxic conditions, due to 
overexpression of glycolytic enzymes and glucose transporters, as compared to 
healthy cells. Therefore, attaching a carbohydrate functionality to a metal-arene 
moiety appears a promising strategy to exploit biochemical and metabolic functions 
used for transport and accumulation of sugars in living organisms. This is discussed 
in the first part of this thesis which comprises the synthesis and biological evaluation 
of ruthenium(II)- and osmium(II)-arene compounds bearing sugar-derived bicyclo-
phosphite ligands. The complexes were characterized with regard to their chemical 
stability in aqueous solution, reaction with proteins and the DNA models 5’-GMP 
and 9-ethylguanine. Different structural modifications such as change of arene, 
metal center and leaving group were made with regard to structure-activity relation-
ships.  [Ru(arene)(sugar-phosphite)Cl2] complexes exhibit IC50 values from moder-
ate to the low micromolar range and are prone to hydrolysis. They undergo aquation 
of the first halido ligand in aqueous solution, and additionally hydrolysis of a P–O 
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bond of the phosphite ligand, leading ultimately to the formation of dinuclear spe-
cies.  
The change of metal center from ruthenium to osmium has no significant impact on 
in vitro anticancer activity, despite a considerably lower rate of hydrolysis and lack 
of reactivity to 5’-GMP for a dichlorido-osmium analogue. In order to study the role 
of the leaving group, the dichlorido ligands were replaced with chelating biscar-
boxylates, i.e., oxalate and malonate. This structural modification has a dramatic 
influence on the chemical and biological properties of the compounds. As expected, 
hydrolysis is markedly inhibited and in vitro anticancer activity is also considerably 
low in all tested cell lines. The reactivity of the organometallic species to the bio-
logical nucleophiles Met, Cys, Ub and 5’-GMP is also significantly reduced, and 
compared to the respective dichlorido complexes, essentially the same adducts are 
formed, but at a lowered rate.  
Variation in the arene ligand of metal arene complexes has demonstrated strong in-
fluence on the antiproliferative activity. It appears that cytotoxicity is increased by 
increasing the lipophilicity of carbohydrate based complexes. The most lipophilic 
compound was the most active with IC50 values in the low micromolar range. The 
following order of cytotoxicity is observed with regard to variation of arene ligand 
with the same sugar moiety in the Ru(II) complexes: biphenyl > cymene > toluene > 
benzene. This trend is also observed when changing the carbohydrate-derived moi-
ety. While keeping the same arene ligand, compound having the most lipophilic 
ligand was the most cytotoxic.  
Overall, carbohydrate-based metal(arene) complexes have demonstrated promising 
anticancer activity in in vitro assays. However, in vivo experiments might give 
deeper insight on the potential of these compounds as chemotherapeutics, as the 
effect of increased glucose uptake due to enhanced glycolytic activity in cancer cells 
can only be exploited in living organisms.  
The second part of this thesis deals with the synthesis and complexation of 3-
hydroxy-2-pyridones to ruthenium(II)- and osmium(II)-arene moieties. Novel 
MII(arene) half-sandwich complexes (M = Ru, Os) with 3-hydroxy-2-pyridone de-
rived ligands were synthesized and characterized chemically and biologically. The 
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compounds undergo fast hydrolysis to the respective aqua species that are stable for 
several days but react quickly, however to a different extent, with the amino acids 
Met, Cys, His and Gly to form M(η6-p-cymene)(amino acid) adducts upon cleavage 
of the hydroxypyridone ligand, as characterized by NMR spectroscopy and ESI 
mass spectrometry. A similar behavior was also observed during the reactions with 
the model proteins ubiquitin and cytochrome c to yield mainly [protein + M(η6-p-
cymene)] adducts (M = Ru, Os). Notably the ligand cleavage of the Os derivative 
was significantly slower than of its Ru analogue which could explain its higher ac-
tivity in in vitro anticancer assays. Furthermore, reaction products with 5’-GMP 
were characterized, to proceed via coordination to the N7 of the guanine moiety, as 
demonstrated by 1H NMR spectroscopy and X-ray diffraction analysis. In 
CDK2/Cyclin A protein kinase inhibition studies, the Ru complexes revealed potent 
activity, comparable to known inhibitors. Ru(arene) complexes of 3-hydroxy-2-
pyridone substituted in a Mannich reaction with thiomorpholine and piperidine, have 
shown promising anticancer activity with IC50 values in the low micro molar range. 
However, a remarkable difference in cytotoxicity was found between Ru(arene) 
complexes of morpholine and thiomorpholine derivatives, the latter being two orders 
of magnitude more active, despite minor difference in their structures .  It would be 
interesting to carry out further investigations on mode of action studies and certain 
enzyme inhibition assays for these two compounds to know more about difference in 
their mechanism of action.  
In future, it would be interesting to evaluate the influence of further structural 
changes in the metal(II)-arene unit, particularly the conjugation of functional groups 
or bioactive segments to the arene ligand, modification of carbohydrate functional-
ity, in particular by introducing a spacer between metal center and carbohydrate 
moiety, change in the nature of the donor system, and substitution at the pyridone 
backbone. Moreover, investigations on the mechanism of action at the molecular 
level would provide deeper insights and rationale for future drug design.  
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